(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) |
(Address of principal executive offices) | (Zip Code) | |||||||||||||||||||
Registrant’s telephone number, including area code: | ||||||||||||||||||||
Former name, former address and former fiscal year, if changed since last report: | N/A |
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
☑ | Accelerated filer | ☐ | |||||||||
Non-accelerated filer | ☐ | Smaller reporting company | |||||||||
Emerging growth company | |||||||||||
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. | ☐ |
TABLE OF CONTENTS | ||||||||
Page | ||||||||
Part I | Financial Information | |||||||
Item 1. | ||||||||
Item 2. | ||||||||
Item 3. | ||||||||
Item 4. | ||||||||
Part II | Other Information | |||||||
Item 1. | ||||||||
Item 1A. | ||||||||
Item 2. | ||||||||
Item 3 | ||||||||
Item 4. | ||||||||
Item 5. | ||||||||
Item 6. | ||||||||
Page | |||||
Condensed Consolidated Statements of Operations (Unaudited) for the three and nine months ended September 30, 2022 and 2021 | |||||
Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited) for the three and nine months ended September 30, 2022 and 2021 | |||||
Condensed Consolidated Balance Sheets (Unaudited) as of September 30, 2022 and December 31, 2021 | |||||
Condensed Consolidated Statements of Cash Flows (Unaudited) for the nine months ended September 30, 2022 and 2021 | |||||
Condensed Consolidated Statements of Shareholders’ Equity (Unaudited) for the three months ended September 30, 2022 and 2021, the three months ended June 30, 2022 and 2021 and the three months ended March 31, 2022 and 2021 | |||||
Notes to Condensed Consolidated Financial Statements (Unaudited) | |||||
Report of Independent Registered Public Accounting Firm |
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
In millions, except per share amounts | 2022 | 2021 | 2022 | 2021 | |||||||||||||||||||
Revenues: | |||||||||||||||||||||||
Products | $ | $ | $ | $ | |||||||||||||||||||
Premiums | |||||||||||||||||||||||
Services | |||||||||||||||||||||||
Net investment income | |||||||||||||||||||||||
Total revenues | |||||||||||||||||||||||
Operating costs: | |||||||||||||||||||||||
Benefit costs | |||||||||||||||||||||||
Opioid litigation charges | |||||||||||||||||||||||
Loss on assets held for sale | |||||||||||||||||||||||
Goodwill impairment | |||||||||||||||||||||||
Operating expenses | |||||||||||||||||||||||
Total operating costs | |||||||||||||||||||||||
Operating income (loss) | ( | ||||||||||||||||||||||
Interest expense | |||||||||||||||||||||||
Loss on early extinguishment of debt | |||||||||||||||||||||||
Other income | ( | ( | ( | ( | |||||||||||||||||||
Income (loss) before income tax provision | ( | ||||||||||||||||||||||
Income tax provision (benefit) | ( | ||||||||||||||||||||||
Net income (loss) | ( | ||||||||||||||||||||||
Net (income) loss attributable to noncontrolling interests | ( | ( | |||||||||||||||||||||
Net income (loss) attributable to CVS Health | $ | ( | $ | $ | $ | ||||||||||||||||||
Net income (loss) per share attributable to CVS Health: | |||||||||||||||||||||||
Basic | $ | ( | $ | $ | $ | ||||||||||||||||||
Diluted | $ | ( | $ | $ | $ | ||||||||||||||||||
Weighted average shares outstanding: | |||||||||||||||||||||||
Basic | |||||||||||||||||||||||
Diluted | |||||||||||||||||||||||
Dividends declared per share | $ | $ | $ | $ |
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
In millions | 2022 | 2021 | 2022 | 2021 | |||||||||||||||||||
Net income (loss) | $ | ( | $ | $ | $ | ||||||||||||||||||
Other comprehensive loss, net of tax: | |||||||||||||||||||||||
Net unrealized investment losses | ( | ( | ( | ( | |||||||||||||||||||
Foreign currency translation adjustments | ( | ( | ( | ( | |||||||||||||||||||
Net cash flow hedges | ( | ( | |||||||||||||||||||||
Pension and other postretirement benefits | |||||||||||||||||||||||
Other comprehensive loss | ( | ( | ( | ( | |||||||||||||||||||
Comprehensive income (loss) | ( | ( | |||||||||||||||||||||
Comprehensive (income) loss attributable to noncontrolling interests | ( | ( | |||||||||||||||||||||
Comprehensive income (loss) attributable to CVS Health | $ | ( | $ | $ | ( | $ |
In millions, except per share amounts | September 30, 2022 | December 31, 2021 | |||||||||
Assets: | |||||||||||
Cash and cash equivalents | $ | $ | |||||||||
Investments | |||||||||||
Accounts receivable, net | |||||||||||
Inventories | |||||||||||
Assets held for sale | |||||||||||
Other current assets | |||||||||||
Total current assets | |||||||||||
Long-term investments | |||||||||||
Property and equipment, net | |||||||||||
Operating lease right-of-use assets | |||||||||||
Goodwill | |||||||||||
Intangible assets, net | |||||||||||
Separate accounts assets | |||||||||||
Other assets | |||||||||||
Total assets | $ | $ | |||||||||
Liabilities: | |||||||||||
Accounts payable | $ | $ | |||||||||
Pharmacy claims and discounts payable | |||||||||||
Health care costs payable | |||||||||||
Policyholders’ funds | |||||||||||
Accrued expenses | |||||||||||
Other insurance liabilities | |||||||||||
Current portion of operating lease liabilities | |||||||||||
Current portion of long-term debt | |||||||||||
Liabilities held for sale | |||||||||||
Total current liabilities | |||||||||||
Long-term operating lease liabilities | |||||||||||
Long-term debt | |||||||||||
Deferred income taxes | |||||||||||
Separate accounts liabilities | |||||||||||
Other long-term insurance liabilities | |||||||||||
Other long-term liabilities | |||||||||||
Total liabilities | |||||||||||
Shareholders’ equity: | |||||||||||
Preferred stock, par value $ | |||||||||||
Common stock, par value $ | |||||||||||
Treasury stock, at cost: | ( | ( | |||||||||
Retained earnings | |||||||||||
Accumulated other comprehensive income (loss) | ( | ||||||||||
Total CVS Health shareholders’ equity | |||||||||||
Noncontrolling interests | |||||||||||
Total shareholders’ equity | |||||||||||
Total liabilities and shareholders’ equity | $ | $ |
Nine Months Ended September 30, | |||||||||||
In millions | 2022 | 2021 | |||||||||
Cash flows from operating activities: | |||||||||||
Cash receipts from customers | $ | $ | |||||||||
Cash paid for inventory and prescriptions dispensed by retail network pharmacies | ( | ( | |||||||||
Insurance benefits paid | ( | ( | |||||||||
Cash paid to other suppliers and employees | ( | ( | |||||||||
Interest and investment income received | |||||||||||
Interest paid | ( | ( | |||||||||
Income taxes paid | ( | ( | |||||||||
Net cash provided by operating activities | |||||||||||
Cash flows from investing activities: | |||||||||||
Proceeds from sales and maturities of investments | |||||||||||
Purchases of investments | ( | ( | |||||||||
Purchases of property and equipment | ( | ( | |||||||||
Acquisitions (net of cash acquired) | ( | ( | |||||||||
Proceeds from sale of subsidiaries (net of cash and restricted cash sold of $ | ( | ||||||||||
Other | |||||||||||
Net cash used in investing activities | ( | ( | |||||||||
Cash flows from financing activities: | |||||||||||
Proceeds from issuance of long-term debt | |||||||||||
Repayments of long-term debt | ( | ( | |||||||||
Repurchase of common stock | ( | ||||||||||
Dividends paid | ( | ( | |||||||||
Proceeds from exercise of stock options | |||||||||||
Payments for taxes related to net share settlement of equity awards | ( | ( | |||||||||
Other | ( | ||||||||||
Net cash used in financing activities | ( | ( | |||||||||
Net increase in cash, cash equivalents and restricted cash | |||||||||||
Cash, cash equivalents and restricted cash at the beginning of the period | |||||||||||
Cash, cash equivalents and restricted cash at the end of the period | $ | $ |
Nine Months Ended September 30, | |||||||||||
In millions | 2022 | 2021 | |||||||||
Reconciliation of net income to net cash provided by operating activities: | |||||||||||
Net income | $ | $ | |||||||||
Adjustments required to reconcile net income to net cash provided by operating activities: | |||||||||||
Depreciation and amortization | |||||||||||
Loss on assets held for sale | |||||||||||
Goodwill impairment | |||||||||||
Stock-based compensation | |||||||||||
Gain on sale of subsidiary | ( | ||||||||||
Loss on early extinguishment of debt | |||||||||||
Deferred income taxes and other noncash items | ( | ( | |||||||||
Change in operating assets and liabilities, net of effects from acquisitions: | |||||||||||
Accounts receivable, net | ( | ( | |||||||||
Inventories | ( | ||||||||||
Other assets | ( | ( | |||||||||
Accounts payable and pharmacy claims and discounts payable | |||||||||||
Health care costs payable and other insurance liabilities | |||||||||||
Other liabilities | |||||||||||
Net cash provided by operating activities | $ | $ |
Attributable to CVS Health | ||||||||||||||||||||||||||||||||
Number of shares outstanding | Common Stock and Capital Surplus (2) | Treasury Stock (1) | Retained Earnings | Accumulated Other Comprehensive Income (Loss) | Total CVS Health Shareholders’ Equity | Noncontrolling Interests | Total Shareholders’ Equity | |||||||||||||||||||||||||
Common Shares | Treasury Shares (1) | |||||||||||||||||||||||||||||||
In millions | ||||||||||||||||||||||||||||||||
Balance at December 31, 2021 | ( | $ | $ | ( | $ | $ | $ | $ | $ | |||||||||||||||||||||||
Net income | — | — | — | — | — | |||||||||||||||||||||||||||
Other comprehensive loss | — | — | — | — | — | ( | ( | — | ( | |||||||||||||||||||||||
Stock option activity, stock awards and other | — | — | — | — | — | |||||||||||||||||||||||||||
Purchase of treasury shares, net of ESPP issuances | — | ( | — | ( | — | — | ( | — | ( | |||||||||||||||||||||||
Common stock dividends | — | — | — | — | ( | — | ( | — | ( | |||||||||||||||||||||||
Other increases in noncontrolling interests | — | — | — | — | — | — | — | |||||||||||||||||||||||||
Balance at March 31, 2022 | ( | ( | ( | |||||||||||||||||||||||||||||
Net income | — | — | — | — | — | |||||||||||||||||||||||||||
Other comprehensive loss | — | — | — | — | — | ( | ( | — | ( | |||||||||||||||||||||||
Stock option activity, stock awards and other | — | — | — | — | — | |||||||||||||||||||||||||||
Purchase of treasury shares, net of ESPP issuances | — | ( | — | ( | — | — | ( | — | ( | |||||||||||||||||||||||
Common stock dividends | — | — | — | — | ( | — | ( | — | ( | |||||||||||||||||||||||
Other increases in noncontrolling interests | — | — | — | — | — | — | — | |||||||||||||||||||||||||
Balance at June 30, 2022 | ( | ( | ( | |||||||||||||||||||||||||||||
Net income (loss) | — | — | — | — | ( | — | ( | ( | ||||||||||||||||||||||||
Other comprehensive loss (Note 8) | — | — | — | — | — | ( | ( | — | ( | |||||||||||||||||||||||
Stock option activity, stock awards and other | — | — | — | — | — | |||||||||||||||||||||||||||
ESPP issuances, net of purchase of treasury shares | — | — | — | — | — | |||||||||||||||||||||||||||
Common stock dividends | — | — | — | — | ( | — | ( | — | ( | |||||||||||||||||||||||
Other decreases in noncontrolling interests | — | — | — | — | — | — | — | ( | ( | |||||||||||||||||||||||
Balance at September 30, 2022 | ( | $ | $ | ( | $ | $ | ( | $ | $ | $ | ||||||||||||||||||||||
Attributable to CVS Health | ||||||||||||||||||||||||||||||||
Number of shares outstanding | Common Stock and Capital Surplus (2) | Treasury Stock (1) | Retained Earnings | Accumulated Other Comprehensive Income | Total CVS Health Shareholders’ Equity | Noncontrolling Interests | Total Shareholders’ Equity | |||||||||||||||||||||||||
Common Shares | Treasury Shares (1) | |||||||||||||||||||||||||||||||
In millions | ||||||||||||||||||||||||||||||||
Balance at December 31, 2020 | ( | $ | $ | ( | $ | $ | $ | $ | $ | |||||||||||||||||||||||
Net income | — | — | — | — | — | |||||||||||||||||||||||||||
Other comprehensive loss | — | — | — | — | — | ( | ( | — | ( | |||||||||||||||||||||||
Stock option activity, stock awards and other | — | — | — | — | — | |||||||||||||||||||||||||||
ESPP issuances, net of purchase of treasury shares | — | — | — | — | — | |||||||||||||||||||||||||||
Common stock dividends | — | — | — | — | ( | — | ( | — | ( | |||||||||||||||||||||||
Other increases in noncontrolling interests | — | — | — | — | — | — | — | |||||||||||||||||||||||||
Balance at March 31, 2021 | ( | ( | ||||||||||||||||||||||||||||||
Net income | — | — | — | — | — | |||||||||||||||||||||||||||
Other comprehensive income | — | — | — | — | — | — | ||||||||||||||||||||||||||
Stock option activity, stock awards and other | — | — | — | — | — | |||||||||||||||||||||||||||
Purchase of treasury shares, net of ESPP issuances | — | ( | — | ( | — | — | ( | — | ( | |||||||||||||||||||||||
Common stock dividends | — | — | — | — | ( | — | ( | — | ( | |||||||||||||||||||||||
Other decreases in noncontrolling interests | — | — | — | — | — | — | — | ( | ( | |||||||||||||||||||||||
Balance at June 30, 2021 | ( | ( | ||||||||||||||||||||||||||||||
Net income | — | — | — | — | — | ( | ||||||||||||||||||||||||||
Other comprehensive loss (Note 8) | — | — | — | — | — | ( | ( | — | ( | |||||||||||||||||||||||
Stock option activity, stock awards and other | — | — | — | — | ||||||||||||||||||||||||||||
ESPP issuances, net of purchase of treasury shares | — | — | — | — | — | |||||||||||||||||||||||||||
Common stock dividends | — | — | — | — | ( | — | ( | — | ( | |||||||||||||||||||||||
Balance at September 30, 2021 | ( | $ | $ | ( | $ | $ | $ | $ | $ | |||||||||||||||||||||||
In millions | September 30, 2022 | December 31, 2021 | September 30, 2021 | ||||||||||||||
Cash and cash equivalents | $ | $ | $ | ||||||||||||||
Restricted cash (included in other current assets) | |||||||||||||||||
Restricted cash (included in other assets) | |||||||||||||||||
Total cash, cash equivalents and restricted cash in the statements of cash flows | $ | $ | $ |
In millions | September 30, 2022 | December 31, 2021 | |||||||||
Trade receivables | $ | $ | |||||||||
Vendor and manufacturer receivables | |||||||||||
Premium receivables | |||||||||||
Other receivables | |||||||||||
Total accounts receivable, net (1) | $ | $ |
In millions | Health Care Benefits | Pharmacy Services | Retail/ LTC | Corporate/ Other | Intersegment Eliminations | Consolidated Totals | |||||||||||||||||||||||||||||
Three Months Ended September 30, 2022 | |||||||||||||||||||||||||||||||||||
Major goods/services lines: | |||||||||||||||||||||||||||||||||||
Pharmacy | $ | $ | $ | $ | $ | ( | $ | ||||||||||||||||||||||||||||
Front Store | |||||||||||||||||||||||||||||||||||
Premiums | |||||||||||||||||||||||||||||||||||
Net investment income (loss) | ( | ||||||||||||||||||||||||||||||||||
Other | ( | ||||||||||||||||||||||||||||||||||
Total | $ | $ | $ | $ | $ | ( | $ | ||||||||||||||||||||||||||||
Pharmacy Services distribution channel: | |||||||||||||||||||||||||||||||||||
Pharmacy network (1) | $ | ||||||||||||||||||||||||||||||||||
Mail choice (2) | |||||||||||||||||||||||||||||||||||
Other | |||||||||||||||||||||||||||||||||||
Total | $ | ||||||||||||||||||||||||||||||||||
Three Months Ended September 30, 2021 | |||||||||||||||||||||||||||||||||||
Major goods/services lines: | |||||||||||||||||||||||||||||||||||
Pharmacy | $ | $ | $ | $ | $ | ( | $ | ||||||||||||||||||||||||||||
Front Store | |||||||||||||||||||||||||||||||||||
Premiums | |||||||||||||||||||||||||||||||||||
Net investment income (loss) | ( | ||||||||||||||||||||||||||||||||||
Other | ( | ||||||||||||||||||||||||||||||||||
Total | $ | $ | $ | $ | $ | ( | $ | ||||||||||||||||||||||||||||
Pharmacy Services distribution channel: | |||||||||||||||||||||||||||||||||||
Pharmacy network (1) | $ | ||||||||||||||||||||||||||||||||||
Mail choice (2) | |||||||||||||||||||||||||||||||||||
Other | |||||||||||||||||||||||||||||||||||
Total | $ |
In millions | Health Care Benefits | Pharmacy Services | Retail/ LTC | Corporate/ Other | Intersegment Eliminations | Consolidated Totals | |||||||||||||||||||||||||||||
Nine Months Ended September 30, 2022 | |||||||||||||||||||||||||||||||||||
Major goods/services lines: | |||||||||||||||||||||||||||||||||||
Pharmacy | $ | $ | $ | $ | $ | ( | $ | ||||||||||||||||||||||||||||
Front Store | |||||||||||||||||||||||||||||||||||
Premiums | |||||||||||||||||||||||||||||||||||
Net investment income (loss) | ( | ||||||||||||||||||||||||||||||||||
Other | ( | ||||||||||||||||||||||||||||||||||
Total | $ | $ | $ | $ | $ | ( | $ | ||||||||||||||||||||||||||||
Pharmacy Services distribution channel: | |||||||||||||||||||||||||||||||||||
Pharmacy network (1) | $ | ||||||||||||||||||||||||||||||||||
Mail choice (2) | |||||||||||||||||||||||||||||||||||
Other | |||||||||||||||||||||||||||||||||||
Total | $ | ||||||||||||||||||||||||||||||||||
Nine Months Ended September 30, 2021 | |||||||||||||||||||||||||||||||||||
Major goods/services lines: | |||||||||||||||||||||||||||||||||||
Pharmacy | $ | $ | $ | $ | $ | ( | $ | ||||||||||||||||||||||||||||
Front Store | |||||||||||||||||||||||||||||||||||
Premiums | |||||||||||||||||||||||||||||||||||
Net investment income | |||||||||||||||||||||||||||||||||||
Other | ( | ||||||||||||||||||||||||||||||||||
Total | $ | $ | $ | $ | $ | ( | $ | ||||||||||||||||||||||||||||
Pharmacy Services distribution channel: | |||||||||||||||||||||||||||||||||||
Pharmacy network (1) | $ | ||||||||||||||||||||||||||||||||||
Mail choice (2) | |||||||||||||||||||||||||||||||||||
Other | |||||||||||||||||||||||||||||||||||
Total | $ |
In millions | September 30, 2022 | December 31, 2021 | |||||||||
Trade receivables (included in accounts receivable, net) | $ | $ | |||||||||
Contract liabilities (included in accrued expenses) |
Nine Months Ended September 30, | |||||||||||
In millions | 2022 | 2021 | |||||||||
Contract liabilities, beginning of the period | $ | $ | |||||||||
Rewards earnings and gift card issuances | |||||||||||
Redemption and breakage | ( | ( | |||||||||
Contract liabilities, end of the period | $ | $ |
In millions | September 30, 2022 | ||||
Assets: | |||||
Accounts receivable, net | $ | ||||
Inventories | |||||
Property and equipment, net | |||||
Goodwill (1) | |||||
Deferred income taxes | |||||
Other | |||||
Total assets held for sale | $ | ||||
Liabilities: | |||||
Accounts payable | $ | ||||
Accrued expenses | |||||
Other | |||||
Total liabilities held for sale | $ |
September 30, 2022 | December 31, 2021 | ||||||||||||||||||||||||||||||||||
In millions | Current | Long-term | Total | Current | Long-term | Total | |||||||||||||||||||||||||||||
Debt securities available for sale | $ | $ | $ | $ | $ | $ | |||||||||||||||||||||||||||||
Mortgage loans | |||||||||||||||||||||||||||||||||||
Other investments | |||||||||||||||||||||||||||||||||||
Total investments (1) | $ | $ | $ | $ | $ | $ |
In millions | Gross Amortized Cost | Allowance for Credit Losses | Net Amortized Cost | Gross Unrealized Gains | Gross Unrealized Losses | Fair Value | |||||||||||||||||||||||||||||
September 30, 2022 | |||||||||||||||||||||||||||||||||||
Debt securities: | |||||||||||||||||||||||||||||||||||
U.S. government securities | $ | $ | $ | $ | $ | ( | $ | ||||||||||||||||||||||||||||
States, municipalities and political subdivisions | ( | ||||||||||||||||||||||||||||||||||
U.S. corporate securities | ( | ||||||||||||||||||||||||||||||||||
Foreign securities | ( | ( | |||||||||||||||||||||||||||||||||
Residential mortgage-backed securities | ( | ||||||||||||||||||||||||||||||||||
Commercial mortgage-backed securities | ( | ||||||||||||||||||||||||||||||||||
Other asset-backed securities | ( | ||||||||||||||||||||||||||||||||||
Redeemable preferred securities | ( | ||||||||||||||||||||||||||||||||||
Total debt securities (1) | $ | $ | ( | $ | $ | $ | ( | $ | |||||||||||||||||||||||||||
December 31, 2021 | |||||||||||||||||||||||||||||||||||
Debt securities: | |||||||||||||||||||||||||||||||||||
U.S. government securities | $ | $ | $ | $ | $ | ( | $ | ||||||||||||||||||||||||||||
States, municipalities and political subdivisions | ( | ||||||||||||||||||||||||||||||||||
U.S. corporate securities | ( | ||||||||||||||||||||||||||||||||||
Foreign securities | ( | ||||||||||||||||||||||||||||||||||
Residential mortgage-backed securities | ( | ||||||||||||||||||||||||||||||||||
Commercial mortgage-backed securities | ( | ||||||||||||||||||||||||||||||||||
Other asset-backed securities | ( | ||||||||||||||||||||||||||||||||||
Redeemable preferred securities | |||||||||||||||||||||||||||||||||||
Total debt securities (1) | $ | $ | $ | $ | $ | ( | $ |
In millions | Net Amortized Cost | Fair Value | |||||||||
Due to mature: | |||||||||||
Less than one year | $ | $ | |||||||||
One year through five years | |||||||||||
After five years through ten years | |||||||||||
Greater than ten years | |||||||||||
Residential mortgage-backed securities | |||||||||||
Commercial mortgage-backed securities | |||||||||||
Other asset-backed securities | |||||||||||
Total | $ | $ |
Less than 12 months | Greater than 12 months | Total | |||||||||||||||||||||||||||||||||||||||||||||||||||
In millions, except number of securities | Number of Securities | Fair Value | Unrealized Losses | Number of Securities | Fair Value | Unrealized Losses | Number of Securities | Fair Value | Unrealized Losses | ||||||||||||||||||||||||||||||||||||||||||||
September 30, 2022 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt securities: | |||||||||||||||||||||||||||||||||||||||||||||||||||||
U.S. government securities | $ | $ | $ | $ | $ | $ | |||||||||||||||||||||||||||||||||||||||||||||||
States, municipalities and political subdivisions | |||||||||||||||||||||||||||||||||||||||||||||||||||||
U.S. corporate securities | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Foreign securities | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Residential mortgage-backed securities | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Commercial mortgage-backed securities | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Other asset-backed securities | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Redeemable preferred securities | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Total debt securities | $ | $ | $ | $ | $ | $ | |||||||||||||||||||||||||||||||||||||||||||||||
December 31, 2021 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt securities: | |||||||||||||||||||||||||||||||||||||||||||||||||||||
U.S. government securities | $ | $ | $ | $ | $ | $ | |||||||||||||||||||||||||||||||||||||||||||||||
States, municipalities and political subdivisions | |||||||||||||||||||||||||||||||||||||||||||||||||||||
U.S. corporate securities | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Foreign securities | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Residential mortgage-backed securities | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Commercial mortgage-backed securities | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Other asset-backed securities | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Redeemable preferred securities | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Total debt securities | $ | $ | $ | $ | $ | $ |
Supporting experience-rated products | Supporting remaining products | Total | |||||||||||||||||||||||||||||||||
In millions | Fair Value | Unrealized Losses | Fair Value | Unrealized Losses | Fair Value | Unrealized Losses | |||||||||||||||||||||||||||||
Due to mature: | |||||||||||||||||||||||||||||||||||
Less than one year | $ | $ | $ | $ | $ | $ | |||||||||||||||||||||||||||||
One year through five years | |||||||||||||||||||||||||||||||||||
After five years through ten years | |||||||||||||||||||||||||||||||||||
Greater than ten years | |||||||||||||||||||||||||||||||||||
Residential mortgage-backed securities | |||||||||||||||||||||||||||||||||||
Commercial mortgage-backed securities | |||||||||||||||||||||||||||||||||||
Other asset-backed securities | |||||||||||||||||||||||||||||||||||
Total | $ | $ | $ | $ | $ | $ |
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
In millions | 2022 | 2021 | 2022 | 2021 | |||||||||||||||||||
New mortgage loans | $ | $ | $ | $ | |||||||||||||||||||
Mortgage loans fully repaid | |||||||||||||||||||||||
Mortgage loans foreclosed |
Amortized Cost Basis by Year of Origination | |||||||||||||||||||||||||||||||||||||||||
In millions, except credit quality indicator | 2022 | 2021 | 2020 | 2019 | 2018 | Prior | Total | ||||||||||||||||||||||||||||||||||
September 30, 2022 | |||||||||||||||||||||||||||||||||||||||||
1 | $ | $ | $ | $ | $ | $ | $ | ||||||||||||||||||||||||||||||||||
2 to 4 | |||||||||||||||||||||||||||||||||||||||||
5 and 6 | |||||||||||||||||||||||||||||||||||||||||
7 | |||||||||||||||||||||||||||||||||||||||||
Total | $ | $ | $ | $ | $ | $ | $ | ||||||||||||||||||||||||||||||||||
December 31, 2021 | |||||||||||||||||||||||||||||||||||||||||
1 | $ | $ | $ | $ | $ | $ | |||||||||||||||||||||||||||||||||||
2 to 4 | |||||||||||||||||||||||||||||||||||||||||
5 and 6 | |||||||||||||||||||||||||||||||||||||||||
7 | |||||||||||||||||||||||||||||||||||||||||
Total | $ | $ | $ | $ | $ | $ |
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
In millions | 2022 | 2021 | 2022 | 2021 | |||||||||||||||||||
Debt securities | $ | $ | $ | $ | |||||||||||||||||||
Mortgage loans | |||||||||||||||||||||||
Other investments | |||||||||||||||||||||||
Gross investment income | |||||||||||||||||||||||
Investment expenses | ( | ( | ( | ( | |||||||||||||||||||
Net investment income (excluding net realized capital gains or losses) | |||||||||||||||||||||||
Net realized capital gains (losses) (1) | ( | ( | ( | ||||||||||||||||||||
Net investment income (2) | $ | $ | $ | $ |
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
In millions | 2022 | 2021 | 2022 | 2021 | |||||||||||||||||||
Proceeds from sales | $ | $ | $ | $ | |||||||||||||||||||
Gross realized capital gains | |||||||||||||||||||||||
Gross realized capital losses |
In millions | Level 1 | Level 2 | Level 3 | Total | |||||||||||||||||||
September 30, 2022 | |||||||||||||||||||||||
Cash and cash equivalents (1) | $ | $ | $ | $ | |||||||||||||||||||
Debt securities: | |||||||||||||||||||||||
U.S. government securities | |||||||||||||||||||||||
States, municipalities and political subdivisions | |||||||||||||||||||||||
U.S. corporate securities | |||||||||||||||||||||||
Foreign securities | |||||||||||||||||||||||
Residential mortgage-backed securities | |||||||||||||||||||||||
Commercial mortgage-backed securities | |||||||||||||||||||||||
Other asset-backed securities | |||||||||||||||||||||||
Redeemable preferred securities | |||||||||||||||||||||||
Total debt securities | |||||||||||||||||||||||
Equity securities | |||||||||||||||||||||||
Total | $ | $ | $ | $ | |||||||||||||||||||
December 31, 2021 | |||||||||||||||||||||||
Cash and cash equivalents | $ | $ | $ | $ | |||||||||||||||||||
Debt securities: | |||||||||||||||||||||||
U.S. government securities | |||||||||||||||||||||||
States, municipalities and political subdivisions | |||||||||||||||||||||||
U.S. corporate securities | |||||||||||||||||||||||
Foreign securities | |||||||||||||||||||||||
Residential mortgage-backed securities | |||||||||||||||||||||||
Commercial mortgage-backed securities | |||||||||||||||||||||||
Other asset-backed securities | |||||||||||||||||||||||
Redeemable preferred securities | |||||||||||||||||||||||
Total debt securities | |||||||||||||||||||||||
Equity securities | |||||||||||||||||||||||
Total | $ | $ | $ | $ |
Carrying Value | Estimated Fair Value | ||||||||||||||||||||||||||||
In millions | Level 1 | Level 2 | Level 3 | Total | |||||||||||||||||||||||||
September 30, 2022 | |||||||||||||||||||||||||||||
Assets: | |||||||||||||||||||||||||||||
Mortgage loans | $ | $ | $ | $ | $ | ||||||||||||||||||||||||
Equity securities (1) | N/A | N/A | N/A | N/A | |||||||||||||||||||||||||
Liabilities: | |||||||||||||||||||||||||||||
Investment contract liabilities: | |||||||||||||||||||||||||||||
With a fixed maturity | |||||||||||||||||||||||||||||
Without a fixed maturity | |||||||||||||||||||||||||||||
Long-term debt (2) | |||||||||||||||||||||||||||||
December 31, 2021 | |||||||||||||||||||||||||||||
Assets: | |||||||||||||||||||||||||||||
Mortgage loans | $ | $ | $ | $ | $ | ||||||||||||||||||||||||
Equity securities (1) | N/A | N/A | N/A | N/A | |||||||||||||||||||||||||
Liabilities: | |||||||||||||||||||||||||||||
Investment contract liabilities: | |||||||||||||||||||||||||||||
With a fixed maturity | |||||||||||||||||||||||||||||
Without a fixed maturity | |||||||||||||||||||||||||||||
Long-term debt |
September 30, 2022 | December 31, 2021 | ||||||||||||||||||||||||||||||||||||||||||||||
In millions | Level 1 | Level 2 | Level 3 | Total | Level 1 | Level 2 | Level 3 | Total | |||||||||||||||||||||||||||||||||||||||
Cash and cash equivalents | $ | $ | $ | $ | $ | $ | $ | $ | |||||||||||||||||||||||||||||||||||||||
Debt securities | |||||||||||||||||||||||||||||||||||||||||||||||
Equity securities | |||||||||||||||||||||||||||||||||||||||||||||||
Common/collective trusts | |||||||||||||||||||||||||||||||||||||||||||||||
Total (1) | $ | $ | $ | $ | $ | $ | $ | $ |
Nine Months Ended September 30, | |||||||||||
In millions | 2022 | 2021 | |||||||||
Health care costs payable, beginning of the period | $ | $ | |||||||||
Less: Reinsurance recoverables | |||||||||||
Health care costs payable, beginning of the period, net | |||||||||||
Add: Components of incurred health care costs | |||||||||||
Current year | |||||||||||
Prior years | ( | ( | |||||||||
Total incurred health care costs (1) | |||||||||||
Less: Claims paid | |||||||||||
Current year | |||||||||||
Prior years | |||||||||||
Total claims paid | |||||||||||
Add: Premium deficiency reserve | |||||||||||
Health care costs payable, end of the period, net | |||||||||||
Add: Reinsurance recoverables | |||||||||||
Health care costs payable, end of the period | $ | $ |
In millions | September 30, 2022 | December 31, 2021 | |||||||||
Long-term debt | |||||||||||
$ | $ | ||||||||||
Other | |||||||||||
Total debt principal | |||||||||||
Debt premiums | |||||||||||
Debt discounts and deferred financing costs | ( | ( | |||||||||
Less: | |||||||||||
Current portion of long-term debt | ( | ( | |||||||||
Long-term debt | $ | $ |
In billions Authorization Date | Authorized | Remaining as of September 30, 2022 | |||||||||
December 9, 2021 (“2021 Repurchase Program”) | $ | $ |
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
In millions | 2022 | 2021 | 2022 | 2021 | |||||||||||||||||||
Net unrealized investment gains (losses): | |||||||||||||||||||||||
Beginning of period balance | $ | ( | $ | $ | $ | ||||||||||||||||||
Other comprehensive loss before reclassifications ($( | ( | ( | ( | ( | |||||||||||||||||||
Amounts reclassified from accumulated other comprehensive income (loss) ($ | ( | ( | |||||||||||||||||||||
Other comprehensive loss | ( | ( | ( | ( | |||||||||||||||||||
End of period balance | ( | ( | |||||||||||||||||||||
Foreign currency translation adjustments: | |||||||||||||||||||||||
Beginning of period balance | |||||||||||||||||||||||
Other comprehensive loss before reclassifications | ( | ( | ( | ( | |||||||||||||||||||
Other comprehensive loss | ( | ( | ( | ( | |||||||||||||||||||
End of period balance | ( | ( | |||||||||||||||||||||
Net cash flow hedges: | |||||||||||||||||||||||
Beginning of period balance | |||||||||||||||||||||||
Other comprehensive income before reclassifications ($ | |||||||||||||||||||||||
Amounts reclassified from accumulated other comprehensive income ($( | ( | ( | ( | ( | |||||||||||||||||||
Other comprehensive income (loss) | ( | ( | |||||||||||||||||||||
End of period balance | |||||||||||||||||||||||
Pension and other postretirement benefits: | |||||||||||||||||||||||
Beginning of period balance | ( | ( | ( | ( | |||||||||||||||||||
Amounts reclassified from accumulated other comprehensive loss ($ | |||||||||||||||||||||||
Other comprehensive income | |||||||||||||||||||||||
End of period balance | ( | ( | ( | ( | |||||||||||||||||||
Total beginning of period accumulated other comprehensive income (loss) | ( | ||||||||||||||||||||||
Total other comprehensive loss | ( | ( | ( | ( | |||||||||||||||||||
Total end of period accumulated other comprehensive income (loss) | $ | ( | $ | $ | ( | $ |
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
In millions, except per share amounts | 2022 | 2021 | 2022 | 2021 | |||||||||||||||||||
Numerator for earnings (loss) per share calculation: | |||||||||||||||||||||||
Net income (loss) attributable to CVS Health | $ | ( | $ | $ | $ | ||||||||||||||||||
Denominator for earnings (loss) per share calculation: | |||||||||||||||||||||||
Weighted average shares, basic | |||||||||||||||||||||||
Restricted stock units and performance stock units | |||||||||||||||||||||||
Stock options and stock appreciation rights | |||||||||||||||||||||||
Weighted average shares, diluted | |||||||||||||||||||||||
Earnings (loss) per share: | |||||||||||||||||||||||
Basic | $ | ( | $ | $ | $ | ||||||||||||||||||
Diluted | $ | ( | $ | $ | $ |
In millions | Health Care Benefits | Pharmacy Services (1) | Retail/ LTC | Corporate/ Other | Intersegment Eliminations (2) | Consolidated Totals | |||||||||||||||||||||||||||||
Three Months Ended | |||||||||||||||||||||||||||||||||||
September 30, 2022 | |||||||||||||||||||||||||||||||||||
Revenues from external customers | $ | $ | $ | $ | $ | — | $ | ||||||||||||||||||||||||||||
Intersegment revenues | — | ( | — | ||||||||||||||||||||||||||||||||
Net investment income (loss) | ( | ||||||||||||||||||||||||||||||||||
Total revenues | ( | ||||||||||||||||||||||||||||||||||
Adjusted operating income (loss) | ( | ( | |||||||||||||||||||||||||||||||||
September 30, 2021 | |||||||||||||||||||||||||||||||||||
Revenues from external customers | $ | $ | $ | $ | $ | — | $ | ||||||||||||||||||||||||||||
Intersegment revenues | — | ( | — | ||||||||||||||||||||||||||||||||
Net investment income (loss) | ( | ||||||||||||||||||||||||||||||||||
Total revenues | ( | ||||||||||||||||||||||||||||||||||
Adjusted operating income (loss) | ( | ( | |||||||||||||||||||||||||||||||||
Nine Months Ended | |||||||||||||||||||||||||||||||||||
September 30, 2022 | |||||||||||||||||||||||||||||||||||
Revenues from external customers | $ | $ | $ | $ | $ | — | $ | ||||||||||||||||||||||||||||
Intersegment revenues | — | ( | — | ||||||||||||||||||||||||||||||||
Net investment income (loss) | ( | ||||||||||||||||||||||||||||||||||
Total revenues | ( | ||||||||||||||||||||||||||||||||||
Adjusted operating income (loss) | ( | ( | |||||||||||||||||||||||||||||||||
September 30, 2021 | |||||||||||||||||||||||||||||||||||
Revenues from external customers | $ | $ | $ | $ | $ | — | $ | ||||||||||||||||||||||||||||
Intersegment revenues | — | ( | — | ||||||||||||||||||||||||||||||||
Net investment income | |||||||||||||||||||||||||||||||||||
Total revenues | ( | ||||||||||||||||||||||||||||||||||
Adjusted operating income (loss) | ( | ( |
Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
In millions | 2022 | 2021 | 2022 | 2021 | |||||||||||||||||||
Operating income (loss) (GAAP measure) | $ | ( | $ | $ | $ | ||||||||||||||||||
Amortization of intangible assets (1) | |||||||||||||||||||||||
Opioid litigation charges (2) | |||||||||||||||||||||||
Loss on assets held for sale (3) | |||||||||||||||||||||||
Gain on divestiture of subsidiary (4) | ( | ||||||||||||||||||||||
Acquisition-related integration costs (5) | |||||||||||||||||||||||
Goodwill impairment (6) | |||||||||||||||||||||||
Acquisition purchase price adjustment outside of measurement period (7) | ( | ||||||||||||||||||||||
Adjusted operating income | $ | $ | $ | $ |
Change | |||||||||||||||||||||||||||||||||||||||||||||||
Three Months Ended September 30, | Nine Months Ended September 30, | Three Months Ended September 30, 2022 vs 2021 | Nine Months Ended September 30, 2022 vs 2021 | ||||||||||||||||||||||||||||||||||||||||||||
In millions | 2022 | 2021 | 2022 | 2021 | $ | % | $ | % | |||||||||||||||||||||||||||||||||||||||
Revenues: | |||||||||||||||||||||||||||||||||||||||||||||||
Products | $ | 57,643 | $ | 51,853 | $ | 166,959 | $ | 149,765 | $ | 5,790 | 11.2 | % | $ | 17,194 | 11.5 | % | |||||||||||||||||||||||||||||||
Premiums | 21,003 | 18,984 | 63,894 | 56,927 | 2,019 | 10.6 | % | 6,967 | 12.2 | % | |||||||||||||||||||||||||||||||||||||
Services | 2,312 | 2,711 | 7,253 | 7,983 | (399) | (14.7) | % | (730) | (9.1) | % | |||||||||||||||||||||||||||||||||||||
Net investment income | 201 | 246 | 515 | 832 | (45) | (18.3) | % | (317) | (38.1) | % | |||||||||||||||||||||||||||||||||||||
Total revenues | 81,159 | 73,794 | 238,621 | 215,507 | 7,365 | 10.0 | % | 23,114 | 10.7 | % | |||||||||||||||||||||||||||||||||||||
Operating costs: | |||||||||||||||||||||||||||||||||||||||||||||||
Cost of products sold | 50,365 | 45,011 | 145,164 | 129,425 | 5,354 | 11.9 | % | 15,739 | 12.2 | % | |||||||||||||||||||||||||||||||||||||
Benefit costs | 17,419 | 16,081 | 52,976 | 47,686 | 1,338 | 8.3 | % | 5,290 | 11.1 | % | |||||||||||||||||||||||||||||||||||||
Opioid litigation charges | 5,220 | — | 5,704 | — | 5,220 | 100.0 | % | 5,704 | 100.0 | % | |||||||||||||||||||||||||||||||||||||
Loss on assets held for sale | 2,480 | — | 2,521 | — | 2,480 | 100.0 | % | 2,521 | 100.0 | % | |||||||||||||||||||||||||||||||||||||
Goodwill impairment | — | 431 | — | 431 | (431) | (100.0) | % | (431) | (100.0) | % | |||||||||||||||||||||||||||||||||||||
Operating expenses | 9,606 | 9,210 | 28,128 | 27,001 | 396 | 4.3 | % | 1,127 | 4.2 | % | |||||||||||||||||||||||||||||||||||||
Total operating costs | 85,090 | 70,733 | 234,493 | 204,543 | 14,357 | 20.3 | % | 29,950 | 14.6 | % | |||||||||||||||||||||||||||||||||||||
Operating income (loss) | (3,931) | 3,061 | 4,128 | 10,964 | (6,992) | (228.4) | % | (6,836) | (62.3) | % | |||||||||||||||||||||||||||||||||||||
Interest expense | 566 | 602 | 1,735 | 1,895 | (36) | (6.0) | % | (160) | (8.4) | % | |||||||||||||||||||||||||||||||||||||
Loss on early extinguishment of debt | — | 363 | — | 363 | (363) | (100.0) | % | (363) | (100.0) | % | |||||||||||||||||||||||||||||||||||||
Other income | (41) | (49) | (126) | (144) | 8 | 16.3 | % | 18 | 12.5 | % | |||||||||||||||||||||||||||||||||||||
Income (loss) before income tax provision | (4,456) | 2,145 | 2,519 | 8,850 | (6,601) | (307.7) | % | (6,331) | (71.5) | % | |||||||||||||||||||||||||||||||||||||
Income tax provision (benefit) | (1,047) | 558 | 654 | 2,248 | (1,605) | (287.6) | % | (1,594) | (70.9) | % | |||||||||||||||||||||||||||||||||||||
Net income (loss) | (3,409) | 1,587 | 1,865 | 6,602 | (4,996) | (314.8) | % | (4,737) | (71.8) | % | |||||||||||||||||||||||||||||||||||||
Net (income) loss attributable to noncontrolling interests | (7) | 11 | (18) | 2 | (18) | (163.6) | % | (20) | (1000.0) | % | |||||||||||||||||||||||||||||||||||||
Net income (loss) attributable to CVS Health | $ | (3,416) | $ | 1,598 | $ | 1,847 | $ | 6,604 | $ | (5,014) | (313.8) | % | $ | (4,757) | (72.0) | % |
In millions | Health Care Benefits | Pharmacy Services (1) | Retail/ LTC | Corporate/ Other | Intersegment Eliminations (2) | Consolidated Totals | |||||||||||||||||||||||||||||
Three Months Ended | |||||||||||||||||||||||||||||||||||
September 30, 2022 | |||||||||||||||||||||||||||||||||||
Total revenues | $ | 22,511 | $ | 43,216 | $ | 26,706 | $ | 142 | $ | (11,416) | $ | 81,159 | |||||||||||||||||||||||
Adjusted operating income (loss) | 1,544 | 1,877 | 1,398 | (417) | (169) | 4,233 | |||||||||||||||||||||||||||||
September 30, 2021 | |||||||||||||||||||||||||||||||||||
Total revenues | 20,479 | 39,046 | 24,992 | 171 | (10,894) | 73,794 | |||||||||||||||||||||||||||||
Adjusted operating income (loss) | 1,106 | 1,773 | 1,723 | (343) | (186) | 4,073 | |||||||||||||||||||||||||||||
Nine Months Ended | |||||||||||||||||||||||||||||||||||
September 30, 2022 | |||||||||||||||||||||||||||||||||||
Total revenues | $ | 68,376 | $ | 125,489 | $ | 78,410 | $ | 378 | $ | (34,032) | $ | 238,621 | |||||||||||||||||||||||
Adjusted operating income (loss) | 5,126 | 5,368 | 4,865 | (1,277) | (556) | 13,526 | |||||||||||||||||||||||||||||
September 30, 2021 | |||||||||||||||||||||||||||||||||||
Total revenues | 61,487 | 113,681 | 72,994 | 488 | (33,143) | 215,507 | |||||||||||||||||||||||||||||
Adjusted operating income (loss) | 4,502 | 5,035 | 5,166 | (1,015) | (523) | 13,165 |
Three Months Ended September 30, 2022 | |||||||||||||||||||||||||||||||||||
In millions | Health Care Benefits | Pharmacy Services | Retail/ LTC | Corporate/ Other | Intersegment Eliminations | Consolidated Totals | |||||||||||||||||||||||||||||
Operating income (loss) (GAAP measure) | $ | 1,244 | $ | 1,836 | $ | (1,205) | $ | (5,637) | $ | (169) | $ | (3,931) | |||||||||||||||||||||||
Amortization of intangible assets (1) | 300 | 41 | 123 | — | — | 464 | |||||||||||||||||||||||||||||
Opioid litigation charges (2) | — | — | — | 5,220 | — | 5,220 | |||||||||||||||||||||||||||||
Loss on assets held for sale (3) | — | — | 2,480 | — | — | 2,480 | |||||||||||||||||||||||||||||
Adjusted operating income (loss) | $ | 1,544 | $ | 1,877 | $ | 1,398 | $ | (417) | $ | (169) | $ | 4,233 |
Three Months Ended September 30, 2021 | |||||||||||||||||||||||||||||||||||
In millions | Health Care Benefits | Pharmacy Services | Retail/ LTC | Corporate/ Other | Intersegment Eliminations | Consolidated Totals | |||||||||||||||||||||||||||||
Operating income (loss) (GAAP measure) | $ | 716 | $ | 1,730 | $ | 1,165 | $ | (364) | $ | (186) | $ | 3,061 | |||||||||||||||||||||||
Amortization of intangible assets (1) | 390 | 43 | 127 | 1 | — | 561 | |||||||||||||||||||||||||||||
Acquisition-related integration costs (4) | — | — | — | 20 | — | 20 | |||||||||||||||||||||||||||||
Goodwill impairment (5) | — | — | 431 | — | — | 431 | |||||||||||||||||||||||||||||
Adjusted operating income (loss) | $ | 1,106 | $ | 1,773 | $ | 1,723 | $ | (343) | $ | (186) | $ | 4,073 |
Nine Months Ended September 30, 2022 | |||||||||||||||||||||||||||||||||||
In millions | Health Care Benefits | Pharmacy Services | Retail/ LTC | Corporate/ Other | Intersegment Eliminations | Consolidated Totals | |||||||||||||||||||||||||||||
Operating income (loss) (GAAP measure) | $ | 4,407 | $ | 5,242 | $ | 2,018 | $ | (6,983) | $ | (556) | $ | 4,128 | |||||||||||||||||||||||
Amortization of intangible assets (1) | 903 | 126 | 367 | 2 | — | 1,398 | |||||||||||||||||||||||||||||
Opioid litigation charges (2) | — | — | — | 5,704 | — | 5,704 | |||||||||||||||||||||||||||||
Loss on assets held for sale (3) | 41 | — | 2,480 | — | — | 2,521 | |||||||||||||||||||||||||||||
Gain on divestiture of subsidiary (6) | (225) | — | — | — | — | (225) | |||||||||||||||||||||||||||||
Adjusted operating income (loss) | $ | 5,126 | $ | 5,368 | $ | 4,865 | $ | (1,277) | $ | (556) | $ | 13,526 |
Nine Months Ended September 30, 2021 | |||||||||||||||||||||||||||||||||||
In millions | Health Care Benefits | Pharmacy Services | Retail/ LTC | Corporate/ Other | Intersegment Eliminations | Consolidated Totals | |||||||||||||||||||||||||||||
Operating income (loss) (GAAP measure) | $ | 3,369 | $ | 4,887 | $ | 4,349 | $ | (1,118) | $ | (523) | $ | 10,964 | |||||||||||||||||||||||
Amortization of intangible assets (1) | 1,194 | 148 | 386 | 2 | — | 1,730 | |||||||||||||||||||||||||||||
Acquisition-related integration costs (4) | — | — | — | 101 | — | 101 | |||||||||||||||||||||||||||||
Goodwill impairment (5) | — | — | 431 | — | — | 431 | |||||||||||||||||||||||||||||
Acquisition purchase price adjustment outside of measurement period (7) | (61) | — | — | — | — | (61) | |||||||||||||||||||||||||||||
Adjusted operating income (loss) | $ | 4,502 | $ | 5,035 | $ | 5,166 | $ | (1,015) | $ | (523) | $ | 13,165 |
Change | |||||||||||||||||||||||||||||||||||||||||||||||
Three Months Ended September 30, | Nine Months Ended September 30, | Three Months Ended September 30, 2022 vs 2021 | Nine Months Ended September 30, 2022 vs 2021 | ||||||||||||||||||||||||||||||||||||||||||||
In millions, except percentages and basis points (“bps”) | 2022 | 2021 | 2022 | 2021 | $ | % | $ | % | |||||||||||||||||||||||||||||||||||||||
Revenues: | |||||||||||||||||||||||||||||||||||||||||||||||
Premiums | $ | 20,989 | $ | 18,959 | $ | 63,848 | $ | 56,869 | $ | 2,030 | 10.7 | % | $ | 6,979 | 12.3 | % | |||||||||||||||||||||||||||||||
Services | 1,421 | 1,373 | 4,250 | 4,186 | 48 | 3.5 | % | 64 | 1.5 | % | |||||||||||||||||||||||||||||||||||||
Net investment income | 101 | 147 | 278 | 432 | (46) | (31.3) | % | (154) | (35.6) | % | |||||||||||||||||||||||||||||||||||||
Total revenues | 22,511 | 20,479 | 68,376 | 61,487 | 2,032 | 9.9 | % | 6,889 | 11.2 | % | |||||||||||||||||||||||||||||||||||||
Benefit costs | 17,531 | 16,260 | 53,191 | 47,971 | 1,271 | 7.8 | % | 5,220 | 10.9 | % | |||||||||||||||||||||||||||||||||||||
MBR | 83.5 | % | 85.8 | % | 83.3 | % | 84.4 | % | (230) | bps | (110) | bps | |||||||||||||||||||||||||||||||||||
Loss on assets held for sale | $ | — | $ | — | $ | 41 | $ | — | $ | — | — | % | $ | 41 | 100.0 | % | |||||||||||||||||||||||||||||||
Operating expenses | 3,736 | 3,503 | 10,737 | 10,147 | 233 | 6.7 | % | 590 | 5.8 | % | |||||||||||||||||||||||||||||||||||||
Operating expenses as a % of total revenues | 16.6 | % | 17.1 | % | 15.7 | % | 16.5 | % | |||||||||||||||||||||||||||||||||||||||
Operating income | $ | 1,244 | $ | 716 | $ | 4,407 | $ | 3,369 | $ | 528 | 73.7 | % | $ | 1,038 | 30.8 | % | |||||||||||||||||||||||||||||||
Operating income as a % of total revenues | 5.5 | % | 3.5 | % | 6.4 | % | 5.5 | % | |||||||||||||||||||||||||||||||||||||||
Adjusted operating income (1) | $ | 1,544 | $ | 1,106 | $ | 5,126 | $ | 4,502 | $ | 438 | 39.6 | % | $ | 624 | 13.9 | % | |||||||||||||||||||||||||||||||
Adjusted operating income as a % of total revenues | 6.9 | % | 5.4 | % | 7.5 | % | 7.3 | % | |||||||||||||||||||||||||||||||||||||||
Premium revenues (by business): | |||||||||||||||||||||||||||||||||||||||||||||||
Government | $ | 15,433 | $ | 13,903 | $ | 47,379 | $ | 41,717 | $ | 1,530 | 11.0 | % | $ | 5,662 | 13.6 | % | |||||||||||||||||||||||||||||||
Commercial | 5,556 | 5,056 | 16,469 | 15,152 | 500 | 9.9 | % | 1,317 | 8.7 | % |
September 30, 2022 | June 30, 2022 | December 31, 2021 | September 30, 2021 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In thousands | Insured | ASC | Total | Insured | ASC | Total | Insured | ASC | Total | Insured | ASC | Total | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical membership: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Commercial | 3,159 | 13,852 | 17,011 | 3,158 | 13,835 | 16,993 | 3,258 | 13,530 | 16,788 | 3,224 | 13,529 | 16,753 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medicare Advantage | 3,260 | — | 3,260 | 3,216 | — | 3,216 | 2,971 | — | 2,971 | 2,953 | — | 2,953 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medicare Supplement | 1,345 | — | 1,345 | 1,314 | — | 1,314 | 1,285 | — | 1,285 | 1,242 | — | 1,242 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medicaid | 2,181 | 490 | 2,671 | 2,425 | 484 | 2,909 | 2,333 | 471 | 2,804 | 2,289 | 460 | 2,749 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total medical membership | 9,945 | 14,342 | 24,287 | 10,113 | 14,319 | 24,432 | 9,847 | 14,001 | 23,848 | 9,708 | 13,989 | 23,697 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Supplemental membership information: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medicare Prescription Drug Plan (stand-alone) | 6,090 | 6,051 | 5,777 | 5,740 |
Change | |||||||||||||||||||||||||||||||||||||||||||||||
Three Months Ended September 30, | Nine Months Ended September 30, | Three Months Ended September 30, 2022 vs 2021 | Nine Months Ended September 30, 2022 vs 2021 | ||||||||||||||||||||||||||||||||||||||||||||
In millions, except percentages | 2022 | 2021 | 2022 | 2021 | $ | % | $ | % | |||||||||||||||||||||||||||||||||||||||
Revenues: | |||||||||||||||||||||||||||||||||||||||||||||||
Products | $ | 42,905 | $ | 38,739 | $ | 124,623 | $ | 112,816 | $ | 4,166 | 10.8 | % | $ | 11,807 | 10.5 | % | |||||||||||||||||||||||||||||||
Services | 311 | 307 | 866 | 865 | 4 | 1.3 | % | 1 | 0.1 | % | |||||||||||||||||||||||||||||||||||||
Total revenues | 43,216 | 39,046 | 125,489 | 113,681 | 4,170 | 10.7 | % | 11,808 | 10.4 | % | |||||||||||||||||||||||||||||||||||||
Cost of products sold | 40,998 | 36,925 | 119,028 | 107,714 | 4,073 | 11.0 | % | 11,314 | 10.5 | % | |||||||||||||||||||||||||||||||||||||
Operating expenses | 382 | 391 | 1,219 | 1,080 | (9) | (2.3) | % | 139 | 12.9 | % | |||||||||||||||||||||||||||||||||||||
Operating expenses as a % of total revenues | 0.9 | % | 1.0 | % | 1.0 | % | 1.0 | % | |||||||||||||||||||||||||||||||||||||||
Operating income | $ | 1,836 | $ | 1,730 | $ | 5,242 | $ | 4,887 | $ | 106 | 6.1 | % | $ | 355 | 7.3 | % | |||||||||||||||||||||||||||||||
Operating income as a % of total revenues | 4.2 | % | 4.4 | % | 4.2 | % | 4.3 | % | |||||||||||||||||||||||||||||||||||||||
Adjusted operating income (1) | $ | 1,877 | $ | 1,773 | $ | 5,368 | $ | 5,035 | $ | 104 | 5.9 | % | $ | 333 | 6.6 | % | |||||||||||||||||||||||||||||||
Adjusted operating income as a % of total revenues | 4.3 | % | 4.5 | % | 4.3 | % | 4.4 | % | |||||||||||||||||||||||||||||||||||||||
Revenues (by distribution channel): | |||||||||||||||||||||||||||||||||||||||||||||||
Pharmacy network (2) | $ | 25,012 | $ | 23,665 | $ | 72,373 | $ | 68,476 | $ | 1,347 | 5.7 | % | $ | 3,897 | 5.7 | % | |||||||||||||||||||||||||||||||
Mail choice (3) | 17,935 | 15,202 | 52,339 | 44,685 | 2,733 | 18.0 | % | 7,654 | 17.1 | % | |||||||||||||||||||||||||||||||||||||
Other | 269 | 179 | 777 | 520 | 90 | 50.3 | % | 257 | 49.4 | % | |||||||||||||||||||||||||||||||||||||
Pharmacy claims processed: (4) | |||||||||||||||||||||||||||||||||||||||||||||||
Total | 584.9 | 564.4 | 1,736.2 | 1,662.5 | 20.5 | 3.6 | % | 73.7 | 4.4 | % | |||||||||||||||||||||||||||||||||||||
Pharmacy network (2) | 502.3 | 481.1 | 1,485.7 | 1,415.8 | 21.2 | 4.4 | % | 69.9 | 4.9 | % | |||||||||||||||||||||||||||||||||||||
Mail choice (3) | 82.6 | 83.3 | 250.5 | 246.7 | (0.7) | (0.8) | % | 3.8 | 1.5 | % | |||||||||||||||||||||||||||||||||||||
Generic dispensing rate: (4) | |||||||||||||||||||||||||||||||||||||||||||||||
Total | 87.5 | % | 87.1 | % | 87.7 | % | 87.3 | % | |||||||||||||||||||||||||||||||||||||||
Pharmacy network (2) | 87.8 | % | 87.4 | % | 88.1 | % | 87.6 | % | |||||||||||||||||||||||||||||||||||||||
Mail choice (3) | 85.4 | % | 85.5 | % | 85.5 | % | 85.6 | % |
Change | |||||||||||||||||||||||||||||||||||||||||||||||
Three Months Ended September 30, | Nine Months Ended September 30, | Three Months Ended September 30, 2022 vs 2021 | Nine Months Ended September 30, 2022 vs 2021 | ||||||||||||||||||||||||||||||||||||||||||||
In millions, except percentages | 2022 | 2021 | 2022 | 2021 | $ | % | $ | % | |||||||||||||||||||||||||||||||||||||||
Revenues: | |||||||||||||||||||||||||||||||||||||||||||||||
Products | $ | 26,115 | $ | 23,971 | $ | 76,248 | $ | 69,974 | $ | 2,144 | 8.9 | % | $ | 6,274 | 9.0 | % | |||||||||||||||||||||||||||||||
Services | 601 | 1,054 | 2,206 | 3,007 | (453) | (43.0) | % | (801) | (26.6) | % | |||||||||||||||||||||||||||||||||||||
Net investment income (loss) | (10) | (33) | (44) | 13 | 23 | 69.7 | % | (57) | (438.5) | % | |||||||||||||||||||||||||||||||||||||
Total revenues | 26,706 | 24,992 | 78,410 | 72,994 | 1,714 | 6.9 | % | 5,416 | 7.4 | % | |||||||||||||||||||||||||||||||||||||
Cost of products sold | 20,272 | 18,381 | 58,591 | 53,375 | 1,891 | 10.3 | % | 5,216 | 9.8 | % | |||||||||||||||||||||||||||||||||||||
Loss on assets held for sale | 2,480 | — | 2,480 | — | 2,480 | 100.0 | % | 2,480 | 100.0 | % | |||||||||||||||||||||||||||||||||||||
Goodwill impairment | — | 431 | — | 431 | (431) | (100.0) | % | (431) | (100.0) | % | |||||||||||||||||||||||||||||||||||||
Operating expenses | 5,159 | 5,015 | 15,321 | 14,839 | 144 | 2.9 | % | 482 | 3.2 | % | |||||||||||||||||||||||||||||||||||||
Operating expenses as a % of total revenues | 19.3 | % | 20.1 | % | 19.5 | % | 20.3 | % | |||||||||||||||||||||||||||||||||||||||
Operating income (loss) | $ | (1,205) | $ | 1,165 | $ | 2,018 | $ | 4,349 | $ | (2,370) | (203.4) | % | $ | (2,331) | (53.6) | % | |||||||||||||||||||||||||||||||
Operating income (loss) as a % of total revenues | (4.5) | % | 4.7 | % | 2.6 | % | 6.0 | % | |||||||||||||||||||||||||||||||||||||||
Adjusted operating income (1) | $ | 1,398 | $ | 1,723 | $ | 4,865 | $ | 5,166 | $ | (325) | (18.9) | % | $ | (301) | (5.8) | % | |||||||||||||||||||||||||||||||
Adjusted operating income as a % of total revenues | 5.2 | % | 6.9 | % | 6.2 | % | 7.1 | % | |||||||||||||||||||||||||||||||||||||||
Revenues (by major goods/service lines): | |||||||||||||||||||||||||||||||||||||||||||||||
Pharmacy | $ | 20,759 | $ | 19,023 | $ | 60,308 | $ | 55,781 | $ | 1,736 | 9.1 | % | $ | 4,527 | 8.1 | % | |||||||||||||||||||||||||||||||
Front Store | 5,581 | 5,359 | 16,630 | 15,255 | 222 | 4.1 | % | 1,375 | 9.0 | % | |||||||||||||||||||||||||||||||||||||
Other | 376 | 643 | 1,516 | 1,945 | (267) | (41.5) | % | (429) | (22.1) | % | |||||||||||||||||||||||||||||||||||||
Net investment income (loss) | (10) | (33) | (44) | 13 | 23 | 69.7 | % | (57) | (438.5) | % | |||||||||||||||||||||||||||||||||||||
Prescriptions filled (2) | 405.3 | 398.0 | 1,200.7 | 1,167.8 | 7.3 | 1.8 | % | 32.9 | 2.8 | % | |||||||||||||||||||||||||||||||||||||
Same store sales increase: (3) | |||||||||||||||||||||||||||||||||||||||||||||||
Total | 9.9 | % | 9.6 | % | 9.5 | % | 7.3 | % | |||||||||||||||||||||||||||||||||||||||
Pharmacy | 11.3 | % | 8.8 | % | 9.7 | % | 8.4 | % | |||||||||||||||||||||||||||||||||||||||
Front Store | 5.1 | % | 12.3 | % | 9.0 | % | 3.7 | % | |||||||||||||||||||||||||||||||||||||||
Prescription volume (2) | 3.8 | % | 9.0 | % | 4.3 | % | 8.1 | % | |||||||||||||||||||||||||||||||||||||||
Generic dispensing rate (2) | 88.0 | % | 86.6 | % | 88.0 | % | 86.6 | % |
Change | |||||||||||||||||||||||||||||||||||||||||||||||
Three Months Ended September 30, | Nine Months Ended September 30, | Three Months Ended September 30, 2022 vs 2021 | Nine Months Ended September 30, 2022 vs 2021 | ||||||||||||||||||||||||||||||||||||||||||||
In millions, except percentages | 2022 | 2021 | 2022 | 2021 | $ | % | $ | % | |||||||||||||||||||||||||||||||||||||||
Revenues: | |||||||||||||||||||||||||||||||||||||||||||||||
Premiums | $ | 14 | $ | 25 | $ | 46 | $ | 58 | $ | (11) | (44.0) | % | $ | (12) | (20.7) | % | |||||||||||||||||||||||||||||||
Services | 18 | 14 | 51 | 43 | 4 | 28.6 | % | 8 | 18.6 | % | |||||||||||||||||||||||||||||||||||||
Net investment income | 110 | 132 | 281 | 387 | (22) | (16.7) | % | (106) | (27.4) | % | |||||||||||||||||||||||||||||||||||||
Total revenues | 142 | 171 | 378 | 488 | (29) | (17.0) | % | (110) | (22.5) | % | |||||||||||||||||||||||||||||||||||||
Cost of products sold | 11 | 11 | 31 | 27 | — | — | % | 4 | 14.8 | % | |||||||||||||||||||||||||||||||||||||
Benefit costs | 53 | 69 | 274 | 168 | (16) | (23.2) | % | 106 | 63.1 | % | |||||||||||||||||||||||||||||||||||||
Opioid litigation charges | 5,220 | — | 5,704 | — | 5,220 | 100.0 | % | 5,704 | 100.0 | % | |||||||||||||||||||||||||||||||||||||
Operating expenses | 495 | 455 | 1,352 | 1,411 | 40 | 8.8 | % | (59) | (4.2) | % | |||||||||||||||||||||||||||||||||||||
Operating loss | (5,637) | (364) | (6,983) | (1,118) | (5,273) | (1,448.6) | % | (5,865) | (524.6) | % | |||||||||||||||||||||||||||||||||||||
Adjusted operating loss (1) | (417) | (343) | (1,277) | (1,015) | (74) | (21.6) | % | (262) | (25.8) | % |
Nine Months Ended September 30, | Change | ||||||||||||||||||||||
In millions, except percentages | 2022 | 2021 | $ | % | |||||||||||||||||||
Net cash provided by operating activities | $ | 18,129 | $ | 14,260 | $ | 3,869 | 27.1 | % | |||||||||||||||
Net cash used in investing activities | (4,928) | (3,821) | (1,107) | (29.0) | % | ||||||||||||||||||
Net cash used in financing activities | (8,329) | (8,442) | 113 | 1.3 | % | ||||||||||||||||||
Net increase in cash, cash equivalents and restricted cash | $ | 4,872 | $ | 1,997 | $ | 2,875 | 144.0 | % |
In billions Authorization Date | Authorized | Remaining as of September 30, 2022 | |||||||||
December 9, 2021 (“2021 Repurchase Program”) | $ | 10.0 | $ | 8.0 |
· | Anticipates | · | Believes | · | Can | · | Continue | · | Could | ||||||||||||||||||||
· | Estimates | · | Evaluate | · | Expects | · | Explore | · | Forecast | ||||||||||||||||||||
· | Guidance | · | Intends | · | Likely | · | May | · | Might | ||||||||||||||||||||
· | Outlook | · | Plans | · | Potential | · | Predict | · | Probable | ||||||||||||||||||||
· | Projects | · | Seeks | · | Should | · | View | · | Will |
Fiscal Period | Total Number of Shares Purchased | Average Price Paid per Share | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs | Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs | |||||||||||||||||||
July 1, 2022 through July 31, 2022 | — | $ | — | — | $ | 8,000,000,137 | |||||||||||||||||
August 1, 2022 through August 31, 2022 | — | $ | — | — | $ | 8,000,000,137 | |||||||||||||||||
September 1, 2022 through September 30, 2022 | — | $ | — | — | $ | 8,000,000,137 | |||||||||||||||||
— | — |
2 | Plan of acquisition, reorganization, arrangement, liquidation or succession | ||||
2.1 | |||||
10 | Material Contracts | ||||
10.1 | |||||
15 | Letter re: unaudited interim financial information | ||||
15.1 | |||||
31 | Rule 13a-14(a)/15d-14(a) Certifications | ||||
31.1 | |||||
31.2 | |||||
32 | Section 1350 Certifications | ||||
32.1 | |||||
32.2 | |||||
101 | |||||
101 | The following materials from the CVS Health Corporation Quarterly Report on Form 10-Q for the three and nine months ended September 30, 2022 formatted in Inline XBRL: (i) the Condensed Consolidated Statements of Operations, (ii) the Condensed Consolidated Statements of Comprehensive Income (Loss), (iii) the Condensed Consolidated Balance Sheets, (iv) the Condensed Consolidated Statements of Cash Flows, (v) the Condensed Consolidated Statements of Shareholders’ Equity and (vi) the related Notes to Condensed Consolidated Financial Statements. The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. | ||||
104 | |||||
104 | Cover Page Interactive Data File - The cover page from the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, formatted in Inline XBRL (included as Exhibit 101). |
CVS HEALTH CORPORATION | ||||||||
Date: | November 2, 2022 | By: | /s/ Shawn M. Guertin | ||||||||
Shawn M. Guertin | |||||||||||
Executive Vice President and Chief Financial Officer | |||||||||||
Date: | November 2, 2022 | /S/ KAREN S. LYNCH | |||||||||
Karen S. Lynch | |||||||||||
President and Chief Executive Officer |
Date: | November 2, 2022 | /S/ SHAWN M. GUERTIN | |||||||||
Shawn M. Guertin | |||||||||||
Executive Vice President and Chief Financial Officer |
Date: | November 2, 2022 | /S/ KAREN S. LYNCH | ||||||
Karen S. Lynch | ||||||||
President and Chief Executive Officer |
Date: | November 2, 2022 | /S/ SHAWN M. GUERTIN | ||||||
Shawn M. Guertin | ||||||||
Executive Vice President and Chief Financial Officer |
Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Millions, $ in Millions |
3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Sep. 30, 2022 |
Sep. 30, 2021 |
Sep. 30, 2022 |
Sep. 30, 2021 |
|
Revenues: | ||||
Premiums | $ 21,003 | $ 18,984 | $ 63,894 | $ 56,927 |
Net investment income | 201 | 246 | 515 | 832 |
Total revenues | 81,159 | 73,794 | 238,621 | 215,507 |
Operating costs: | ||||
Cost of products sold | 50,365 | 45,011 | 145,164 | 129,425 |
Benefit costs | 17,419 | 16,081 | 52,976 | 47,686 |
Opioid litigation charges | 5,220 | 0 | 5,704 | 0 |
Loss on assets held for sale | 2,480 | 0 | 2,521 | 0 |
Goodwill impairment | 0 | 431 | 0 | 431 |
Operating expenses | 9,606 | 9,210 | 28,128 | 27,001 |
Total operating costs | 85,090 | 70,733 | 234,493 | 204,543 |
Operating income (loss) | (3,931) | 3,061 | 4,128 | 10,964 |
Interest expense | 566 | 602 | 1,735 | 1,895 |
Loss on early extinguishment of debt | 0 | 363 | 0 | 363 |
Other income | (41) | (49) | (126) | (144) |
Income (loss) before income tax provision | (4,456) | 2,145 | 2,519 | 8,850 |
Income tax provision (benefit) | (1,047) | 558 | 654 | 2,248 |
Net income (loss) | (3,409) | 1,587 | 1,865 | 6,602 |
Net (income) loss attributable to noncontrolling interests | (7) | 11 | (18) | 2 |
Net income (loss) attributable to CVS Health | $ (3,416) | $ 1,598 | $ 1,847 | $ 6,604 |
Net income (loss) per share attributable to CVS Health: | ||||
Basic (in dollars per share) | $ (2.60) | $ 1.21 | $ 1.41 | $ 5.01 |
Diluted (in dollars per share) | $ (2.60) | $ 1.20 | $ 1.40 | $ 4.98 |
Weighted average shares outstanding: | ||||
Basic (in shares) | 1,315 | 1,321 | 1,313 | 1,318 |
Diluted (in shares) | 1,315 | 1,329 | 1,324 | 1,326 |
Dividends declared per share (in dollars per share) | $ 0.55 | $ 0.50 | $ 1.65 | $ 1.50 |
Cost, Product and Service [Extensible List] | Products | Products | Products | Products |
Products | ||||
Revenues: | ||||
Revenues | $ 57,643 | $ 51,853 | $ 166,959 | $ 149,765 |
Services | ||||
Revenues: | ||||
Revenues | $ 2,312 | $ 2,711 | $ 7,253 | $ 7,983 |
Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited) - USD ($) $ in Millions |
3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Sep. 30, 2022 |
Sep. 30, 2021 |
Sep. 30, 2022 |
Sep. 30, 2021 |
|
Statement of Comprehensive Income [Abstract] | ||||
Net income (loss) | $ (3,409) | $ 1,587 | $ 1,865 | $ 6,602 |
Other comprehensive loss, net of tax: | ||||
Net unrealized investment losses | (623) | (73) | (2,591) | (310) |
Foreign currency translation adjustments | (7) | (5) | (5) | (6) |
Net cash flow hedges | 8 | (15) | 20 | (22) |
Pension and other postretirement benefits | 1 | 0 | 2 | 1 |
Other comprehensive loss | (621) | (93) | (2,574) | (337) |
Comprehensive income (loss) | (4,030) | 1,494 | (709) | 6,265 |
Comprehensive (income) loss attributable to noncontrolling interests | (7) | 11 | (18) | 2 |
Comprehensive income (loss) attributable to CVS Health | $ (4,037) | $ 1,505 | $ (727) | $ 6,267 |
Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares |
Sep. 30, 2022 |
Dec. 31, 2021 |
---|---|---|
Statement of Financial Position [Abstract] | ||
Preferred stock, par value (in dollars per share) | $ 0.01 | $ 0.01 |
Preferred stock, shares authorized (in shares) | 100,000 | 100,000 |
Preferred stock, shares issued (in shares) | 0 | 0 |
Preferred stock, shares outstanding (in shares) | 0 | 0 |
Common stock, par value (in dollars per share) | $ 0.01 | $ 0.01 |
Common stock, shares authorized (in shares) | 3,200,000,000 | 3,200,000,000 |
Common stock, shares issued (in shares) | 1,757,000,000 | 1,744,000,000 |
Common stock, shares outstanding (in shares) | 1,315,000,000 | 1,322,000,000 |
Treasury stock (in shares) | 442,000,000 | 422,000,000 |
Condensed Consolidated Statements of Shareholders' Equity (Parenthetical) - USD ($) shares in Millions, $ in Millions |
Sep. 30, 2022 |
Jun. 30, 2022 |
Mar. 31, 2022 |
Dec. 31, 2021 |
Sep. 30, 2021 |
Jun. 30, 2021 |
Mar. 31, 2021 |
Dec. 31, 2020 |
---|---|---|---|---|---|---|---|---|
Statement of Stockholders' Equity [Abstract] | ||||||||
Treasury shares held in trust (in shares) | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
Treasury share held in trust | $ 29 | $ 29 | $ 29 | $ 29 | $ 29 | $ 29 | $ 29 | $ 29 |
Common stock | $ 18 | $ 18 | $ 17 | $ 17 | $ 17 | $ 17 | $ 17 | $ 17 |
Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical) - USD ($) $ in Millions |
9 Months Ended | |
---|---|---|
Sep. 30, 2022 |
Sep. 30, 2021 |
|
Statement of Cash Flows [Abstract] | ||
Cash and restricted cash sold | $ 2,808 | $ 0 |
Significant Accounting Policies |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2022 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accounting Policies [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Significant Accounting Policies | Significant Accounting Policies Description of Business CVS Health Corporation, together with its subsidiaries (collectively, “CVS Health” or the “Company”), has more than 9,000 retail locations, more than 1,100 walk-in medical clinics, a leading pharmacy benefits manager with over 110 million plan members with expanding specialty pharmacy solutions and a dedicated senior pharmacy care business serving more than one million patients per year. The Company also serves an estimated 35 million people through traditional, voluntary and consumer-directed health insurance products and related services, including expanding Medicare Advantage offerings and a leading standalone Medicare Part D prescription drug plan (“PDP”). The Company believes its innovative health care model increases access to quality care, delivers better health outcomes and lowers overall health care costs. The coronavirus disease 2019 (“COVID-19”) and its emerging new variants continue to impact the economies of the U.S. and other countries around the world. The impact of COVID-19 on the Company’s businesses, operating results, cash flows and financial condition, as well as information regarding certain expected impacts of COVID-19 on the Company, is discussed throughout this Quarterly Report on Form 10-Q. The Company has four reportable segments: Health Care Benefits, Pharmacy Services, Retail/LTC and Corporate/Other, which are described below. Health Care Benefits Segment The Health Care Benefits segment operates as one of the nation’s leading diversified health care benefits providers. The Health Care Benefits segment has the information and resources to help members, in consultation with their health care professionals, make more informed decisions about their health care. The Health Care Benefits segment offers a broad range of traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental and behavioral health plans, medical management capabilities, Medicare Advantage and Medicare Supplement plans, PDPs, Medicaid health care management services and health information technology products and services. The Health Care Benefits segment’s customers include employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers (“providers”), governmental units, government-sponsored plans, labor groups and expatriates. The Company refers to insurance products (where it assumes all or a majority of the risk for medical and dental care costs) as “Insured” and administrative services contract products (where the plan sponsor assumes all or a majority of the risk for medical and dental care costs) as “ASC.” In addition, effective January 2022, the Company entered the individual public health insurance exchanges (“Public Exchanges”) in eight states through which it sells Insured plans directly to individual consumers. The Company will enter Public Exchanges in four additional states effective January 2023. Open enrollment for the 2023 calendar year has begun in each of these twelve states. Pharmacy Services Segment The Pharmacy Services segment provides a full range of pharmacy benefit management (“PBM”) solutions, including plan design offerings and administration, formulary management, retail pharmacy network management services and mail order pharmacy. In addition, through the Pharmacy Services segment, the Company provides specialty pharmacy and infusion services, clinical services, disease management services, medical spend management and pharmacy and/or other administrative services for providers and federal 340B drug pricing program covered entities (“Covered Entities”). The Company operates a group purchasing organization that negotiates pricing for the purchase of pharmaceuticals and rebates with pharmaceutical manufacturers on behalf of its participants. The Company also provides various administrative, management and reporting services to pharmaceutical manufacturers. The Pharmacy Services segment’s clients are primarily employers, insurance companies, unions, government employee groups, health plans, PDPs, Medicaid managed care plans, plans offered on Public Exchanges and private health insurance exchanges, other sponsors of health benefit plans throughout the United States and Covered Entities. The Pharmacy Services segment operates retail specialty pharmacy stores, specialty mail order pharmacies, mail order dispensing pharmacies, compounding pharmacies and branches for infusion and enteral nutrition services. Retail/LTC Segment The Retail/LTC segment sells prescription drugs and a wide assortment of health and wellness products and general merchandise, provides health care services through its MinuteClinic® walk-in medical clinics, provides medical diagnostic testing, administers vaccinations for illnesses such as influenza, COVID-19 and shingles and conducts long-term care pharmacy (“LTC”) operations, which distribute prescription drugs and provide related pharmacy consulting and other ancillary services to long-term care facilities and other care settings. As of September 30, 2022, the Retail/LTC segment operated more than 9,000 retail locations, more than 1,100 MinuteClinic locations as well as online retail pharmacy websites, LTC pharmacies and on-site pharmacies. Corporate/Other Segment The Company presents the remainder of its financial results in the Corporate/Other segment, which primarily consists of: •Management and administrative expenses to support the Company’s overall operations, which include certain aspects of executive management and the corporate relations, legal, compliance, human resources, information technology and finance departments, expenses associated with the Company’s investments in its transformation and enterprise modernization programs and acquisition-related integration costs; and •Products for which the Company no longer solicits or accepts new customers such as its large case pensions and long-term care insurance products. Basis of Presentation The accompanying unaudited condensed consolidated financial statements of CVS Health and its subsidiaries have been prepared in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”) regarding interim financial reporting. In accordance with such rules and regulations, certain information and accompanying note disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) have been omitted, although the Company believes the disclosures included herein are adequate to make the information presented not misleading. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto, which are included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 (the “2021 Form 10-K”). In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the results for the interim periods presented. Because of the influence of various factors on the Company’s operations, including business combinations, certain holidays and other seasonal influences, net income for any interim period may not be comparable to the same interim period in previous years or necessarily indicative of income for the full year. Principles of Consolidation The unaudited condensed consolidated financial statements include the accounts of the Company and its majority-owned subsidiaries and variable interest entities (“VIEs”) for which the Company is the primary beneficiary. All material intercompany balances and transactions have been eliminated. The Company continually evaluates its investments to determine if they represent variable interests in a VIE. If the Company determines that it has a variable interest in a VIE, the Company then evaluates if it is the primary beneficiary of the VIE. The evaluation is a qualitative assessment as to whether the Company has the ability to direct the activities of a VIE that most significantly impact the entity’s economic performance. The Company consolidates a VIE if it is considered to be the primary beneficiary. Assets and liabilities of VIEs for which the Company is the primary beneficiary were not significant to the Company’s unaudited condensed consolidated financial statements. VIE creditors do not have recourse against the general credit of the Company. Reclassifications Certain prior year amounts have been reclassified to conform with the current year presentation. Restricted Cash Restricted cash included in other current assets on the unaudited condensed consolidated balance sheets represents funds held on behalf of members, including health savings account funds associated with high deductible health plans. Restricted cash included in other assets on the unaudited condensed consolidated balance sheets represents amounts held in a trust in one of the Company’s captive insurance companies to satisfy collateral requirements associated with the assignment of certain insurance policies. All restricted cash is invested in time deposits and money market funds. The following is a reconciliation of cash and cash equivalents on the unaudited condensed consolidated balance sheets to total cash, cash equivalents and restricted cash on the unaudited condensed consolidated statements of cash flows:
The decrease in restricted cash included in other current assets as of September 30, 2022 compared to December 31, 2021 was primarily due to a decrease in health savings account funds held on behalf of customers as a result of the sale of PayFlex Holdings, Inc. (“PayFlex”). See Note 2 ‘‘Acquisition, Divestitures and Asset Sales’’ for additional information on the Company’s sale of PayFlex. Accounts Receivable Accounts receivable are stated net of allowances for credit losses, customer credit allowances, contractual allowances and estimated terminations. Accounts receivable, net is composed of the following:
_____________________________________________ (1)Includes accounts receivable of $248 million which have been accounted for as assets held for sale and are included in assets held for sale on the unaudited condensed consolidated balance sheet at September 30, 2022. See Note 2 ‘‘Acquisition, Divestitures and Asset Sales’’ for additional information. The Company’s allowance for credit losses was $344 million and $339 million as of September 30, 2022 and December 31, 2021, respectively. When developing an estimate of the Company’s expected credit losses, the Company considers all available relevant information regarding the collectability of cash flows, including historical information, current conditions and reasonable and supportable forecasts of future economic conditions over the contractual life of the receivable. The Company’s accounts receivable are short duration in nature and typically settle in less than 30 days. Revenue Recognition Disaggregation of Revenue The following tables disaggregate the Company’s revenue by major source in each segment for the three and nine months ended September 30, 2022 and 2021:
_____________________________________________ (1)Pharmacy Services pharmacy network is defined as claims filled at retail and specialty retail pharmacies, including the Company’s retail pharmacies and LTC pharmacies, but excluding Maintenance Choice® activity, which is included within the mail choice category. Maintenance Choice permits eligible client plan members to fill their maintenance prescriptions through mail order delivery or at a CVS pharmacy retail store for the same price as mail order. (2)Pharmacy Services mail choice is defined as claims filled at a Pharmacy Services mail order facility, which includes specialty mail claims inclusive of Specialty Connect® claims picked up at a retail pharmacy, as well as prescriptions filled at the Company’s retail pharmacies under the Maintenance Choice program. Contract Balances Contract liabilities primarily represent the Company’s obligation to transfer additional goods or services to a customer for which the Company has received consideration, and include ExtraBucks® Rewards and unredeemed Company gift cards. The consideration received remains a contract liability until goods or services have been provided to the customer. In addition, the Company recognizes breakage on Company gift cards based on historical redemption patterns. The following table provides information about receivables and contract liabilities from contracts with customers:
During the nine months ended September 30, 2022 and 2021, the contract liabilities balance includes increases related to customers’ earnings in ExtraBucks Rewards or issuances of Company gift cards and decreases for revenues recognized during the period as a result of the redemption of ExtraBucks Rewards or Company gift cards and breakage of Company gift cards. Below is a summary of such changes:
Related Party Transactions The Company has an equity method investment in SureScripts, LLC (“SureScripts”), which operates a clinical health information network. The Company utilizes this clinical health information network in providing services to its client plan members and retail customers. The Company expensed fees for the use of this network of $16 million in each of the three-month periods ended September 30, 2022 and 2021, and expensed fees for the use of this network of approximately $47 million and $35 million in the nine months ended September 30, 2022 and 2021, respectively. The Company’s investment in and equity in the earnings of SureScripts for all periods presented is immaterial. The Company has an equity method investment in Heartland Healthcare Services, LLC (“Heartland”). Heartland operates several LTC pharmacies in four states. Heartland paid the Company $22 million and $20 million for pharmaceutical inventory purchases during the three months ended September 30, 2022 and 2021, respectively, and $66 million and $57 million for pharmaceutical inventory purchases during the nine months ended September 30, 2022 and 2021, respectively. Additionally, the Company performs certain collection functions for Heartland and then transfers those customer cash collections to Heartland. The Company’s investment in and equity in the earnings of Heartland for all periods presented is immaterial. New Accounting Pronouncements Not Yet Adopted Targeted Improvements to the Accounting for Long-Duration Insurance Contracts In August 2018, the Financial Accounting Standards Board issued Accounting Standards Update 2018-12, Targeted Improvements to the Accounting for Long-Duration Contracts (Topic 944). This standard requires the Company to review cash flow assumptions for its long-duration insurance contracts at least annually and recognize the effect of changes in future cash flow assumptions in net income. This standard also requires the Company to update discount rate assumptions quarterly and recognize the effect of changes in these assumptions in other comprehensive income. The rate used to discount the Company’s liability for future policy benefits will be based on an estimate of the yield for an upper-medium grade fixed-income instrument with a duration profile matching that of the Company’s liabilities. In addition, this standard changes the amortization method for deferred acquisition costs and requires additional disclosures regarding the long duration insurance contract liabilities in the Company’s interim and annual financial statements. The standard is effective for public companies for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2022. The Company will adopt the new standard on January 1, 2023, using the modified retrospective transition method as of the earliest period presented, January 1, 2021, also referred to as the transition date, for changes to the liability for future policy benefits and deferred acquisition costs. While the Company is still evaluating the impact of the new standard on its financial statements, the Company anticipates an increase to its liability for future policy benefits with a corresponding change in accumulated other comprehensive income on the transition date of approximately $1 billion as a result of updating the rate used to discount the liabilities to reflect the yield for an upper-medium grade fixed-income instrument compared to the Company’s expected investment yield under the existing guidance.
|
Acquisition, Divestitures and Asset Sales |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2022 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Business Combination and Asset Acquisition [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Acquisition, Divestitures and Asset Sales | Acquisition, Divestitures and Asset Sales Proposed Signify Health Acquisition On September 2, 2022, the Company entered into a definitive merger agreement to acquire all of the outstanding shares of Signify Health, Inc. (“Signify Health”) for cash. Under the terms of the merger agreement, Signify Health stockholders will receive $30.50 per share in cash. The total value of the transaction is approximately $8 billion. The proposed acquisition was approved by the Board of Directors at each of the respective companies and the Signify Health stockholders and remains subject to receipt of regulatory approval and satisfaction of other customary closing conditions. On October 19, 2022, Signify Health and CVS Health each received a request for additional information (also known as a “second request”) from the U.S. Department of Justice (the “DOJ”) in connection with the review of the transactions contemplated by the merger agreement by the DOJ under the federal Hart-Scott-Rodino Antitrust Improvements Act of 1976. The transaction is expected to close in the first half of 2023. If the merger agreement is terminated under certain specified circumstances and receipt of regulatory approval has not been obtained by such time, the Company will be required to pay Signify Health a termination fee in an amount equal to $380 million. If the merger agreement is terminated under other certain specified circumstances, including due to Signify Health accepting a superior proposal, Signify Health will be required to pay the Company a termination fee in an amount equal to $228 million. Assets Held For Sale Long-Term Care Business The Company continually evaluates its portfolio for nonstrategic assets. The Company determined that its Omnicare® long-term care business (“LTC business”), which is included within the Retail/LTC segment, was no longer a strategic asset and during the third quarter of 2022 committed to a plan to sell the LTC business. The carrying value of the LTC business was determined to be greater than its fair value and, accordingly, the Company recorded a loss on assets held for sale of $2.5 billion in the three and nine months ended September 30, 2022 in the Company’s unaudited condensed consolidated statements of operations within the Retail/LTC segment. The LTC business income before income tax provision was not material for the three and nine months ended September 30, 2022 and 2021. bswift Business In October 2022, the Company reached an agreement to sell its wholly-owned subsidiary bswift LLC (“bswift business”) which is included in the Health Care Benefits segment. bswift offers software and services that streamline benefits and human resource administration. The sale is expected to close in the fourth quarter of 2022, subject to the satisfaction of customary closing conditions. The bswift business income before income tax provision was not material for the three and nine months ended September 30, 2022 and 2021. Held-For-Sale Classification The LTC and bswift businesses met the criteria to be classified as held for sale at September 30, 2022, but did not meet the criteria to be classified as discontinued operations. As a result, the related assets and liabilities were included in the separate held-for-sale line items of the asset and liability sections of the unaudited condensed consolidated balance sheet. The following table summarizes the assets and liabilities held for sale at September 30, 2022:
_____________________________________________ (1) $475 million of goodwill within the Commercial Business reporting unit was specifically allocated to the bswift business at September 30, 2022. Divestiture of PayFlex In June 2022, the Company sold PayFlex for approximately $775 million. PayFlex provides services to employers, their employees, and their former employees in the areas of tax-advantaged account reimbursement administration (flexible spending, health reimbursement, health savings, transit and parking), Consolidated Omnibus Budget Reconciliation Act (“COBRA”) administration and special-member billing administration. The results of this business have historically been reported within the Health Care Benefits segment. The Company recorded a pre-tax gain on the divestiture of $225 million in the nine months ended September 30, 2022, which is reflected as a reduction in operating expenses in the Company’s unaudited condensed consolidated statements of operations within the Health Care Benefits segment. Divestiture of Thailand Health Care Business In March 2022, the Company reached an agreement to sell its international health care business domiciled in Thailand (“Thailand business”), comprised of approximately 266,000 medical members, which was included in the Commercial Business reporting unit within the Health Care Benefits segment. At that time, a portion of the Commercial Business goodwill was specifically allocated to the Thailand business. The net assets of the Thailand business were accounted for as assets held for sale at March 31, 2022. The carrying value of the Thailand business was determined to be greater than its fair value and, accordingly, the Company recorded a $41 million loss on assets held for sale within the Health Care Benefits segment during the first quarter of 2022. The sale closed in the second quarter of 2022, and the consideration received and ultimate loss on the sale were not material. International Health Care Benefits Renewal Rights Asset Sale In May 2022, the Company sold the renewal rights of approximately 200,000 international medical members outside of the Americas, Thailand and India in connection with an Asset Purchase Agreement. As part of this agreement, the Company will introduce and help migrate these existing international medical members to the purchaser upon renewal. The Company expects the migration process to occur over a 16-month period between July 2022 and October 2023. The Company expects to cease writing any new or renewal business for international medical members outside of the Americas after October 31, 2022. The consideration received related to this agreement was not material.
|
Investments |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2022 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Investments [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Investments | Investments Total investments at September 30, 2022 and December 31, 2021 were as follows:
_____________________________________________ (1)Includes long-term investments of $18 million which have been accounted for as assets held for sale and are included in assets held for sale on the unaudited condensed consolidated balance sheet at September 30, 2022. See Note 2 ‘‘Acquisition, Divestitures and Asset Sales’’ for additional information. Debt Securities Debt securities available for sale at September 30, 2022 and December 31, 2021 were as follows:
_____________________________________________ (1)Investment risks associated with the Company’s experience-rated products generally do not impact the Company’s consolidated operating results. At September 30, 2022, debt securities with a fair value of $612 million, gross unrealized capital gains of $2 million and gross unrealized capital losses of $73 million and at December 31, 2021, debt securities with a fair value of $864 million, gross unrealized capital gains of $94 million and gross unrealized capital losses of $2 million were included in total debt securities, but support experience-rated products. Changes in net unrealized capital gains (losses) on these securities are not reflected in accumulated other comprehensive income (loss). The net amortized cost and fair value of debt securities at September 30, 2022 are shown below by contractual maturity. Actual maturities may differ from contractual maturities because securities may be restructured, called or prepaid, or the Company intends to sell a security prior to maturity.
Summarized below are the debt securities the Company held at September 30, 2022 and December 31, 2021 that were in an unrealized capital loss position, aggregated by the length of time the investments have been in that position:
The Company reviewed the securities in the table above and concluded that they are performing assets generating investment income to support the needs of the Company’s business. In performing this review, the Company considered factors such as the quality of the investment security based on research performed by the Company’s internal credit analysts and external rating agencies and the prospects of realizing the carrying value of the security based on the investment’s current prospects for recovery. Unrealized capital losses at September 30, 2022 were generally caused by interest rate increases and not by unfavorable changes in the credit quality associated with these securities. As of September 30, 2022, the Company did not intend to sell these securities, and did not believe it was more likely than not that it would be required to sell these securities prior to the anticipated recovery of their amortized cost basis. The maturity dates for debt securities in an unrealized capital loss position at September 30, 2022 were as follows:
Mortgage Loans The Company’s mortgage loans are collateralized by commercial real estate. During the three and nine months ended September 30, 2022 and 2021, the Company had the following activity in its mortgage loan portfolio:
The Company assesses mortgage loans on a regular basis for credit impairments, and assigns a credit quality indicator to each loan. The Company’s credit quality indicator is internally developed and categorizes each loan in its portfolio on a scale from 1 to 7. These indicators are based upon several factors, including current loan-to-value ratios, current and future property cash flow, property condition, market trends, creditworthiness of the borrower and deal structure. •Category 1 - Represents loans of superior quality. •Categories 2 to 4 - Represent loans where credit risk is minimal to acceptable; however, these loans may display some susceptibility to economic changes. •Categories 5 and 6 - Represent loans where credit risk is not substantial, but these loans warrant management’s close attention. •Category 7 - Represents loans where collections are potentially at risk; if necessary, an impairment is recorded. Based on the Company’s assessments at September 30, 2022 and December 31, 2021, the amortized cost basis of the Company's mortgage loans within each credit quality indicator by year of origination was as follows:
Net Investment Income Sources of net investment income for the three and nine months ended September 30, 2022 and 2021 were as follows:
_____________________________________________ (1)Net realized capital losses include credit-related losses on debt securities of $1 million and yield-related impairment losses on debt securities of $73 million in the three months ended September 30, 2022. Net realized capital losses include credit-related losses on debt securities of $17 million and yield-related impairment losses on debt securities of $121 million in the nine months ended September 30, 2022. Net realized capital losses include yield-related impairment losses on debt securities of $3 million in the three months ended September 30, 2021. Net realized capital gains are net of yield-related impairment losses on debt securities of $35 million in the nine months ended September 30, 2021. There were no credit-related losses on debt securities in the three and nine months ended September 30, 2021. (2)Net investment income includes $8 million and $26 million for the three and nine months ended September 30, 2022, respectively, and $9 million and $28 million for the three and nine months ended September 30, 2021, respectively, related to investments supporting experience-rated products. Excluding amounts related to experience-rated products, proceeds from the sale of available-for-sale debt securities and the related gross realized capital gains and losses for the three and nine months ended September 30, 2022 and 2021 were as follows:
|
Fair Value |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2022 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value Disclosures [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value | Fair Value The preparation of the Company’s unaudited condensed consolidated financial statements in accordance with GAAP requires certain assets and liabilities to be reflected at their fair value and others to be reflected on another basis, such as an adjusted historical cost basis. The Company’s assets and liabilities carried at fair value have been classified within one of three levels of a hierarchy established by GAAP. The following are the levels of the hierarchy and a brief description of the type of valuation information (“valuation inputs”) that qualifies a financial asset or liability for each level: •Level 1 – Unadjusted quoted prices for identical assets or liabilities in active markets. •Level 2 – Valuation inputs other than Level 1 that are based on observable market data. These include: quoted prices for similar assets in active markets, quoted prices for identical assets in inactive markets, valuation inputs that are observable that are not prices (such as interest rates and credit risks) and valuation inputs that are derived from or corroborated by observable markets. •Level 3 – Developed from unobservable data, reflecting the Company’s assumptions. For a description of the methods and assumptions that are used to estimate the fair value and determine the fair value hierarchy classification of each class of financial instrument, see Note 4 “Fair Value” in the 2021 Form 10-K. There were no financial liabilities measured at fair value on a recurring basis on the unaudited condensed consolidated balance sheets at September 30, 2022 or December 31, 2021. Financial assets measured at fair value on a recurring basis on the unaudited condensed consolidated balance sheets at September 30, 2022 and December 31, 2021 were as follows:
_____________________________________________ (1)Includes cash and cash equivalents of $7 million which have been accounted for as assets held for sale and are included in assets held for sale on the unaudited condensed consolidated balance sheet at September 30, 2022. See Note 2 ‘‘Acquisition, Divestitures and Asset Sales’’ for additional information. During the three months ended September 30, 2022 there were no transfers into or out of Level 3. During the nine months ended September 30, 2022 there were $29 million of transfers out of Level 3. During the three and nine months ended September 30, 2021, there were no transfers into or out of Level 3. The carrying value and estimated fair value classified by level of fair value hierarchy for financial instruments carried on the unaudited condensed consolidated balance sheets at adjusted cost or contract value at September 30, 2022 and December 31, 2021 were as follows:
_____________________________________________ (1)It was not practical to estimate the fair value of these cost-method investments as it represents shares of unlisted companies. (2)Includes long-term debt of $3 million which has been accounted for as liabilities held for sale and are included in liabilities held for sale on the unaudited condensed consolidated balance sheet at September 30, 2022. See Note 2 ‘‘Acquisition, Divestitures and Asset Sales’’ for additional information. Separate Accounts assets relate to the Company’s large case pensions products which represent funds maintained to meet specific objectives of contract holders. Since contract holders bear the investment risk of these assets, a corresponding Separate Accounts liability has been established equal to the assets. These assets and liabilities are carried at fair value. Separate Accounts financial assets as of September 30, 2022 and December 31, 2021 were as follows:
_____________________________________________ (1)Excludes $20 million and $70 million of other receivables at September 30, 2022 and December 31, 2021, respectively.
|
Health Care Costs Payable |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2022 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Health Care and Other Insurance Liabilities [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Health Care Costs Payable | Health Care Costs Payable The following table shows the components of the change in health care costs payable during the nine months ended September 30, 2022 and 2021:
_____________________________________________ (1)Total incurred health care costs for the nine months ended September 30, 2022 and 2021 in the table above exclude (i) $5 million and $1 million, respectively, for premium deficiency reserves related to the Company’s Medicaid products, (ii) $56 million and $45 million, respectively, of benefit costs recorded in the Health Care Benefits segment that are included in other insurance liabilities on the unaudited condensed consolidated balance sheets and (iii) $274 million and $168 million, respectively, of benefit costs recorded in the Corporate/Other segment that are included in other insurance liabilities on the unaudited condensed consolidated balance sheets. The Company’s estimates of prior years’ health care costs payable decreased by $670 million and $771 million, respectively, in the nine months ended September 30, 2022 and 2021, because claims were settled for amounts less than originally estimated (i.e., the amount of claims incurred was lower than originally estimated), primarily due to lower health care cost trends as well as the actual claim submission time being faster than originally assumed (i.e., the Company’s completion factors were higher than originally assumed) in estimating health care costs payable at the end of the prior year. At September 30, 2022, the Company’s liabilities for the ultimate cost of (i) services rendered to the Company’s Insured members but not yet reported to the Company and (ii) claims which have been reported to the Company but not yet paid (collectively, “IBNR”) plus expected development on reported claims totaled approximately $7.9 billion. Substantially all of the Company’s liabilities for IBNR plus expected development on reported claims at September 30, 2022 related to the current year.
|
Borrowings |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2022 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Borrowings | Borrowings The following table is a summary of the Company’s borrowings at September 30, 2022 and December 31, 2021:
_____________________________________________________________________________________________________________________________ (1)Includes long-term debt of $3 million which has been accounted for as liabilities held for sale and are included in liabilities held for sale on the unaudited condensed consolidated balance sheet at September 30, 2022. See Note 2 ‘‘Acquisition, Divestitures and Asset Sales’’ for additional information. Long-term Borrowings In May 2022, the Company exercised the par call option on its outstanding 3.5% senior notes due July 2022 and redeemed for cash on hand the entire $1.5 billion aggregate principal amount. In August 2022, the Company exercised the par call option on its outstanding 2.75% senior notes due November 2022 (issued by Aetna Inc.) and redeemed for cash on hand the entire $1.0 billion aggregate principal amount. In September 2022, the Company exercised the par call options on its outstanding 2.75% senior notes due December 2022 and 4.75% senior notes due December 2022 (including notes issued by Omnicare, Inc.) and redeemed for cash on hand the entire $1.25 billion and $399 million aggregate principal amounts, respectively.
|
Shareholders' Equity |
9 Months Ended | ||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2022 | |||||||||||||||||||||||||||||||||||||
Equity [Abstract] | |||||||||||||||||||||||||||||||||||||
Shareholders' Equity | Shareholders’ Equity Share Repurchases The following share repurchase program has been authorized by CVS Health Corporation’s Board of Directors (the “Board”):
The 2021 Repurchase Program permits the Company to effect repurchases from time to time through a combination of open market repurchases, privately negotiated transactions, accelerated share repurchase (“ASR”) transactions, and/or other derivative transactions. The 2021 Repurchase Program can be modified or terminated by the Board at any time. During the nine months ended September 30, 2022, the Company repurchased approximately 19.1 million shares of common stock for approximately $2.0 billion pursuant to the 2021 Repurchase Program, including share repurchases under the ASR transaction described below. During the nine months ended September 30, 2021, the Company did not repurchase any shares of its common stock. Pursuant to the authorization under the 2021 Repurchase Program, the Company entered into a $1.5 billion fixed dollar ASR with Barclays Bank PLC (“Barclays”). Upon payment of the $1.5 billion purchase price on January 4, 2022, the Company received a number of shares of CVS Health Corporation’s common stock equal to 80% of the $1.5 billion notional amount of the ASR or approximately 11.6 million shares at a price of $103.34 per share, which were placed into treasury stock in January 2022. The ASR was accounted for as an initial treasury stock transaction for $1.2 billion and a forward contract for $0.3 billion. The forward contract was classified as an equity instrument and was recorded within capital surplus. In February 2022, the Company received approximately 2.7 million shares of CVS Health Corporation’s common stock, representing the remaining 20% of the $1.5 billion notional amount of the ASR, thereby concluding the ASR. These shares were placed into treasury stock and the forward contract was reclassified from capital surplus to treasury stock in February 2022. At the time they were received, the initial and final receipt of shares resulted in an immediate reduction of the outstanding shares used to calculate the weighted average common shares outstanding for basic and diluted earnings per share. Dividends The quarterly cash dividend declared by the Board was $0.55 and $0.50 per share in the three months ended September 30, 2022 and 2021, respectively. Cash dividends declared by the Board were $1.65 and $1.50 per share in the nine months ended September 30, 2022 and 2021, respectively. CVS Health Corporation has paid cash dividends every quarter since becoming a public company. Future dividend payments will depend on the Company’s earnings, capital requirements, financial condition and other factors considered relevant by the Board.
|
Other Comprehensive Income (Loss) |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2022 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other Comprehensive Income (Loss), Net of Tax [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other Comprehensive Income (Loss) | Other Comprehensive Income (Loss) Shareholders’ equity included the following activity in accumulated other comprehensive income (loss) for the three and nine months ended September 30, 2022 and 2021:
_____________________________________________ (1)Amounts reclassified from accumulated other comprehensive income (loss) for specifically identified debt securities are included in net investment income in the unaudited condensed consolidated statements of operations. (2)Amounts reclassified from accumulated other comprehensive income for specifically identified cash flow hedges are included in interest expense in the unaudited condensed consolidated statements of operations. The Company expects to reclassify approximately $11 million, net of tax, in net gains associated with its cash flow hedges into net income within the next 12 months. (3)Amounts reclassified from accumulated other comprehensive loss for specifically identified pension and other postretirement benefits are included in other income in the unaudited condensed consolidated statements of operations.
|
Earnings (Loss) Per Share |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2022 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Earnings Per Share [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Earnings (Loss) Per Share | Earnings (Loss) Per Share Earnings (loss) per share is computed using the treasury stock method. For periods in which the Company reports net income, diluted earnings per share is determined using the weighted average number of common and dilutive common equivalent shares outstanding during the period, unless the effect is antidilutive. Stock options and stock appreciation rights to purchase 4 million shares of common stock were outstanding, but were excluded from the calculation of diluted earnings per share in each of the three and nine-month periods ended September 30, 2022 because their exercise prices were greater than the average market price of the common shares and, therefore, the effect would be antidilutive. For the same reason, stock options and stock appreciation rights to purchase 8 million shares of common stock were outstanding, but were excluded from the calculation of diluted earnings per share in each of the three and nine-month periods ended September 30, 2021. In addition, due to the net loss attributable to CVS Health in the three months ended September 30, 2022, 8 million potentially dilutive common equivalent shares were excluded from the calculation of diluted earnings per share, as the impact of these shares were antidilutive for that period. The following is a reconciliation of basic and diluted earnings (loss) per share for the respective periods:
|
Commitments and Contingencies |
9 Months Ended |
---|---|
Sep. 30, 2022 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies | Commitments and Contingencies COVID-19 The COVID-19 pandemic continues to evolve. The Company believes COVID-19’s impact on its businesses, operating results, cash flows and/or financial condition primarily will be driven by the geographies impacted and the severity and duration of the pandemic; the pandemic’s impact on the U.S. and global economies and consumer behavior and health care utilization patterns; and the timing, scope and impact of stimulus legislation as well as other federal, state and local governmental responses to the pandemic. Those primary drivers are beyond the Company’s knowledge and control. As a result, the impact COVID-19 will have on the Company’s businesses, operating results, cash flows and/or financial condition is uncertain, but the impact could be adverse and material. COVID-19 also may result in legal and regulatory proceedings, investigations and claims against the Company. Lease Guarantees Between 1995 and 1997, the Company sold or spun off a number of subsidiaries, including Bob’s Stores and Linens ‘n Things, each of which subsequently filed for bankruptcy, and Marshalls. In many cases, when a former subsidiary leased a store, the Company provided a guarantee of the former subsidiary’s lease obligations for the initial lease term and any extension thereof pursuant to a renewal option provided for in the lease prior to the time of the disposition. When the subsidiaries were disposed of and accounted for as discontinued operations, the Company’s guarantees remained in place, although each initial purchaser agreed to indemnify the Company for any lease obligations the Company was required to satisfy. If any of the purchasers or any of the former subsidiaries fail to make the required payments under a store lease, the Company could be required to satisfy those obligations, and any significant adverse impact of COVID-19 on such purchasers and/or former subsidiaries increases the risk that the Company will be required to satisfy those obligations. As of September 30, 2022, the Company guaranteed 68 such store leases (excluding the lease guarantees related to Linens ‘n Things, which have been recorded as a liability on the unaudited condensed consolidated balance sheets), with the maximum remaining lease term extending through 2034. Guaranty Fund Assessments, Market Stabilization and Other Non-Voluntary Risk Sharing Pools Under guaranty fund laws existing in all states, insurers doing business in those states can be assessed (in most states up to prescribed limits) for certain obligations of insolvent insurance companies to policyholders and claimants. The life and health insurance guaranty associations in which the Company participates that operate under these laws respond to insolvencies of long-term care insurers and life insurers as well as health insurers. The Company’s assessments generally are based on a formula relating to the Company’s health care premiums in the state compared to the premiums of other insurers. Certain states allow assessments to be recovered over time as offsets to premium taxes. Some states have similar laws relating to HMOs and/or other payors such as not-for-profit consumer-governed health plans established under the Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010. In 2009, the Pennsylvania Insurance Commissioner placed long-term care insurer Penn Treaty Network America Insurance Company and one of its subsidiaries (collectively, “Penn Treaty”) in rehabilitation, an intermediate action before insolvency, and subsequently petitioned a state court to convert the rehabilitation into a liquidation. Penn Treaty was placed in liquidation in March 2017. The Company has recorded a liability for its estimated share of future assessments by applicable life and health insurance guaranty associations. It is reasonably possible that in the future the Company may record a liability and expense relating to other insolvencies which could have a material adverse effect on the Company’s operating results, financial condition and cash flows, and the risk is heightened by any significant adverse impact of the COVID-19 pandemic on the solvency of other insurers, including long-term care and life insurers. While historically the Company has ultimately recovered more than half of guaranty fund assessments through statutorily permitted premium tax offsets, significant increases in assessments could lead to legislative and/or regulatory actions that limit future offsets. HMOs in certain states in which the Company does business are subject to assessments, including market stabilization and other risk-sharing pools, for which the Company is assessed charges based on incurred claims, demographic membership mix and other factors. The Company establishes liabilities for these assessments based on applicable laws and regulations. In certain states, the ultimate assessments the Company pays are dependent upon the Company’s experience relative to other entities subject to the assessment, and the ultimate liability is not known at the financial statement date. While the ultimate amount of the assessment is dependent upon the experience of all pool participants, the Company believes it has adequate reserves to cover such assessments. Litigation and Regulatory Proceedings The Company has been involved or is currently involved in numerous legal proceedings, including litigation, arbitration, government investigations, audits, reviews and claims. These include routine, regular and special investigations, audits and reviews by the U.S. Centers for Medicare & Medicaid Services (“CMS”), state insurance and health and welfare departments, the DOJ, state attorneys general, the U.S. Drug Enforcement Administration (the “DEA”), the Federal Trade Commission (the “FTC”) and other governmental authorities. Legal proceedings, in general, and securities, class action and multi-district litigation, in particular, and governmental special investigations, audits and reviews can be expensive and disruptive. Some of the litigation matters may purport or be determined to be class actions and/or involve parties seeking large and/or indeterminate amounts, including punitive or exemplary damages, and may remain unresolved for several years. The Company also may be named from time to time in qui tam actions initiated by private third parties that could also be separately pursued by a governmental body. The results of legal proceedings, including government investigations, are often uncertain and difficult to predict, and the costs incurred in these matters can be substantial, regardless of the outcome. The Company records accruals for outstanding legal matters when it believes it is probable that a loss will be incurred and the amount can be reasonably estimated. The Company evaluates, on a quarterly basis, developments in legal matters that could affect the amount of any accrual and developments that would make a loss contingency both probable and reasonably estimable. If a loss contingency is not both probable and reasonably estimable, the Company does not establish an accrued liability. None of the Company’s accruals for outstanding legal matters are material individually or in the aggregate to the Company’s financial condition. Except as otherwise noted, the Company cannot predict with certainty the timing or outcome of the legal matters described below, and the Company is unable to reasonably estimate a possible loss or range of possible loss in excess of amounts already accrued for these matters. The Company believes that its defenses and assertions in pending legal proceedings have merit and does not believe that any of these pending matters, after consideration of applicable reserves and rights to indemnification, will have a material adverse effect on the Company’s financial position. Substantial unanticipated verdicts, fines and rulings, however, do sometimes occur, which could result in judgments against the Company, entry into settlements or a revision to its expectations regarding the outcome of certain matters, and such developments could have a material adverse effect on its results of operations. In addition, as a result of governmental investigations or proceedings, the Company may be subject to damages, civil or criminal fines or penalties, or other sanctions including possible suspension or loss of licensure and/or exclusion from participating in government programs. The outcome of such governmental investigations of proceedings could be material to the Company. Usual and Customary Pricing Litigation The Company and certain current and former directors and officers are named as a defendant in a number of lawsuits that allege that the Company’s retail pharmacies overcharged for prescription drugs by not submitting the correct usual and customary price during the claims adjudication process. These actions are brought by a number of different types of plaintiffs, including plan members, private payors, government payors, and shareholders based on different legal theories. Some of these cases are brought as putative class actions, and in some instances, classes have been certified. In October 2022, one of the litigating shareholders made a litigation demand to the Board related to these and other issues after his amended derivative complaint was dismissed for failing to demonstrate demand futility. The Company is defending itself against these claims. PBM Litigation and Investigations The Company is named as a defendant in a number of lawsuits and is subject to a number of investigations concerning its PBM practices. The Company is facing multiple lawsuits, including by a State Attorney General, governmental subdivisions and several putative class actions, regarding drug pricing and its rebate arrangements with drug manufacturers. These complaints, brought by a number of different types of plaintiffs under a variety of legal theories, generally allege that rebate agreements between the drug manufacturers and PBMs caused inflated prices for certain drug products. The Company is defending itself against these claims. The Company has also received subpoenas, civil investigative demands (“CIDs”) and other requests for documents and information from, and is being investigated by, the FTC and Attorneys General of several states and the District of Columbia regarding its PBM practices, including pricing and rebates. The Company has been providing documents and information in response to these subpoenas, CIDs and requests for information. United States ex rel. Behnke v. CVS Caremark Corporation, et al. (U.S. District Court for the Eastern District of Pennsylvania). In April 2018, the Court unsealed a complaint filed in February 2014. The government has declined to intervene in this case. The relator alleges that the Company submitted, or caused to be submitted, to Part D of the Medicare program Prescription Drug Event data and/or Direct and Indirect Remuneration reports that misrepresented true prices paid by the Company’s PBM to pharmacies for drugs dispensed to Part D beneficiaries with prescription benefits administered by the Company’s PBM. The Company is defending itself against these claims. Controlled Substances Litigation, Audits and Subpoenas In December 2017, the U.S. Judicial Panel on Multidistrict Litigation consolidated numerous cases filed against various defendants by plaintiffs such as counties, cities, hospitals, Indian tribes and third-party payors, alleging claims beginning as far back as the early 2000s generally concerning the impacts of widespread prescription opioid abuse. The consolidated multidistrict litigation captioned In re National Prescription Opiate Litigation (MDL No. 2804) is pending in the U.S. District Court for the Northern District of Ohio. This multidistrict litigation presumptively includes hundreds of relevant federal court cases that name the Company as a defendant. A significant number of similar cases that name the Company as a defendant in some capacity are pending in state courts. In addition, the Company has been named as a defendant in similar cases brought by certain state Attorneys General. The Company is defending itself against all such claims. Additionally, the Company has received subpoenas, CIDs and/or other requests for information regarding opioids from state Attorneys General and insurance and other regulators of several U.S. jurisdictions. The Company has been cooperating with the government with respect to these subpoenas, CIDs and other requests for information. In November 2021, the Company was among the chain pharmacies found liable by a jury in a trial in federal court in Ohio; in August 2022, the court issued a judgment jointly against the three defendants in the amount of $651 million to be paid over 15 years, and also ordered certain injunctive relief. The Company is appealing the judgment. In March 2022, CVS Health Corporation and CVS Pharmacy, Inc. entered into a settlement agreement with the State of Florida to resolve claims related to opioid medications dating back more than a decade. Under the terms of the settlement agreement, CVS Health Corporation settled all opioid claims against it and its subsidiaries by the State of Florida for $484 million, which is to be paid over a period of 18 years. During the three months ended March 31, 2022, the Company recorded a $484 million liability associated with this legal settlement. In August 2022, CVS Pharmacy, Inc. entered into an agreement with the State of New Mexico to settle all opioid claims against it and its parents and subsidiaries by the State of New Mexico and participating subdivisions. In September 2022, CVS Pharmacy, Inc. entered into an agreement with the State of West Virginia to settle all opioid claims against it and its parents and subsidiaries by the State of West Virginia and participating subdivisions. Also in September 2022, CVS Pharmacy, Inc. entered into an agreement with the Cherokee Nation to settle all opioid claims against it and its parents and subsidiaries by the Cherokee Nation. On October 18, 2022, the Company began mediation with a leadership group of a number of state attorneys general and the Plaintiffs’ Executive Committee (“PEC”) to resolve substantially all opioid lawsuits and claims against Company entities. Discussions progress and the Company agreed in principle to a financial amount to resolve substantially all opioid lawsuits and claims against Company entities by states, political subdivisions and tribes, but not private plaintiffs (the “Settlement Framework”). This Settlement Framework is subject to contingencies and uncertainties as to final terms, but is the basis for our negotiation of definitive terms and documentation. The Settlement Framework provides for payment by the Company of approximately $5.0 billion (approximately $4.9 billion to states and political subdivisions and approximately $130 million to tribes) over ten years, beginning in 2023. The non-monetary terms are subject to ongoing negotiations. Under the Settlement Framework, before the Company determines whether to enter into any final settlement, it will assess the sufficiency of the scope of settlement, based in part on the number and identities of the governmental entities that will participate in any such settlement. The Settlement Framework contemplates that if certain governmental entities do not agree to a settlement under the Settlement Framework, but the Company nonetheless concluded that there was sufficient participation to warrant going forward with the settlement, there would be a corresponding reduction in the amount due from the Company to account for the governmental entities that did not agree. Those non-participating governmental entities would be entitled to pursue their claims against the Company and other defendants. Private plaintiff litigation will also continue. The Company has concluded that discussions under the Settlement Framework have reached a stage at which a broad settlement of opioid claims by governmental entities is probable, and the loss related thereto can be reasonably estimated as of September 30, 2022. As a result of that conclusion, and its assessment of certain other opioid-related claims including those for which the Company reached agreement in August and September, the Company recorded a total pre-tax charge of $5.2 billion during the three months ended September 30, 2022 reflecting the cash component of the estimated loss. In addition, the Company expects the cash impact in 2023 and 2024 to be less than $500 million in each year. Because loss contingencies are inherently unpredictable and unfavorable developments or resolutions can occur, the assessment is highly subjective and requires judgments about future events. Moreover, the Settlement Framework is in its early phases, and there is no assurance that the necessary parties will agree to a definitive settlement agreement or that the contingencies to any agreement will be satisfied. The amount of ultimate loss may differ materially from this accrual. Because of the many uncertainties associated with any potential settlement arrangement or other resolution of all opioid-related litigation matters, including the uncertain scope of participation by governmental entities in any potential settlement under the Settlement Framework described above and that the Company continues to actively defend ongoing litigation for which it believes it has defenses and assertions that have merit, the Company is not able to reasonably estimate the range of ultimate possible loss for all opioid-related litigation matters at this time. The outcome of these legal matters could have a material effect on the Company’s business, financial condition, operating results and/or cash flows. In January 2020, the DOJ served the Company with a DEA administrative subpoena. The subpoena seeks documents relating to practices with respect to prescription opioids and other controlled substances at CVS pharmacy locations concerning potential violations of the federal Controlled Substances Act and the federal False Claims Act. In January 2022, the DOJ served the Company with a CID regarding similar subjects. The Company is providing documents and information in response to these matters. Prescription Processing Litigation and Investigations The Company is named as a defendant in a number of lawsuits and is subject to a number of investigations concerning its prescription processing practices, including the following: U.S. ex rel. Bassan et al. v. Omnicare, Inc. and CVS Health Corp. (U.S. District Court for the Southern District of New York). In December 2019, the U.S. Attorney’s Office for the Southern District of New York (the “SDNY”) filed a complaint-in-intervention in this previously sealed qui tam case. The complaint alleges that for certain non-skilled nursing facilities, Omnicare improperly filled prescriptions beyond one year where a valid prescription did not exist and that these dispensing events violated the federal False Claims Act. The Company is defending itself against these claims. U.S. ex rel. Gill et al. v. CVS Health Corp. et al. (U.S. District Court for the Northern District of Illinois). In July 2022, the Delaware Attorney General’s Office moved for partial intervention as to allegations under the Delaware false claims act related to not escheating alleged overpayments in this previously sealed qui tam case. The federal government and the remaining states declined to intervene on other additional theories in the relator’s complaint. The Company is defending itself against all of the claims. In July 2017, the Company also received a subpoena from the California Department of Insurance requesting documents concerning the Company’s Omnicare pharmacies’ cycle fill process for assisted living facilities. The Company has been cooperating with the California Department of Insurance and providing documents and information in response to this subpoena. In December 2016, the Company received a CID from the U.S. Attorney’s Office for the Northern District of New York requesting documents and information in connection with a federal False Claims Act investigation concerning whether the Company’s retail pharmacies improperly submitted certain insulin claims to Part D of the Medicare program rather than Part B of the Medicare program. The Company has been cooperating with the government and providing documents and information in response to this CID. Provider Proceedings The Company is named as a defendant in purported class actions and individual lawsuits arising out of its practices related to the payment of claims for services rendered to its members by providers with whom the Company has a contract and with whom the Company does not have a contract (“out-of-network providers”). Among other things, these lawsuits allege that the Company paid too little to its health plan members and/or providers for out-of-network services (including COVID-19 testing) and/or otherwise allege that the Company failed to timely or appropriately pay or administer out-of-network claims and benefits (including the Company’s post payment audit and collection practices and reductions in payments to providers due to sequestration). Other major health insurers are the subject of similar litigation or have settled similar litigation. The Company also has received subpoenas and/or requests for documents and other information from, and been investigated by, state Attorneys General and other state and/or federal regulators, legislators and agencies relating to, and the Company is involved in other litigation regarding, its out-of-network benefit payment and administration practices. It is reasonably possible that others could initiate additional litigation or additional regulatory action against the Company with respect to its out-of-network benefit payment and/or administration practices. CMS Actions CMS regularly audits the Company’s performance to determine its compliance with CMS’s regulations and its contracts with CMS and to assess the quality of services it provides to Medicare beneficiaries. CMS uses various payment mechanisms to allocate and adjust premium payments to the Company’s and other companies’ Medicare plans by considering the applicable health status of Medicare members as supported by information prepared, maintained and provided by providers. The Company collects claim and encounter data from providers and generally relies on providers to appropriately code their submissions to the Company and document their medical records, including the diagnosis data submitted to the Company with claims. CMS pays increased premiums to Medicare Advantage plans and Medicare PDP plans for members who have certain medical conditions identified with specific diagnosis codes. Federal regulators review and audit the providers’ medical records to determine whether those records support the related diagnosis codes that determine the members’ health status and the resulting risk-adjusted premium payments to the Company. In that regard, CMS has instituted risk adjustment data validation (“RADV”) audits of various Medicare Advantage plans, including certain of the Company’s plans, to validate coding practices and supporting medical record documentation maintained by providers and the resulting risk-adjusted premium payments to the plans. CMS may require the Company to refund premium payments if the Company’s risk-adjusted premiums are not properly supported by medical record data. The Office of the Inspector General of the U.S. Department of Health and Human Services (“OIG”) also is auditing the Company’s risk adjustment-related data and that of other companies. The Company expects CMS and the OIG to continue these types of audits. In 2012, CMS revised its audit methodology for RADV audits to determine refunds payable by Medicare Advantage plans for contract year 2011 and forward. Under the revised methodology, among other things, CMS will extrapolate the error rate identified in the audit sample of approximately 200 members to all risk-adjusted premium payments made under the contract being audited. For contract years prior to 2011, CMS did not extrapolate sample error rates to the entire contract. As a result, the revised methodology may increase the Company’s exposure to premium refunds to CMS based on incomplete medical records maintained by providers. Since 2013, CMS has selected certain of the Company’s Medicare Advantage contracts for various contract years for RADV audit, and the number of RADV audits continues to increase. The Company is currently unable to predict which of its Medicare Advantage contracts will be selected for future audit, the amounts of any retroactive refunds of, or prospective adjustments to, Medicare Advantage premium payments made to the Company, the effect of any such refunds or adjustments on the actuarial soundness of the Company’s Medicare Advantage bids, or whether any RADV audit findings would require the Company to change its method of estimating future premium revenue in future bid submissions to CMS or compromise premium assumptions made in the Company’s bids for prior contract years, the current contract year or future contract years. Any premium or fee refunds or adjustments resulting from regulatory audits, whether as a result of RADV, Public Exchange related or other audits by CMS, the OIG or otherwise, including audits of the Company’s minimum medical loss ratio rebates, methodology and/or reports, could be material and could adversely affect the Company’s operating results, cash flows and/or financial condition. Medicare and Medicaid CIDs The Company has received CIDs from the Civil Division of the DOJ in connection with a current investigation of the Company’s patient chart review processes in connection with risk adjustment data submissions under Parts C and D of the Medicare program. The Company has been cooperating with the government and providing documents and information in response to these CIDs. In May 2017, the Company received a CID from the SDNY requesting documents and information concerning possible false claims submitted to Medicare in connection with reimbursements for prescription drugs under the Medicare Part D program. The Company has been cooperating with the government and providing documents and information in response to this CID. Stockholder Matters Beginning in February 2019, multiple class action complaints, as well as a derivative complaint, were filed by putative plaintiffs against the Company and certain current and former officers and directors. The plaintiffs in these cases assert a variety of causes of action under federal securities laws that are premised on allegations that the defendants made certain omissions and misrepresentations relating to the performance of the Company’s LTC business unit. The Company and its current and former officers and directors are defending themselves against these claims. Since filing, several of the cases have been consolidated, and the first-filed federal case, City of Miami Fire Fighters’ and Police Officers’ Retirement Trust, et al. (formerly known as Anarkat), was dismissed with prejudice in February 2021. Plaintiffs appealed that decision to the First Circuit after their motion for reconsideration was denied, and in August 2022 the First Circuit affirmed the dismissal. In re CVS Health Corp. Securities Act Litigation (formerly known as Waterford) and In re CVS Health Corp. Securities Litigation (formerly known as City of Warren and Freundlich) have been stayed pending the outcome of the First Circuit appeal. Plaintiffs in In re CVS Health Corp. Securities Litigation filed an amended complaint, which the Company moved to dismiss in October 2022. In August and September 2020, two class actions under the Employee Retirement Income Security Act of 1974 (“ERISA”) were filed in the U.S. District Court for the District of Connecticut against CVS Health, Aetna Inc. (“Aetna”), and several current and former executives, directors and/or members of Aetna’s Compensation and Talent Management Committee: Radcliffe v. Aetna Inc., et al. and Flaim v. Aetna Inc., et al. The plaintiffs in these cases assert a variety of causes of action premised on allegations that the defendants breached fiduciary duties and engaged in prohibited transactions relating to participants in the Aetna 401(k) Plan’s investment in company stock between December 3, 2017 and February 20, 2019, claiming losses related to the performance of the Company’s LTC business unit. The district court consolidated the actions, and in October 2021, dismissed the consolidated action without prejudice. Plaintiffs filed an amended consolidated complaint, which the Company has moved to dismiss. In October 2022, the court granted the Company’s motion to dismiss with prejudice. Plaintiffs have appealed this decision to the Second Circuit. The Company also received a related document request pursuant to ERISA § 104(b), to which the Company has responded. The Company and its current and former officers and directors are defending themselves against these claims. In December 2021, the Company received a demand for inspection of books and records pursuant to Delaware Corporation Law Section 220 (the “Demand”). The Demand purports to be related to potential breaches of fiduciary duties by the Board in relation to certain matters concerning opioids. Other Legal and Regulatory Proceedings The Company is also a party to other legal proceedings and is subject to government investigations, inquiries and audits and has received and is cooperating with the government in response to CIDs, subpoenas or similar process from various governmental agencies requesting information. These other legal proceedings and government actions include claims of or relating to bad faith, medical or professional malpractice, breach of fiduciary duty, claims processing, dispensing of medications, non-compliance with state and federal regulatory regimes, marketing misconduct, denial of or failure to timely or appropriately pay or administer claims and benefits, provider network structure (including the use of performance-based networks and termination of provider contracts), rescission of insurance coverage, improper disclosure or use of personal information, anticompetitive practices, general contractual matters, product liability, intellectual property litigation and employment litigation. Some of these other legal proceedings are or are purported to be class actions or derivative claims. The Company is defending itself against the claims brought in these matters. Awards to the Company and others of certain government contracts, particularly Medicaid contracts and other contracts with government customers in the Company’s Health Care Benefits segment, frequently are subject to protests by unsuccessful bidders. These protests may result in awards to the Company being reversed, delayed or modified. The loss or delay in implementation of any government contract could adversely affect the Company’s operating results. The Company will continue to defend contract awards it receives. There also continues to be a heightened level of review and/or audit by regulatory authorities and legislators of, and increased litigation regarding, the Company’s and the rest of the health care and related benefits industry’s business and reporting practices, including premium rate increases, utilization management, development and application of medical policies, complaint, grievance and appeal processing, information privacy, provider network structure (including provider network adequacy, the use of performance-based networks and termination of provider contracts), provider directory accuracy, calculation of minimum medical loss ratios and/or payment of related rebates, delegated arrangements, rescission of insurance coverage, limited benefit health products, student health products, pharmacy benefit management practices (including manufacturers’ rebates, pricing, the use of narrow networks and the placement of drugs in formulary tiers), sales practices, customer service practices, vendor oversight and claim payment practices (including payments to out-of-network providers). As a leading national health solutions company, the Company regularly is the subject of government actions of the types described above. These government actions may prevent or delay the Company from implementing planned premium rate increases and may result, and have resulted, in restrictions on the Company’s businesses, changes to or clarifications of the Company’s business practices, retroactive adjustments to premiums, refunds or other payments to members, beneficiaries, states or the federal government, withholding of premium payments to the Company by government agencies, assessments of damages, civil or criminal fines or penalties, or other sanctions, including the possible suspension or loss of licensure and/or suspension or exclusion from participation in government programs. The Company can give no assurance that its businesses, financial condition, operating results and/or cash flows will not be materially adversely affected, or that the Company will not be required to materially change its business practices, based on: (i) future enactment of new health care or other laws or regulations; (ii) the interpretation or application of existing laws or regulations as they may relate to one or more of the Company’s businesses, one or more of the industries in which the Company competes and/or the health care industry generally; (iii) pending or future federal or state government investigations of one or more of the Company’s businesses, one or more of the industries in which the Company competes and/or the health care industry generally; (iv) pending or future government audits, investigations or enforcement actions against the Company; (v) adverse developments in any pending qui tam lawsuit against the Company, whether sealed or unsealed, or in any future qui tam lawsuit that may be filed against the Company; or (vi) adverse developments in pending or future legal proceedings against the Company or affecting one or more of the industries in which the Company competes and/or the health care industry generally.
|
Segment Reporting |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2022 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Segment Reporting [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Segment Reporting | Segment ReportingThe Company has three operating segments, Health Care Benefits, Pharmacy Services and Retail/LTC, as well as a Corporate/Other segment. The Company’s segments maintain separate financial information, and the Company’s chief operating decision maker (the “CODM”) evaluates the segments’ operating results on a regular basis in deciding how to allocate resources among the segments and in assessing segment performance. The CODM evaluates the performance of the Company’s segments based on adjusted operating income, which is defined as operating income (loss) (GAAP measure) excluding the impact of amortization of intangible assets and other items, if any, that neither relate to the ordinary course of the Company’s business nor reflect the Company’s underlying business performance. See the reconciliations of consolidated operating income (loss) (GAAP measure) to consolidated adjusted operating income below for further context regarding the items excluded from operating income (loss) in determining adjusted operating income. The Company uses adjusted operating income as its principal measure of segment performance as it enhances the Company’s ability to compare past financial performance with current performance and analyze underlying business performance and trends. Non-GAAP financial measures the Company discloses, such as consolidated adjusted operating income, should not be considered a substitute for, or superior to, financial measures determined or calculated in accordance with GAAP. The following is a reconciliation of financial measures of the Company’s segments to the consolidated totals:
_____________________________________________ (1)Total revenues of the Pharmacy Services segment include approximately $2.9 billion and $2.8 billion of retail co-payments for the three months ended September 30, 2022 and 2021, respectively, and $9.8 billion and $9.0 billion of retail co-payments for the nine months ended September 30, 2022 and 2021, respectively. (2)Intersegment revenue eliminations relate to intersegment revenue generating activities that occur between the Health Care Benefits segment, the Pharmacy Services segment, and/or the Retail/LTC segment. Intersegment adjusted operating income eliminations occur when members of Pharmacy Services Segment clients (“PSS members”) enrolled in Maintenance Choice® elect to pick up maintenance prescriptions at one of the Company’s retail pharmacies instead of receiving them through the mail. When this occurs, both the Pharmacy Services and Retail/LTC segments record the adjusted operating income on a stand-alone basis. The following are reconciliations of consolidated operating income (loss) to adjusted operating income for the three and nine months ended September 30, 2022 and 2021:
_____________________________________________ (1)The Company’s acquisition activities have resulted in the recognition of intangible assets as required under the acquisition method of accounting which consist primarily of trademarks, customer contracts/relationships, covenants not to compete, technology, provider networks and value of business acquired. Definite-lived intangible assets are amortized over their estimated useful lives and are tested for impairment when events indicate that the carrying value may not be recoverable. The amortization of intangible assets is reflected in the unaudited condensed consolidated statements of operations in operating expenses within each segment. Although intangible assets contribute to the Company’s revenue generation, the amortization of intangible assets does not directly relate to the underwriting of the Company’s insurance products, the services performed for the Company’s customers or the sale of the Company’s products or services. Additionally, intangible asset amortization expense typically fluctuates based on the size and timing of the Company’s acquisition activity. Accordingly, the Company believes excluding the amortization of intangible assets enhances the Company’s and investors’ ability to compare the Company’s past financial performance with its current performance and to analyze underlying business performance and trends. Intangible asset amortization excluded from the related non-GAAP financial measure represents the entire amount recorded within the Company’s GAAP financial statements, and the revenue generated by the associated intangible assets has not been excluded from the related non-GAAP financial measure. Intangible asset amortization is excluded from the related non-GAAP financial measure because the amortization, unlike the related revenue, is not affected by operations of any particular period unless an intangible asset becomes impaired or the estimated useful life of an intangible asset is revised. (2)During the three and nine months ended September 30, 2022 the opioid litigation charges relate to agreements to resolve substantially all opioid claims against the Company by certain states and governmental entities. The opioid litigation charges are reflected within the Corporate/Other segment. (3)During the three and nine months ended September 30, 2022, the loss on assets held for sale relates to the LTC reporting unit within the Retail/LTC segment. The Company continually evaluates its portfolio for nonstrategic assets. The Company determined that its LTC business was no longer a strategic asset and during the third quarter of 2022 committed to a plan to sell the LTC business. As of September 30, 2022, the LTC business met the criteria for held-for-sale accounting and the net assets were accounted for as assets held for sale. The carrying value of the LTC business was determined to be greater than its fair value and a loss on assets held for sale was recorded during the third quarter of 2022. During the nine months ended September 30, 2022, the loss on assets held for sale also relates to the Commercial Business reporting unit within the Health Care Benefits segment. In March 2022, the Company reached an agreement to sell its Thailand business, which was included in the Commercial Business reporting unit. At that time, a portion of the Commercial Business goodwill was specifically allocated to the Thailand business. The net assets of the Thailand business were accounted for as assets held for sale at March 31, 2022. The carrying value of the Thailand business was determined to be greater than its fair value and a loss on assets held for sale was recorded during the first quarter of 2022. The sale closed in the second quarter of 2022, and the ultimate loss on the sale was not material. (4)During the nine months ended September 30, 2022, the gain on divestiture of subsidiary represents the pre-tax gain on the sale of PayFlex, which the Company sold in June 2022, for approximately $775 million. The gain on divestiture is reflected as a reduction in operating expenses in the Company’s unaudited condensed consolidated statement of operations within the Health Care Benefits segment. (5)During the three and nine months ended September 30, 2021, acquisition-related integration costs relate to the acquisition of Aetna. The acquisition-related integration costs are reflected in the unaudited condensed consolidated statements of operations in operating expenses within the Corporate/Other segment. (6)During the three and nine months ended September 30, 2021, the goodwill impairment charge relates to an impairment of the remaining goodwill of the LTC reporting unit within the Retail/LTC segment. (7)In June 2021, the Company received $61 million related to a purchase price working capital adjustment for an acquisition completed during the first quarter of 2020. The resolution of this matter occurred subsequent to the acquisition accounting measurement period and is reflected in the Company’s unaudited condensed consolidated statement of operations for the nine months ended September 30, 2021 as a reduction of operating expenses within the Health Care Benefits segment.
|
Significant Accounting Policies (Policies) |
9 Months Ended |
---|---|
Sep. 30, 2022 | |
Accounting Policies [Abstract] | |
Segment Reporting | The Company has four reportable segments: Health Care Benefits, Pharmacy Services, Retail/LTC and Corporate/Other, which are described below. Health Care Benefits Segment The Health Care Benefits segment operates as one of the nation’s leading diversified health care benefits providers. The Health Care Benefits segment has the information and resources to help members, in consultation with their health care professionals, make more informed decisions about their health care. The Health Care Benefits segment offers a broad range of traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental and behavioral health plans, medical management capabilities, Medicare Advantage and Medicare Supplement plans, PDPs, Medicaid health care management services and health information technology products and services. The Health Care Benefits segment’s customers include employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers (“providers”), governmental units, government-sponsored plans, labor groups and expatriates. The Company refers to insurance products (where it assumes all or a majority of the risk for medical and dental care costs) as “Insured” and administrative services contract products (where the plan sponsor assumes all or a majority of the risk for medical and dental care costs) as “ASC.” In addition, effective January 2022, the Company entered the individual public health insurance exchanges (“Public Exchanges”) in eight states through which it sells Insured plans directly to individual consumers. The Company will enter Public Exchanges in four additional states effective January 2023. Open enrollment for the 2023 calendar year has begun in each of these twelve states. Pharmacy Services Segment The Pharmacy Services segment provides a full range of pharmacy benefit management (“PBM”) solutions, including plan design offerings and administration, formulary management, retail pharmacy network management services and mail order pharmacy. In addition, through the Pharmacy Services segment, the Company provides specialty pharmacy and infusion services, clinical services, disease management services, medical spend management and pharmacy and/or other administrative services for providers and federal 340B drug pricing program covered entities (“Covered Entities”). The Company operates a group purchasing organization that negotiates pricing for the purchase of pharmaceuticals and rebates with pharmaceutical manufacturers on behalf of its participants. The Company also provides various administrative, management and reporting services to pharmaceutical manufacturers. The Pharmacy Services segment’s clients are primarily employers, insurance companies, unions, government employee groups, health plans, PDPs, Medicaid managed care plans, plans offered on Public Exchanges and private health insurance exchanges, other sponsors of health benefit plans throughout the United States and Covered Entities. The Pharmacy Services segment operates retail specialty pharmacy stores, specialty mail order pharmacies, mail order dispensing pharmacies, compounding pharmacies and branches for infusion and enteral nutrition services. Retail/LTC Segment The Retail/LTC segment sells prescription drugs and a wide assortment of health and wellness products and general merchandise, provides health care services through its MinuteClinic® walk-in medical clinics, provides medical diagnostic testing, administers vaccinations for illnesses such as influenza, COVID-19 and shingles and conducts long-term care pharmacy (“LTC”) operations, which distribute prescription drugs and provide related pharmacy consulting and other ancillary services to long-term care facilities and other care settings. As of September 30, 2022, the Retail/LTC segment operated more than 9,000 retail locations, more than 1,100 MinuteClinic locations as well as online retail pharmacy websites, LTC pharmacies and on-site pharmacies. Corporate/Other Segment The Company presents the remainder of its financial results in the Corporate/Other segment, which primarily consists of: •Management and administrative expenses to support the Company’s overall operations, which include certain aspects of executive management and the corporate relations, legal, compliance, human resources, information technology and finance departments, expenses associated with the Company’s investments in its transformation and enterprise modernization programs and acquisition-related integration costs; and •Products for which the Company no longer solicits or accepts new customers such as its large case pensions and long-term care insurance products.
|
Basis of Presentation | Basis of Presentation The accompanying unaudited condensed consolidated financial statements of CVS Health and its subsidiaries have been prepared in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”) regarding interim financial reporting. In accordance with such rules and regulations, certain information and accompanying note disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) have been omitted, although the Company believes the disclosures included herein are adequate to make the information presented not misleading. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto, which are included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 (the “2021 Form 10-K”). In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the results for the interim periods presented. Because of the influence of various factors on the Company’s operations, including business combinations, certain holidays and other seasonal influences, net income for any interim period may not be comparable to the same interim period in previous years or necessarily indicative of income for the full year.
|
Principles of Consolidation | Principles of Consolidation The unaudited condensed consolidated financial statements include the accounts of the Company and its majority-owned subsidiaries and variable interest entities (“VIEs”) for which the Company is the primary beneficiary. All material intercompany balances and transactions have been eliminated. The Company continually evaluates its investments to determine if they represent variable interests in a VIE. If the Company determines that it has a variable interest in a VIE, the Company then evaluates if it is the primary beneficiary of the VIE. The evaluation is a qualitative assessment as to whether the Company has the ability to direct the activities of a VIE that most significantly impact the entity’s economic performance. The Company consolidates a VIE if it is considered to be the primary beneficiary. Assets and liabilities of VIEs for which the Company is the primary beneficiary were not significant to the Company’s unaudited condensed consolidated financial statements. VIE creditors do not have recourse against the general credit of the Company.
|
Reclassifications | Reclassifications Certain prior year amounts have been reclassified to conform with the current year presentation.
|
Restricted Cash | Restricted CashRestricted cash included in other current assets on the unaudited condensed consolidated balance sheets represents funds held on behalf of members, including health savings account funds associated with high deductible health plans. Restricted cash included in other assets on the unaudited condensed consolidated balance sheets represents amounts held in a trust in one of the Company’s captive insurance companies to satisfy collateral requirements associated with the assignment of certain insurance policies. All restricted cash is invested in time deposits and money market funds. |
Accounts Receivable | Accounts ReceivableAccounts receivable are stated net of allowances for credit losses, customer credit allowances, contractual allowances and estimated terminations |
Accounts Receivable, Allowance for Credit Losses | When developing an estimate of the Company’s expected credit losses, the Company considers all available relevant information regarding the collectability of cash flows, including historical information, current conditions and reasonable and supportable forecasts of future economic conditions over the contractual life of the receivable. The Company’s accounts receivable are short duration in nature and typically settle in less than 30 days. |
Contract Balances | Contract Balances Contract liabilities primarily represent the Company’s obligation to transfer additional goods or services to a customer for which the Company has received consideration, and include ExtraBucks® Rewards and unredeemed Company gift cards. The consideration received remains a contract liability until goods or services have been provided to the customer. In addition, the Company recognizes breakage on Company gift cards based on historical redemption patterns.
|
Related Party Transactions | Related Party Transactions The Company has an equity method investment in SureScripts, LLC (“SureScripts”), which operates a clinical health information network. The Company utilizes this clinical health information network in providing services to its client plan members and retail customers. The Company expensed fees for the use of this network of $16 million in each of the three-month periods ended September 30, 2022 and 2021, and expensed fees for the use of this network of approximately $47 million and $35 million in the nine months ended September 30, 2022 and 2021, respectively. The Company’s investment in and equity in the earnings of SureScripts for all periods presented is immaterial. The Company has an equity method investment in Heartland Healthcare Services, LLC (“Heartland”). Heartland operates several LTC pharmacies in four states. Heartland paid the Company $22 million and $20 million for pharmaceutical inventory purchases during the three months ended September 30, 2022 and 2021, respectively, and $66 million and $57 million for pharmaceutical inventory purchases during the nine months ended September 30, 2022 and 2021, respectively. Additionally, the Company performs certain collection functions for Heartland and then transfers those customer cash collections to Heartland. The Company’s investment in and equity in the earnings of Heartland for all periods presented is immaterial.
|
New Accounting Pronouncements Not Yet Adopted | New Accounting Pronouncements Not Yet Adopted Targeted Improvements to the Accounting for Long-Duration Insurance Contracts In August 2018, the Financial Accounting Standards Board issued Accounting Standards Update 2018-12, Targeted Improvements to the Accounting for Long-Duration Contracts (Topic 944). This standard requires the Company to review cash flow assumptions for its long-duration insurance contracts at least annually and recognize the effect of changes in future cash flow assumptions in net income. This standard also requires the Company to update discount rate assumptions quarterly and recognize the effect of changes in these assumptions in other comprehensive income. The rate used to discount the Company’s liability for future policy benefits will be based on an estimate of the yield for an upper-medium grade fixed-income instrument with a duration profile matching that of the Company’s liabilities. In addition, this standard changes the amortization method for deferred acquisition costs and requires additional disclosures regarding the long duration insurance contract liabilities in the Company’s interim and annual financial statements. The standard is effective for public companies for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2022. The Company will adopt the new standard on January 1, 2023, using the modified retrospective transition method as of the earliest period presented, January 1, 2021, also referred to as the transition date, for changes to the liability for future policy benefits and deferred acquisition costs. While the Company is still evaluating the impact of the new standard on its financial statements, the Company anticipates an increase to its liability for future policy benefits with a corresponding change in accumulated other comprehensive income on the transition date of approximately $1 billion as a result of updating the rate used to discount the liabilities to reflect the yield for an upper-medium grade fixed-income instrument compared to the Company’s expected investment yield under the existing guidance.
|
Significant Accounting Policies (Tables) |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2022 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accounting Policies [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reconciliation of cash and cash equivalents | The following is a reconciliation of cash and cash equivalents on the unaudited condensed consolidated balance sheets to total cash, cash equivalents and restricted cash on the unaudited condensed consolidated statements of cash flows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of accounts receivable, net | Accounts receivable, net is composed of the following:
_____________________________________________ (1)Includes accounts receivable of $248 million which have been accounted for as assets held for sale and are included in assets held for sale on the unaudited condensed consolidated balance sheet at September 30, 2022. See Note 2 ‘‘Acquisition, Divestitures and Asset Sales’’ for additional information.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Disaggregation of revenue | The following tables disaggregate the Company’s revenue by major source in each segment for the three and nine months ended September 30, 2022 and 2021:
_____________________________________________ (1)Pharmacy Services pharmacy network is defined as claims filled at retail and specialty retail pharmacies, including the Company’s retail pharmacies and LTC pharmacies, but excluding Maintenance Choice® activity, which is included within the mail choice category. Maintenance Choice permits eligible client plan members to fill their maintenance prescriptions through mail order delivery or at a CVS pharmacy retail store for the same price as mail order. (2)Pharmacy Services mail choice is defined as claims filled at a Pharmacy Services mail order facility, which includes specialty mail claims inclusive of Specialty Connect® claims picked up at a retail pharmacy, as well as prescriptions filled at the Company’s retail pharmacies under the Maintenance Choice program.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of receivables and contract liabilities from contracts with customers | The following table provides information about receivables and contract liabilities from contracts with customers:
During the nine months ended September 30, 2022 and 2021, the contract liabilities balance includes increases related to customers’ earnings in ExtraBucks Rewards or issuances of Company gift cards and decreases for revenues recognized during the period as a result of the redemption of ExtraBucks Rewards or Company gift cards and breakage of Company gift cards. Below is a summary of such changes:
|
Acquisition, Divestitures and Asset Sales (Tables) |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2022 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Business Combination and Asset Acquisition [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of Assets and Liabilities Held for Sale | The following table summarizes the assets and liabilities held for sale at September 30, 2022:
_____________________________________________ (1) $475 million of goodwill within the Commercial Business reporting unit was specifically allocated to the bswift business at September 30, 2022.
|
Investments (Tables) |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2022 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Investments [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Total Investments | Total investments at September 30, 2022 and December 31, 2021 were as follows:
_____________________________________________ (1)Includes long-term investments of $18 million which have been accounted for as assets held for sale and are included in assets held for sale on the unaudited condensed consolidated balance sheet at September 30, 2022. See Note 2 ‘‘Acquisition, Divestitures and Asset Sales’’ for additional information.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Debt Securities Available For Sale | Debt securities available for sale at September 30, 2022 and December 31, 2021 were as follows:
_____________________________________________ (1)Investment risks associated with the Company’s experience-rated products generally do not impact the Company’s consolidated operating results. At September 30, 2022, debt securities with a fair value of $612 million, gross unrealized capital gains of $2 million and gross unrealized capital losses of $73 million and at December 31, 2021, debt securities with a fair value of $864 million, gross unrealized capital gains of $94 million and gross unrealized capital losses of $2 million were included in total debt securities, but support experience-rated products. Changes in net unrealized capital gains (losses) on these securities are not reflected in accumulated other comprehensive income (loss).
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Net Amortized Cost and Fair Value of Debt Securities by Contractual Maturity | The net amortized cost and fair value of debt securities at September 30, 2022 are shown below by contractual maturity. Actual maturities may differ from contractual maturities because securities may be restructured, called or prepaid, or the Company intends to sell a security prior to maturity.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Debt Securities In An Unrealized Capital Loss Position | Summarized below are the debt securities the Company held at September 30, 2022 and December 31, 2021 that were in an unrealized capital loss position, aggregated by the length of time the investments have been in that position:
The maturity dates for debt securities in an unrealized capital loss position at September 30, 2022 were as follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Activity in Mortgage Loan Portfolio | During the three and nine months ended September 30, 2022 and 2021, the Company had the following activity in its mortgage loan portfolio:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Mortgage Loan Amortized Cost and Credit Quality Indicator | Based on the Company’s assessments at September 30, 2022 and December 31, 2021, the amortized cost basis of the Company's mortgage loans within each credit quality indicator by year of origination was as follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Net Investment Income | Sources of net investment income for the three and nine months ended September 30, 2022 and 2021 were as follows:
_____________________________________________ (1)Net realized capital losses include credit-related losses on debt securities of $1 million and yield-related impairment losses on debt securities of $73 million in the three months ended September 30, 2022. Net realized capital losses include credit-related losses on debt securities of $17 million and yield-related impairment losses on debt securities of $121 million in the nine months ended September 30, 2022. Net realized capital losses include yield-related impairment losses on debt securities of $3 million in the three months ended September 30, 2021. Net realized capital gains are net of yield-related impairment losses on debt securities of $35 million in the nine months ended September 30, 2021. There were no credit-related losses on debt securities in the three and nine months ended September 30, 2021. (2)Net investment income includes $8 million and $26 million for the three and nine months ended September 30, 2022, respectively, and $9 million and $28 million for the three and nine months ended September 30, 2021, respectively, related to investments supporting experience-rated products.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Proceeds and Related Gross Realized Capital Gains and Losses From the Sale of Debt Securities | Excluding amounts related to experience-rated products, proceeds from the sale of available-for-sale debt securities and the related gross realized capital gains and losses for the three and nine months ended September 30, 2022 and 2021 were as follows:
|
Fair Value (Tables) |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2022 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value Disclosures [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis | Financial assets measured at fair value on a recurring basis on the unaudited condensed consolidated balance sheets at September 30, 2022 and December 31, 2021 were as follows:
_____________________________________________ (1)Includes cash and cash equivalents of $7 million which have been accounted for as assets held for sale and are included in assets held for sale on the unaudited condensed consolidated balance sheet at September 30, 2022. See Note 2 ‘‘Acquisition, Divestitures and Asset Sales’’ for additional information.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value, by Balance Sheet Grouping | The carrying value and estimated fair value classified by level of fair value hierarchy for financial instruments carried on the unaudited condensed consolidated balance sheets at adjusted cost or contract value at September 30, 2022 and December 31, 2021 were as follows:
_____________________________________________ (1)It was not practical to estimate the fair value of these cost-method investments as it represents shares of unlisted companies. (2)Includes long-term debt of $3 million which has been accounted for as liabilities held for sale and are included in liabilities held for sale on the unaudited condensed consolidated balance sheet at September 30, 2022. See Note 2 ‘‘Acquisition, Divestitures and Asset Sales’’ for additional information.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Fair Value of Separate Accounts by Major Category of Investment | Separate Accounts financial assets as of September 30, 2022 and December 31, 2021 were as follows:
_____________________________________________ (1)Excludes $20 million and $70 million of other receivables at September 30, 2022 and December 31, 2021, respectively.
|
Health Care Costs Payable (Tables) |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2022 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Health Care and Other Insurance Liabilities [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Liability for Unpaid Claims and Claims Adjustment Expense | The following table shows the components of the change in health care costs payable during the nine months ended September 30, 2022 and 2021:
_____________________________________________ (1)Total incurred health care costs for the nine months ended September 30, 2022 and 2021 in the table above exclude (i) $5 million and $1 million, respectively, for premium deficiency reserves related to the Company’s Medicaid products, (ii) $56 million and $45 million, respectively, of benefit costs recorded in the Health Care Benefits segment that are included in other insurance liabilities on the unaudited condensed consolidated balance sheets and (iii) $274 million and $168 million, respectively, of benefit costs recorded in the Corporate/Other segment that are included in other insurance liabilities on the unaudited condensed consolidated balance sheets.
|
Borrowings (Tables) |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2022 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of Company's Borrowings | The following table is a summary of the Company’s borrowings at September 30, 2022 and December 31, 2021:
_____________________________________________________________________________________________________________________________ (1)Includes long-term debt of $3 million which has been accounted for as liabilities held for sale and are included in liabilities held for sale on the unaudited condensed consolidated balance sheet at September 30, 2022. See Note 2 ‘‘Acquisition, Divestitures and Asset Sales’’ for additional information.
|
Shareholders' Equity (Tables) |
9 Months Ended | ||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2022 | |||||||||||||||||||||||||||||||||||||
Equity [Abstract] | |||||||||||||||||||||||||||||||||||||
Share repurchase programs | The following share repurchase program has been authorized by CVS Health Corporation’s Board of Directors (the “Board”):
|
Other Comprehensive Income (Loss) (Tables) |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2022 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Other Comprehensive Income (Loss), Net of Tax [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Accumulated Other Comprehensive Income | Shareholders’ equity included the following activity in accumulated other comprehensive income (loss) for the three and nine months ended September 30, 2022 and 2021:
_____________________________________________ (1)Amounts reclassified from accumulated other comprehensive income (loss) for specifically identified debt securities are included in net investment income in the unaudited condensed consolidated statements of operations. (2)Amounts reclassified from accumulated other comprehensive income for specifically identified cash flow hedges are included in interest expense in the unaudited condensed consolidated statements of operations. The Company expects to reclassify approximately $11 million, net of tax, in net gains associated with its cash flow hedges into net income within the next 12 months. (3)Amounts reclassified from accumulated other comprehensive loss for specifically identified pension and other postretirement benefits are included in other income in the unaudited condensed consolidated statements of operations.
|
Earnings (Loss) Per Share (Tables) |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2022 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Earnings Per Share [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Earnings (Loss) Per Share | The following is a reconciliation of basic and diluted earnings (loss) per share for the respective periods:
|
Segment Reporting (Tables) |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2022 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Segment Reporting [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summarized Financial Information Of Segments | The following is a reconciliation of financial measures of the Company’s segments to the consolidated totals:
_____________________________________________ (1)Total revenues of the Pharmacy Services segment include approximately $2.9 billion and $2.8 billion of retail co-payments for the three months ended September 30, 2022 and 2021, respectively, and $9.8 billion and $9.0 billion of retail co-payments for the nine months ended September 30, 2022 and 2021, respectively. (2)Intersegment revenue eliminations relate to intersegment revenue generating activities that occur between the Health Care Benefits segment, the Pharmacy Services segment, and/or the Retail/LTC segment. Intersegment adjusted operating income eliminations occur when members of Pharmacy Services Segment clients (“PSS members”) enrolled in Maintenance Choice® elect to pick up maintenance prescriptions at one of the Company’s retail pharmacies instead of receiving them through the mail. When this occurs, both the Pharmacy Services and Retail/LTC segments record the adjusted operating income on a stand-alone basis.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reconciliation of Consolidated Operating Income to Adjusted Operating Income | The following are reconciliations of consolidated operating income (loss) to adjusted operating income for the three and nine months ended September 30, 2022 and 2021:
_____________________________________________ (1)The Company’s acquisition activities have resulted in the recognition of intangible assets as required under the acquisition method of accounting which consist primarily of trademarks, customer contracts/relationships, covenants not to compete, technology, provider networks and value of business acquired. Definite-lived intangible assets are amortized over their estimated useful lives and are tested for impairment when events indicate that the carrying value may not be recoverable. The amortization of intangible assets is reflected in the unaudited condensed consolidated statements of operations in operating expenses within each segment. Although intangible assets contribute to the Company’s revenue generation, the amortization of intangible assets does not directly relate to the underwriting of the Company’s insurance products, the services performed for the Company’s customers or the sale of the Company’s products or services. Additionally, intangible asset amortization expense typically fluctuates based on the size and timing of the Company’s acquisition activity. Accordingly, the Company believes excluding the amortization of intangible assets enhances the Company’s and investors’ ability to compare the Company’s past financial performance with its current performance and to analyze underlying business performance and trends. Intangible asset amortization excluded from the related non-GAAP financial measure represents the entire amount recorded within the Company’s GAAP financial statements, and the revenue generated by the associated intangible assets has not been excluded from the related non-GAAP financial measure. Intangible asset amortization is excluded from the related non-GAAP financial measure because the amortization, unlike the related revenue, is not affected by operations of any particular period unless an intangible asset becomes impaired or the estimated useful life of an intangible asset is revised. (2)During the three and nine months ended September 30, 2022 the opioid litigation charges relate to agreements to resolve substantially all opioid claims against the Company by certain states and governmental entities. The opioid litigation charges are reflected within the Corporate/Other segment. (3)During the three and nine months ended September 30, 2022, the loss on assets held for sale relates to the LTC reporting unit within the Retail/LTC segment. The Company continually evaluates its portfolio for nonstrategic assets. The Company determined that its LTC business was no longer a strategic asset and during the third quarter of 2022 committed to a plan to sell the LTC business. As of September 30, 2022, the LTC business met the criteria for held-for-sale accounting and the net assets were accounted for as assets held for sale. The carrying value of the LTC business was determined to be greater than its fair value and a loss on assets held for sale was recorded during the third quarter of 2022. During the nine months ended September 30, 2022, the loss on assets held for sale also relates to the Commercial Business reporting unit within the Health Care Benefits segment. In March 2022, the Company reached an agreement to sell its Thailand business, which was included in the Commercial Business reporting unit. At that time, a portion of the Commercial Business goodwill was specifically allocated to the Thailand business. The net assets of the Thailand business were accounted for as assets held for sale at March 31, 2022. The carrying value of the Thailand business was determined to be greater than its fair value and a loss on assets held for sale was recorded during the first quarter of 2022. The sale closed in the second quarter of 2022, and the ultimate loss on the sale was not material. (4)During the nine months ended September 30, 2022, the gain on divestiture of subsidiary represents the pre-tax gain on the sale of PayFlex, which the Company sold in June 2022, for approximately $775 million. The gain on divestiture is reflected as a reduction in operating expenses in the Company’s unaudited condensed consolidated statement of operations within the Health Care Benefits segment. (5)During the three and nine months ended September 30, 2021, acquisition-related integration costs relate to the acquisition of Aetna. The acquisition-related integration costs are reflected in the unaudited condensed consolidated statements of operations in operating expenses within the Corporate/Other segment. (6)During the three and nine months ended September 30, 2021, the goodwill impairment charge relates to an impairment of the remaining goodwill of the LTC reporting unit within the Retail/LTC segment. (7)In June 2021, the Company received $61 million related to a purchase price working capital adjustment for an acquisition completed during the first quarter of 2020. The resolution of this matter occurred subsequent to the acquisition accounting measurement period and is reflected in the Company’s unaudited condensed consolidated statement of operations for the nine months ended September 30, 2021 as a reduction of operating expenses within the Health Care Benefits segment.
|
Significant Accounting Policies - Narrative (Details) people in Millions, patient in Millions, $ in Millions |
1 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended | ||
---|---|---|---|---|---|---|
Jan. 31, 2023
state
|
Sep. 30, 2022
USD ($)
clinic
patient
people
state
store
|
Sep. 30, 2021
USD ($)
|
Sep. 30, 2022
USD ($)
clinic
patient
people
state
Segment
store
|
Sep. 30, 2021
USD ($)
|
Dec. 31, 2023
state
|
|
Significant Accounting Policies [Line Items] | ||||||
Number of pharmacy plan members | people | 110 | 110 | ||||
Number of patients served per year | patient | 1 | 1 | ||||
Number of reportable segments | Segment | 4 | |||||
Expenses from transactions with related party | $ | $ 16 | $ 16 | $ 47 | $ 35 | ||
Other revenues from transactions with related party | $ | $ 22 | $ 20 | $ 66 | $ 57 | ||
Heartland Healthcare Services | ||||||
Significant Accounting Policies [Line Items] | ||||||
Number of states in which entity operates | 4 | 4 | ||||
Retail/ LTC | ||||||
Significant Accounting Policies [Line Items] | ||||||
Number of retail locations (more than) | store | 9,000 | 9,000 | ||||
Number of walk in medical clinics | clinic | 1,100 | 1,100 | ||||
Health Care Benefits | ||||||
Significant Accounting Policies [Line Items] | ||||||
Number of people served | people | 35 | 35 | ||||
Number of states in which the Company has entered the individual public health insurance exchange | 8 | |||||
Health Care Benefits | Forecast | ||||||
Significant Accounting Policies [Line Items] | ||||||
Number of states in which the Company has entered the individual public health insurance exchange | 12 | |||||
Additional number of states in which the Company will enter the individual public health insurance exchange | 4 |
Significant Accounting Policies - Cash and Cash Equivalents, Restricted Cash and Cash Equivalents (Details) - USD ($) $ in Millions |
Sep. 30, 2022 |
Dec. 31, 2021 |
Sep. 30, 2021 |
Dec. 31, 2020 |
---|---|---|---|---|
Accounting Policies [Abstract] | ||||
Cash and cash equivalents | $ 17,197 | $ 9,408 | $ 9,826 | |
Restricted cash (included in other current assets) | 151 | 3,065 | 2,996 | |
Restricted cash (included in other assets) | 215 | 218 | 218 | |
Total cash, cash equivalents and restricted cash in the statements of cash flows | $ 17,563 | $ 12,691 | $ 13,040 | $ 11,043 |
Significant Accounting Policies - Accounts Receivable (Details) - USD ($) $ in Millions |
Sep. 30, 2022 |
Dec. 31, 2021 |
---|---|---|
Accounts, Notes, Loans and Financing Receivable [Line Items] | ||
Trade receivables | $ 8,016 | $ 7,932 |
Vendor and manufacturer receivables | 13,534 | 10,573 |
Premium receivables | 2,368 | 2,537 |
Other receivables | 2,647 | 3,389 |
Total accounts receivable, net | 26,565 | 24,431 |
Allowance for credit losses | 344 | $ 339 |
Disposal Group, Held-for-sale, Not Discontinued Operations | ||
Accounts, Notes, Loans and Financing Receivable [Line Items] | ||
Total accounts receivable, net | $ 248 |
Significant Accounting Policies - Disaggregation of Revenue (Details) - USD ($) $ in Millions |
3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Sep. 30, 2022 |
Sep. 30, 2021 |
Sep. 30, 2022 |
Sep. 30, 2021 |
|
Disaggregation of Revenue [Line Items] | ||||
Revenues | $ 80,958 | $ 73,548 | $ 238,106 | $ 214,675 |
Net investment income (loss) | 201 | 246 | 515 | 832 |
Total revenues | 81,159 | 73,794 | 238,621 | 215,507 |
Pharmacy | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 52,375 | 47,033 | 151,191 | 135,917 |
Front Store | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 5,581 | 5,359 | 16,630 | 15,255 |
Premiums | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 21,003 | 18,984 | 63,894 | 56,927 |
Other | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 1,999 | 2,172 | 6,391 | 6,576 |
Health Care Benefits | ||||
Disaggregation of Revenue [Line Items] | ||||
Total revenues | 22,511 | 20,479 | 68,376 | 61,487 |
Pharmacy Services | ||||
Disaggregation of Revenue [Line Items] | ||||
Total revenues | 43,216 | 39,046 | 125,489 | 113,681 |
Retail/ LTC | ||||
Disaggregation of Revenue [Line Items] | ||||
Total revenues | 26,706 | 24,992 | 78,410 | 72,994 |
Operating Segments | Health Care Benefits | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 22,387 | 20,311 | 68,029 | 60,993 |
Net investment income (loss) | 101 | 147 | 278 | 432 |
Total revenues | 22,511 | 20,479 | 68,376 | 61,487 |
Operating Segments | Health Care Benefits | Pharmacy | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 0 | 0 | 0 | 0 |
Operating Segments | Health Care Benefits | Front Store | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 0 | 0 | 0 | 0 |
Operating Segments | Health Care Benefits | Premiums | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 20,989 | 18,959 | 63,848 | 56,869 |
Operating Segments | Health Care Benefits | Other | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 1,421 | 1,373 | 4,250 | 4,186 |
Operating Segments | Pharmacy Services | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 40,545 | 36,851 | 116,600 | 105,909 |
Net investment income (loss) | 0 | 0 | 0 | 0 |
Total revenues | 43,216 | 39,046 | 125,489 | 113,681 |
Operating Segments | Pharmacy Services | Pharmacy network | ||||
Disaggregation of Revenue [Line Items] | ||||
Total revenues | 25,012 | 23,665 | 72,373 | 68,476 |
Operating Segments | Pharmacy Services | Mail choice | ||||
Disaggregation of Revenue [Line Items] | ||||
Total revenues | 17,935 | 15,202 | 52,339 | 44,685 |
Operating Segments | Pharmacy Services | Other | ||||
Disaggregation of Revenue [Line Items] | ||||
Total revenues | 269 | 179 | 777 | 520 |
Operating Segments | Pharmacy Services | Pharmacy | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 42,947 | 38,867 | 124,712 | 113,161 |
Operating Segments | Pharmacy Services | Front Store | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 0 | 0 | 0 | 0 |
Operating Segments | Pharmacy Services | Premiums | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 0 | 0 | 0 | 0 |
Operating Segments | Pharmacy Services | Other | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 269 | 179 | 777 | 520 |
Operating Segments | Retail/ LTC | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 17,994 | 16,347 | 53,380 | 47,672 |
Net investment income (loss) | (10) | (33) | (44) | 13 |
Total revenues | 26,706 | 24,992 | 78,410 | 72,994 |
Operating Segments | Retail/ LTC | Pharmacy | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 20,759 | 19,023 | 60,308 | 55,781 |
Operating Segments | Retail/ LTC | Front Store | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 5,581 | 5,359 | 16,630 | 15,255 |
Operating Segments | Retail/ LTC | Premiums | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 0 | 0 | 0 | 0 |
Operating Segments | Retail/ LTC | Other | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 376 | 643 | 1,516 | 1,945 |
Corporate/ Other | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 32 | 39 | 97 | 101 |
Net investment income (loss) | 110 | 132 | 281 | 387 |
Total revenues | 142 | 171 | 378 | 488 |
Corporate/ Other | Pharmacy | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 0 | 0 | 0 | 0 |
Corporate/ Other | Front Store | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 0 | 0 | 0 | 0 |
Corporate/ Other | Premiums | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 14 | 25 | 46 | 58 |
Corporate/ Other | Other | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 18 | 14 | 51 | 43 |
Intersegment Eliminations | ||||
Disaggregation of Revenue [Line Items] | ||||
Net investment income (loss) | 0 | 0 | 0 | 0 |
Total revenues | (11,416) | (10,894) | (34,032) | (33,143) |
Intersegment Eliminations | Pharmacy | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | (11,331) | (10,857) | (33,829) | (33,025) |
Intersegment Eliminations | Front Store | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 0 | 0 | 0 | 0 |
Intersegment Eliminations | Premiums | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | 0 | 0 | 0 | 0 |
Intersegment Eliminations | Other | ||||
Disaggregation of Revenue [Line Items] | ||||
Revenues | $ (85) | $ (37) | $ (203) | $ (118) |
Significant Accounting Policies - Receivables and Contracted Balances (Details) - USD ($) $ in Millions |
Sep. 30, 2022 |
Dec. 31, 2021 |
Sep. 30, 2021 |
Dec. 31, 2020 |
---|---|---|---|---|
Accounting Policies [Abstract] | ||||
Trade receivables (included in accounts receivable, net) | $ 8,016 | $ 7,932 | ||
Contract liabilities (included in accrued expenses) | $ 74 | $ 87 | $ 78 | $ 71 |
Significant Accounting Policies - Contract Balances (Details) - USD ($) $ in Millions |
9 Months Ended | |
---|---|---|
Sep. 30, 2022 |
Sep. 30, 2021 |
|
Change in Contract with Customer, Liability [Roll Forward] | ||
Contract liabilities, beginning of the period | $ 87 | $ 71 |
Rewards earnings and gift card issuances | 250 | 286 |
Redemption and breakage | (263) | (279) |
Contract liabilities, end of the period | $ 74 | $ 78 |
Significant Accounting Policies - New Accounting Pronouncements Not Yet Adopted (Details) $ in Billions |
Jan. 01, 2023
USD ($)
|
---|---|
Accounting Standards Update 2018-12 | Forecast | Cumulative Effect, Period of Adoption, Adjustment | |
New Accounting Pronouncements or Change in Accounting Principle [Line Items] | |
Increase to liability for future policy benefits | $ 1 |
Acquisition, Divestitures and Asset Sales - Narrative (Details) $ / shares in Units, member in Thousands, $ in Millions |
1 Months Ended | 3 Months Ended | 9 Months Ended | |||||
---|---|---|---|---|---|---|---|---|
Sep. 02, 2022
USD ($)
$ / shares
|
Jun. 30, 2022
USD ($)
|
Sep. 30, 2022
USD ($)
|
Mar. 31, 2022
USD ($)
member
|
Sep. 30, 2021
USD ($)
|
Sep. 30, 2022
USD ($)
|
Sep. 30, 2021
USD ($)
|
May 31, 2022
member
|
|
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | ||||||||
Loss on assets held for sale | $ 2,480 | $ 0 | $ 2,521 | $ 0 | ||||
Gain (loss) on divestiture, pretax | 0 | $ 0 | 225 | $ 0 | ||||
Signify Health, Inc. | ||||||||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | ||||||||
Cash to be received by shareholders in proposed acquisition (in dollars per share) | $ / shares | $ 30.50 | |||||||
Total value of proposed acquisition | $ 8,000 | |||||||
Termination fee | 380 | |||||||
Signify Health, Inc. | Signify Health, Inc. | ||||||||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | ||||||||
Termination fee | $ 228 | |||||||
Disposal Group, Held-for-sale, Not Discontinued Operations | Omnicare Long-Term Care Business | Retail/ LTC | ||||||||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | ||||||||
Loss on assets held for sale | $ 2,500 | 2,500 | ||||||
Disposal Group, Disposed of by Sale, Not Discontinued Operations | Payflex | Health Care Benefits | ||||||||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | ||||||||
Proceeds from divestiture of subsidiary | $ 775 | |||||||
Gain (loss) on divestiture, pretax | 225 | |||||||
Disposal Group, Disposed of by Sale, Not Discontinued Operations | Thailand Business | Health Care Benefits | ||||||||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | ||||||||
Loss on assets held for sale | $ 41 | $ 41 | ||||||
Number of medical members | member | 266 | |||||||
Disposal Group, Disposed of by Sale, Not Discontinued Operations | International Health Care Renewal Rights | ||||||||
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | ||||||||
Number of international health care members, renewal rights sold | member | 200 | |||||||
Member migration period | 16 months |
Acquisition, Divestitures and Asset Sales - Summary of Assets and Liabilities Held for Sale (Details) - Disposal Group, Held-for-sale, Not Discontinued Operations $ in Millions |
Sep. 30, 2022
USD ($)
|
---|---|
Assets: | |
Accounts receivable, net | $ 248 |
Inventories | 201 |
Property and equipment, net | 254 |
Goodwill | 475 |
Deferred income taxes | 130 |
Other | 190 |
Total assets held for sale | 1,498 |
Liabilities: | |
Accounts payable | 98 |
Accrued expenses | 94 |
Other | 104 |
Total liabilities held for sale | 296 |
bswift LLC | |
Assets: | |
Goodwill | $ 475 |
Investments - Total Investment Schedule (Details) - USD ($) $ in Millions |
Sep. 30, 2022 |
Dec. 31, 2021 |
---|---|---|
Total Investments [Line Items] | ||
Current | $ 2,792 | $ 3,117 |
Long-term | 20,583 | 23,025 |
Total | 23,375 | 26,142 |
Disposal Group, Held-for-sale, Not Discontinued Operations | ||
Total Investments [Line Items] | ||
Long-term | 18 | |
Debt securities available for sale | ||
Total Investments [Line Items] | ||
Current | 2,729 | 3,009 |
Long-term | 17,311 | 20,231 |
Total | 20,040 | 23,240 |
Mortgage loans | ||
Total Investments [Line Items] | ||
Current | 58 | 58 |
Long-term | 989 | 844 |
Total | 1,047 | 902 |
Other investments | ||
Total Investments [Line Items] | ||
Current | 5 | 50 |
Long-term | 2,283 | 1,950 |
Total | $ 2,288 | $ 2,000 |
Investments - Debt Securities (Details) - USD ($) $ in Millions |
Sep. 30, 2022 |
Dec. 31, 2021 |
---|---|---|
Debt Securities, Available-for-sale [Line Items] | ||
Gross Amortized Cost | $ 22,248 | $ 22,174 |
Allowance for Credit Losses | (9) | 0 |
Net Amortized Cost | 22,239 | 22,174 |
Gross Unrealized Gains | 26 | 1,172 |
Gross Unrealized Losses | (2,225) | (106) |
Fair Value | 20,040 | 23,240 |
Supporting experience-rated products | ||
Debt Securities, Available-for-sale [Line Items] | ||
Gross Unrealized Gains | 2 | 94 |
Gross Unrealized Losses | (73) | (2) |
Fair Value | 612 | 864 |
U.S. government securities | ||
Debt Securities, Available-for-sale [Line Items] | ||
Gross Amortized Cost | 2,172 | 2,349 |
Allowance for Credit Losses | 0 | 0 |
Net Amortized Cost | 2,172 | 2,349 |
Gross Unrealized Gains | 0 | 70 |
Gross Unrealized Losses | (191) | (3) |
Fair Value | 1,981 | 2,416 |
States, municipalities and political subdivisions | ||
Debt Securities, Available-for-sale [Line Items] | ||
Gross Amortized Cost | 2,455 | 2,947 |
Allowance for Credit Losses | 0 | 0 |
Net Amortized Cost | 2,455 | 2,947 |
Gross Unrealized Gains | 1 | 148 |
Gross Unrealized Losses | (182) | (4) |
Fair Value | 2,274 | 3,091 |
U.S. corporate securities | ||
Debt Securities, Available-for-sale [Line Items] | ||
Gross Amortized Cost | 9,923 | 9,093 |
Allowance for Credit Losses | 0 | 0 |
Net Amortized Cost | 9,923 | 9,093 |
Gross Unrealized Gains | 13 | 682 |
Gross Unrealized Losses | (1,080) | (40) |
Fair Value | 8,856 | 9,735 |
Foreign securities | ||
Debt Securities, Available-for-sale [Line Items] | ||
Gross Amortized Cost | 2,820 | 2,821 |
Allowance for Credit Losses | (9) | 0 |
Net Amortized Cost | 2,811 | 2,821 |
Gross Unrealized Gains | 7 | 196 |
Gross Unrealized Losses | (324) | (24) |
Fair Value | 2,494 | 2,993 |
Residential mortgage-backed securities | ||
Debt Securities, Available-for-sale [Line Items] | ||
Gross Amortized Cost | 859 | 870 |
Allowance for Credit Losses | 0 | 0 |
Net Amortized Cost | 859 | 870 |
Gross Unrealized Gains | 0 | 15 |
Gross Unrealized Losses | (109) | (10) |
Fair Value | 750 | 875 |
Commercial mortgage-backed securities | ||
Debt Securities, Available-for-sale [Line Items] | ||
Gross Amortized Cost | 1,203 | 1,278 |
Allowance for Credit Losses | 0 | 0 |
Net Amortized Cost | 1,203 | 1,278 |
Gross Unrealized Gains | 0 | 44 |
Gross Unrealized Losses | (166) | (12) |
Fair Value | 1,037 | 1,310 |
Other asset-backed securities | ||
Debt Securities, Available-for-sale [Line Items] | ||
Gross Amortized Cost | 2,791 | 2,791 |
Allowance for Credit Losses | 0 | 0 |
Net Amortized Cost | 2,791 | 2,791 |
Gross Unrealized Gains | 5 | 14 |
Gross Unrealized Losses | (171) | (13) |
Fair Value | 2,625 | 2,792 |
Redeemable preferred securities | ||
Debt Securities, Available-for-sale [Line Items] | ||
Gross Amortized Cost | 25 | 25 |
Allowance for Credit Losses | 0 | 0 |
Net Amortized Cost | 25 | 25 |
Gross Unrealized Gains | 0 | 3 |
Gross Unrealized Losses | (2) | 0 |
Fair Value | $ 23 | $ 28 |
Investments - Debt Securities by Maturity (Details) - USD ($) $ in Millions |
Sep. 30, 2022 |
Dec. 31, 2021 |
---|---|---|
Net Amortized Cost | ||
Less than one year | $ 1,299 | |
One year through five years | 6,704 | |
After five years through ten years | 4,980 | |
Greater than ten years | 4,403 | |
Net Amortized Cost | 22,239 | $ 22,174 |
Fair Value | ||
Less than one year | 1,288 | |
One year through five years | 6,260 | |
After five years through ten years | 4,347 | |
Greater than ten years | 3,733 | |
Total | 20,040 | 23,240 |
Residential mortgage-backed securities | ||
Net Amortized Cost | ||
Debt securities, maturity, without single maturity date | 859 | |
Net Amortized Cost | 859 | 870 |
Fair Value | ||
Debt securities, maturity, without single maturity date | 750 | |
Total | 750 | 875 |
Commercial mortgage-backed securities | ||
Net Amortized Cost | ||
Debt securities, maturity, without single maturity date | 1,203 | |
Net Amortized Cost | 1,203 | 1,278 |
Fair Value | ||
Debt securities, maturity, without single maturity date | 1,037 | |
Total | 1,037 | 1,310 |
Other asset-backed securities | ||
Net Amortized Cost | ||
Debt securities, maturity, without single maturity date | 2,791 | |
Net Amortized Cost | 2,791 | 2,791 |
Fair Value | ||
Debt securities, maturity, without single maturity date | 2,625 | |
Total | $ 2,625 | $ 2,792 |
Investments - Unrealized Loss Position (Details) $ in Millions |
Sep. 30, 2022
USD ($)
security
|
Dec. 31, 2021
USD ($)
security
|
---|---|---|
Number of Securities | ||
Number of Securities, Less than 12 months | security | 11,362 | 3,700 |
Number of Securities, Greater than 12 months | security | 1,609 | 317 |
Number of Securities | security | 12,971 | 4,017 |
Fair Value | ||
Fair Value, Less than 12 months | $ 16,967 | $ 6,800 |
Fair Value, Greater than 12 months | 2,489 | 584 |
Fair Value | 19,456 | 7,384 |
Unrealized Losses | ||
Unrealized Losses, Less than 12 months | 1,786 | 84 |
Unrealized Losses, Greater than 12 months | 439 | 22 |
Unrealized Losses | $ 2,225 | $ 106 |
U.S. government securities | ||
Number of Securities | ||
Number of Securities, Less than 12 months | security | 570 | 43 |
Number of Securities, Greater than 12 months | security | 25 | 10 |
Number of Securities | security | 595 | 53 |
Fair Value | ||
Fair Value, Less than 12 months | $ 1,845 | $ 242 |
Fair Value, Greater than 12 months | 125 | 40 |
Fair Value | 1,970 | 282 |
Unrealized Losses | ||
Unrealized Losses, Less than 12 months | 179 | 2 |
Unrealized Losses, Greater than 12 months | 12 | 1 |
Unrealized Losses | $ 191 | $ 3 |
States, municipalities and political subdivisions | ||
Number of Securities | ||
Number of Securities, Less than 12 months | security | 1,129 | 233 |
Number of Securities, Greater than 12 months | security | 122 | 13 |
Number of Securities | security | 1,251 | 246 |
Fair Value | ||
Fair Value, Less than 12 months | $ 1,949 | $ 428 |
Fair Value, Greater than 12 months | 207 | 33 |
Fair Value | 2,156 | 461 |
Unrealized Losses | ||
Unrealized Losses, Less than 12 months | 153 | 3 |
Unrealized Losses, Greater than 12 months | 29 | 1 |
Unrealized Losses | $ 182 | $ 4 |
U.S. corporate securities | ||
Number of Securities | ||
Number of Securities, Less than 12 months | security | 6,083 | 1,610 |
Number of Securities, Greater than 12 months | security | 848 | 165 |
Number of Securities | security | 6,931 | 1,775 |
Fair Value | ||
Fair Value, Less than 12 months | $ 7,503 | $ 2,296 |
Fair Value, Greater than 12 months | 1,027 | 238 |
Fair Value | 8,530 | 2,534 |
Unrealized Losses | ||
Unrealized Losses, Less than 12 months | 889 | 31 |
Unrealized Losses, Greater than 12 months | 191 | 9 |
Unrealized Losses | $ 1,080 | $ 40 |
Foreign securities | ||
Number of Securities | ||
Number of Securities, Less than 12 months | security | 1,443 | 449 |
Number of Securities, Greater than 12 months | security | 254 | 57 |
Number of Securities | security | 1,697 | 506 |
Fair Value | ||
Fair Value, Less than 12 months | $ 2,005 | $ 747 |
Fair Value, Greater than 12 months | 383 | 91 |
Fair Value | 2,388 | 838 |
Unrealized Losses | ||
Unrealized Losses, Less than 12 months | 246 | 20 |
Unrealized Losses, Greater than 12 months | 78 | 4 |
Unrealized Losses | $ 324 | $ 24 |
Residential mortgage-backed securities | ||
Number of Securities | ||
Number of Securities, Less than 12 months | security | 489 | 165 |
Number of Securities, Greater than 12 months | security | 69 | 10 |
Number of Securities | security | 558 | 175 |
Fair Value | ||
Fair Value, Less than 12 months | $ 562 | $ 593 |
Fair Value, Greater than 12 months | 187 | 36 |
Fair Value | 749 | 629 |
Unrealized Losses | ||
Unrealized Losses, Less than 12 months | 68 | 9 |
Unrealized Losses, Greater than 12 months | 41 | 1 |
Unrealized Losses | $ 109 | $ 10 |
Commercial mortgage-backed securities | ||
Number of Securities | ||
Number of Securities, Less than 12 months | security | 368 | 188 |
Number of Securities, Greater than 12 months | security | 127 | 35 |
Number of Securities | security | 495 | 223 |
Fair Value | ||
Fair Value, Less than 12 months | $ 772 | $ 462 |
Fair Value, Greater than 12 months | 265 | 112 |
Fair Value | 1,037 | 574 |
Unrealized Losses | ||
Unrealized Losses, Less than 12 months | 101 | 7 |
Unrealized Losses, Greater than 12 months | 65 | 5 |
Unrealized Losses | $ 166 | $ 12 |
Other asset-backed securities | ||
Number of Securities | ||
Number of Securities, Less than 12 months | security | 1,266 | 1,011 |
Number of Securities, Greater than 12 months | security | 163 | 26 |
Number of Securities | security | 1,429 | 1,037 |
Fair Value | ||
Fair Value, Less than 12 months | $ 2,311 | $ 2,030 |
Fair Value, Greater than 12 months | 292 | 31 |
Fair Value | 2,603 | 2,061 |
Unrealized Losses | ||
Unrealized Losses, Less than 12 months | 148 | 12 |
Unrealized Losses, Greater than 12 months | 23 | 1 |
Unrealized Losses | $ 171 | $ 13 |
Redeemable preferred securities | ||
Number of Securities | ||
Number of Securities, Less than 12 months | security | 14 | 1 |
Number of Securities, Greater than 12 months | security | 1 | 1 |
Number of Securities | security | 15 | 2 |
Fair Value | ||
Fair Value, Less than 12 months | $ 20 | $ 2 |
Fair Value, Greater than 12 months | 3 | 3 |
Fair Value | 23 | 5 |
Unrealized Losses | ||
Unrealized Losses, Less than 12 months | 2 | 0 |
Unrealized Losses, Greater than 12 months | 0 | 0 |
Unrealized Losses | $ 2 | $ 0 |
Investments - Unrealized Loss Position Maturities (Details) - USD ($) $ in Millions |
Sep. 30, 2022 |
Dec. 31, 2021 |
---|---|---|
Fair Value | ||
Less than one year | $ 1,211 | |
One year through five years | 6,018 | |
After five years through ten years | 4,267 | |
Greater than ten years | 3,571 | |
Fair Value | 19,456 | $ 7,384 |
Unrealized Losses | ||
Less than one year | 14 | |
One year through five years | 451 | |
After five years through ten years | 637 | |
Greater than ten years | 677 | |
Unrealized Losses | 2,225 | 106 |
Residential mortgage-backed securities | ||
Fair Value | ||
Debt securities, maturity, without single maturity date, fair value | 749 | |
Fair Value | 749 | 629 |
Unrealized Losses | ||
Debt securities, maturity, without single maturity date, unrealized losses | 109 | |
Unrealized Losses | 109 | 10 |
Commercial mortgage-backed securities | ||
Fair Value | ||
Debt securities, maturity, without single maturity date, fair value | 1,037 | |
Fair Value | 1,037 | 574 |
Unrealized Losses | ||
Debt securities, maturity, without single maturity date, unrealized losses | 166 | |
Unrealized Losses | 166 | 12 |
Other asset-backed securities | ||
Fair Value | ||
Debt securities, maturity, without single maturity date, fair value | 2,603 | |
Fair Value | 2,603 | 2,061 |
Unrealized Losses | ||
Debt securities, maturity, without single maturity date, unrealized losses | 171 | |
Unrealized Losses | 171 | $ 13 |
Supporting experience-rated products | ||
Fair Value | ||
Less than one year | 35 | |
One year through five years | 128 | |
After five years through ten years | 154 | |
Greater than ten years | 213 | |
Fair Value | 590 | |
Unrealized Losses | ||
Less than one year | 0 | |
One year through five years | 6 | |
After five years through ten years | 22 | |
Greater than ten years | 39 | |
Unrealized Losses | 73 | |
Supporting experience-rated products | Residential mortgage-backed securities | ||
Fair Value | ||
Debt securities, maturity, without single maturity date, fair value | 11 | |
Unrealized Losses | ||
Debt securities, maturity, without single maturity date, unrealized losses | 1 | |
Supporting experience-rated products | Commercial mortgage-backed securities | ||
Fair Value | ||
Debt securities, maturity, without single maturity date, fair value | 32 | |
Unrealized Losses | ||
Debt securities, maturity, without single maturity date, unrealized losses | 3 | |
Supporting experience-rated products | Other asset-backed securities | ||
Fair Value | ||
Debt securities, maturity, without single maturity date, fair value | 17 | |
Unrealized Losses | ||
Debt securities, maturity, without single maturity date, unrealized losses | 2 | |
Supporting remaining products | ||
Fair Value | ||
Less than one year | 1,176 | |
One year through five years | 5,890 | |
After five years through ten years | 4,113 | |
Greater than ten years | 3,358 | |
Fair Value | 18,866 | |
Unrealized Losses | ||
Less than one year | 14 | |
One year through five years | 445 | |
After five years through ten years | 615 | |
Greater than ten years | 638 | |
Unrealized Losses | 2,152 | |
Supporting remaining products | Residential mortgage-backed securities | ||
Fair Value | ||
Debt securities, maturity, without single maturity date, fair value | 738 | |
Unrealized Losses | ||
Debt securities, maturity, without single maturity date, unrealized losses | 108 | |
Supporting remaining products | Commercial mortgage-backed securities | ||
Fair Value | ||
Debt securities, maturity, without single maturity date, fair value | 1,005 | |
Unrealized Losses | ||
Debt securities, maturity, without single maturity date, unrealized losses | 163 | |
Supporting remaining products | Other asset-backed securities | ||
Fair Value | ||
Debt securities, maturity, without single maturity date, fair value | 2,586 | |
Unrealized Losses | ||
Debt securities, maturity, without single maturity date, unrealized losses | $ 169 |
Investments - Mortgage Loans (Details) - Commercial Real Estate - USD ($) $ in Millions |
3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Sep. 30, 2022 |
Sep. 30, 2021 |
Sep. 30, 2022 |
Sep. 30, 2021 |
|
Mortgage Loans on Real Estate [Line Items] | ||||
New mortgage loans | $ 125 | $ 53 | $ 305 | $ 173 |
Mortgage loans fully repaid | 62 | 88 | 136 | 260 |
Mortgage loans foreclosed | $ 0 | $ 0 | $ 0 | $ 0 |
Investments - Mortgage Loans Credit Ratings Indicator (Details) - Commercial Real Estate - USD ($) $ in Millions |
Sep. 30, 2022 |
Dec. 31, 2021 |
---|---|---|
Mortgage Loans on Real Estate [Line Items] | ||
Mortgage loans | $ 1,047 | $ 902 |
1 | ||
Mortgage Loans on Real Estate [Line Items] | ||
Mortgage loans | 16 | 28 |
2 to 4 | ||
Mortgage Loans on Real Estate [Line Items] | ||
Mortgage loans | 1,018 | 861 |
5 and 6 | ||
Mortgage Loans on Real Estate [Line Items] | ||
Mortgage loans | 13 | 13 |
7 | ||
Mortgage Loans on Real Estate [Line Items] | ||
Mortgage loans | 0 | 0 |
2022 | ||
Mortgage Loans on Real Estate [Line Items] | ||
Mortgage loans | 279 | |
2022 | 1 | ||
Mortgage Loans on Real Estate [Line Items] | ||
Mortgage loans | 0 | |
2022 | 2 to 4 | ||
Mortgage Loans on Real Estate [Line Items] | ||
Mortgage loans | 279 | |
2022 | 5 and 6 | ||
Mortgage Loans on Real Estate [Line Items] | ||
Mortgage loans | 0 | |
2022 | 7 | ||
Mortgage Loans on Real Estate [Line Items] | ||
Mortgage loans | 0 | |
2021 | ||
Mortgage Loans on Real Estate [Line Items] | ||
Mortgage loans | 247 | 255 |
2021 | 1 | ||
Mortgage Loans on Real Estate [Line Items] | ||
Mortgage loans | 0 | 0 |
2021 | 2 to 4 | ||
Mortgage Loans on Real Estate [Line Items] | ||
Mortgage loans | 247 | 255 |
2021 | 5 and 6 | ||
Mortgage Loans on Real Estate [Line Items] | ||
Mortgage loans | 0 | 0 |
2021 | 7 | ||
Mortgage Loans on Real Estate [Line Items] | ||
Mortgage loans | 0 | 0 |
2020 | ||
Mortgage Loans on Real Estate [Line Items] | ||
Mortgage loans | 48 | 48 |
2020 | 1 | ||
Mortgage Loans on Real Estate [Line Items] | ||
Mortgage loans | 0 | 0 |
2020 | 2 to 4 | ||
Mortgage Loans on Real Estate [Line Items] | ||
Mortgage loans | 48 | 48 |
2020 | 5 and 6 | ||
Mortgage Loans on Real Estate [Line Items] | ||
Mortgage loans | 0 | 0 |
2020 | 7 | ||
Mortgage Loans on Real Estate [Line Items] | ||
Mortgage loans | 0 | 0 |
2019 | ||
Mortgage Loans on Real Estate [Line Items] | ||
Mortgage loans | 11 | 40 |
2019 | 1 | ||
Mortgage Loans on Real Estate [Line Items] | ||
Mortgage loans | 0 | 0 |
2019 | 2 to 4 | ||
Mortgage Loans on Real Estate [Line Items] | ||
Mortgage loans | 11 | 40 |
2019 | 5 and 6 | ||
Mortgage Loans on Real Estate [Line Items] | ||
Mortgage loans | 0 | 0 |
2019 | 7 | ||
Mortgage Loans on Real Estate [Line Items] | ||
Mortgage loans | 0 | 0 |
2018 | ||
Mortgage Loans on Real Estate [Line Items] | ||
Mortgage loans | 57 | 75 |
2018 | 1 | ||
Mortgage Loans on Real Estate [Line Items] | ||
Mortgage loans | 0 | 0 |
2018 | 2 to 4 | ||
Mortgage Loans on Real Estate [Line Items] | ||
Mortgage loans | 54 | 72 |
2018 | 5 and 6 | ||
Mortgage Loans on Real Estate [Line Items] | ||
Mortgage loans | 3 | 3 |
2018 | 7 | ||
Mortgage Loans on Real Estate [Line Items] | ||
Mortgage loans | 0 | 0 |
Prior | ||
Mortgage Loans on Real Estate [Line Items] | ||
Mortgage loans | 405 | 484 |
Prior | 1 | ||
Mortgage Loans on Real Estate [Line Items] | ||
Mortgage loans | 16 | 28 |
Prior | 2 to 4 | ||
Mortgage Loans on Real Estate [Line Items] | ||
Mortgage loans | 379 | 446 |
Prior | 5 and 6 | ||
Mortgage Loans on Real Estate [Line Items] | ||
Mortgage loans | 10 | 10 |
Prior | 7 | ||
Mortgage Loans on Real Estate [Line Items] | ||
Mortgage loans | $ 0 | $ 0 |
Investments - Net Investment Income (Details) - USD ($) $ in Millions |
3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Sep. 30, 2022 |
Sep. 30, 2021 |
Sep. 30, 2022 |
Sep. 30, 2021 |
|
Schedule of Investment Income, Reported Amounts, by Category [Line Items] | ||||
Gross investment income | $ 322 | $ 279 | $ 827 | $ 822 |
Investment expenses | (11) | (11) | (29) | (28) |
Net investment income (excluding net realized capital gains or losses) | 311 | 268 | 798 | 794 |
Net realized capital gains (losses) | (110) | (22) | (283) | 38 |
Net investment income | 201 | 246 | 515 | 832 |
Credit-related impairment loss | 1 | 0 | 17 | 0 |
Yield-related impairment loss | 73 | 3 | 121 | 35 |
Supporting experience-rated products | ||||
Schedule of Investment Income, Reported Amounts, by Category [Line Items] | ||||
Net investment income | 8 | 9 | 26 | 28 |
Debt securities | ||||
Schedule of Investment Income, Reported Amounts, by Category [Line Items] | ||||
Gross investment income | 174 | 157 | 510 | 474 |
Mortgage loans | ||||
Schedule of Investment Income, Reported Amounts, by Category [Line Items] | ||||
Gross investment income | 14 | 13 | 38 | 41 |
Other investments | ||||
Schedule of Investment Income, Reported Amounts, by Category [Line Items] | ||||
Gross investment income | $ 134 | $ 109 | $ 279 | $ 307 |
Investments - Realized Gains (Details) - USD ($) $ in Millions |
3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Sep. 30, 2022 |
Sep. 30, 2021 |
Sep. 30, 2022 |
Sep. 30, 2021 |
|
Investments [Abstract] | ||||
Proceeds from sales | $ 593 | $ 668 | $ 3,556 | $ 2,935 |
Gross realized capital gains | 3 | 19 | 20 | 61 |
Gross realized capital losses | $ 28 | $ 2 | $ 135 | $ 12 |
Fair Value - Measurement on a Recurring Basis (Details) - USD ($) $ in Millions |
Sep. 30, 2022 |
Dec. 31, 2021 |
---|---|---|
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt securities | $ 20,040 | $ 23,240 |
U.S. government securities | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt securities | 1,981 | 2,416 |
States, municipalities and political subdivisions | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt securities | 2,274 | 3,091 |
U.S. corporate securities | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt securities | 8,856 | 9,735 |
Foreign securities | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt securities | 2,494 | 2,993 |
Residential mortgage-backed securities | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt securities | 750 | 875 |
Commercial mortgage-backed securities | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt securities | 1,037 | 1,310 |
Other asset-backed securities | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt securities | 2,625 | 2,792 |
Redeemable preferred securities | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt securities | 23 | 28 |
Recurring | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Financial liabilities measured at fair value on a recurring basis | 0 | 0 |
Cash and cash equivalents | 17,204 | 9,408 |
Debt securities | 20,040 | 23,240 |
Equity securities | 170 | 169 |
Total | 37,414 | 32,817 |
Recurring | Disposal Group, Held-for-sale, Not Discontinued Operations | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Cash and cash equivalents | 7 | |
Recurring | Level 1 | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Cash and cash equivalents | 10,118 | 4,954 |
Debt securities | 1,949 | 2,372 |
Equity securities | 104 | 114 |
Total | 12,171 | 7,440 |
Recurring | Level 2 | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Cash and cash equivalents | 7,086 | 4,454 |
Debt securities | 18,045 | 20,812 |
Equity securities | 0 | 0 |
Total | 25,131 | 25,266 |
Recurring | Level 3 | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Cash and cash equivalents | 0 | 0 |
Debt securities | 46 | 56 |
Equity securities | 66 | 55 |
Total | 112 | 111 |
Recurring | U.S. government securities | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt securities | 1,981 | 2,416 |
Recurring | U.S. government securities | Level 1 | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt securities | 1,949 | 2,372 |
Recurring | U.S. government securities | Level 2 | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt securities | 32 | 44 |
Recurring | U.S. government securities | Level 3 | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt securities | 0 | 0 |
Recurring | States, municipalities and political subdivisions | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt securities | 2,274 | 3,091 |
Recurring | States, municipalities and political subdivisions | Level 1 | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt securities | 0 | 0 |
Recurring | States, municipalities and political subdivisions | Level 2 | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt securities | 2,274 | 3,086 |
Recurring | States, municipalities and political subdivisions | Level 3 | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt securities | 0 | 5 |
Recurring | U.S. corporate securities | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt securities | 8,856 | 9,735 |
Recurring | U.S. corporate securities | Level 1 | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt securities | 0 | 0 |
Recurring | U.S. corporate securities | Level 2 | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt securities | 8,818 | 9,697 |
Recurring | U.S. corporate securities | Level 3 | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt securities | 38 | 38 |
Recurring | Foreign securities | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt securities | 2,494 | 2,993 |
Recurring | Foreign securities | Level 1 | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt securities | 0 | 0 |
Recurring | Foreign securities | Level 2 | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt securities | 2,486 | 2,983 |
Recurring | Foreign securities | Level 3 | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt securities | 8 | 10 |
Recurring | Residential mortgage-backed securities | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt securities | 750 | 875 |
Recurring | Residential mortgage-backed securities | Level 1 | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt securities | 0 | 0 |
Recurring | Residential mortgage-backed securities | Level 2 | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt securities | 750 | 875 |
Recurring | Residential mortgage-backed securities | Level 3 | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt securities | 0 | 0 |
Recurring | Commercial mortgage-backed securities | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt securities | 1,037 | 1,310 |
Recurring | Commercial mortgage-backed securities | Level 1 | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt securities | 0 | 0 |
Recurring | Commercial mortgage-backed securities | Level 2 | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt securities | 1,037 | 1,310 |
Recurring | Commercial mortgage-backed securities | Level 3 | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt securities | 0 | 0 |
Recurring | Other asset-backed securities | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt securities | 2,625 | 2,792 |
Recurring | Other asset-backed securities | Level 1 | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt securities | 0 | 0 |
Recurring | Other asset-backed securities | Level 2 | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt securities | 2,625 | 2,789 |
Recurring | Other asset-backed securities | Level 3 | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt securities | 0 | 3 |
Recurring | Redeemable preferred securities | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt securities | 23 | 28 |
Recurring | Redeemable preferred securities | Level 1 | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt securities | 0 | 0 |
Recurring | Redeemable preferred securities | Level 2 | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt securities | 23 | 28 |
Recurring | Redeemable preferred securities | Level 3 | ||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | ||
Debt securities | $ 0 | $ 0 |
Fair Value - Narrative (Details) - USD ($) $ in Millions |
3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Sep. 30, 2022 |
Sep. 30, 2021 |
Sep. 30, 2022 |
Sep. 30, 2021 |
|
Fair Value Disclosures [Abstract] | ||||
Transfers out of Level 3 | $ 0 | $ 0 | $ 29 | $ 0 |
Transfers into Level 3 | $ 0 | $ 0 | $ 0 |
Fair Value - Carrying Value and Fair Value Classified by Level (Details) - Nonrecurring - USD ($) $ in Millions |
Sep. 30, 2022 |
Dec. 31, 2021 |
---|---|---|
Carrying Value | ||
Assets: | ||
Mortgage loans | $ 1,047 | $ 902 |
Equity securities | 183 | 126 |
Liabilities: | ||
Investment contracts liabilities with a fixed maturity | 4 | 5 |
Investment contracts liabilities without a fixed maturity | 331 | 336 |
Long-term debt | 52,214 | 56,176 |
Carrying Value | Disposal Group, Held-for-sale, Not Discontinued Operations | ||
Liabilities: | ||
Long-term debt | 3 | |
Estimated Fair Value | ||
Assets: | ||
Mortgage loans | 982 | 907 |
Liabilities: | ||
Investment contracts liabilities with a fixed maturity | 4 | 5 |
Investment contracts liabilities without a fixed maturity | 296 | 373 |
Long-term debt | 46,375 | 64,157 |
Level 1 | Estimated Fair Value | ||
Assets: | ||
Mortgage loans | 0 | 0 |
Liabilities: | ||
Investment contracts liabilities with a fixed maturity | 0 | 0 |
Investment contracts liabilities without a fixed maturity | 0 | 0 |
Long-term debt | 46,375 | 64,157 |
Level 2 | Estimated Fair Value | ||
Assets: | ||
Mortgage loans | 0 | 0 |
Liabilities: | ||
Investment contracts liabilities with a fixed maturity | 0 | 0 |
Investment contracts liabilities without a fixed maturity | 0 | 0 |
Long-term debt | 0 | 0 |
Level 3 | Estimated Fair Value | ||
Assets: | ||
Mortgage loans | 982 | 907 |
Liabilities: | ||
Investment contracts liabilities with a fixed maturity | 4 | 5 |
Investment contracts liabilities without a fixed maturity | 296 | 373 |
Long-term debt | $ 0 | $ 0 |
Fair Value - Separate Accounts Fair Value (Details) - USD ($) $ in Millions |
Sep. 30, 2022 |
Dec. 31, 2021 |
---|---|---|
Fair Value, Separate Account Investment [Line Items] | ||
Separate accounts assets | $ 3,318 | $ 5,087 |
Recurring | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate accounts assets | 3,298 | 5,017 |
Recurring | Other Receivables | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate accounts assets | 20 | 70 |
Recurring | Cash and cash equivalents | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate accounts assets | 152 | 188 |
Recurring | Debt securities | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate accounts assets | 2,735 | 4,281 |
Recurring | Equity securities | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate accounts assets | 1 | 1 |
Recurring | Common/collective trusts | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate accounts assets | 410 | 547 |
Recurring | Level 1 | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate accounts assets | 756 | 1,235 |
Recurring | Level 1 | Cash and cash equivalents | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate accounts assets | 0 | 2 |
Recurring | Level 1 | Debt securities | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate accounts assets | 756 | 1,233 |
Recurring | Level 1 | Equity securities | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate accounts assets | 0 | 0 |
Recurring | Level 1 | Common/collective trusts | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate accounts assets | 0 | 0 |
Recurring | Level 2 | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate accounts assets | 2,542 | 3,782 |
Recurring | Level 2 | Cash and cash equivalents | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate accounts assets | 152 | 186 |
Recurring | Level 2 | Debt securities | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate accounts assets | 1,979 | 3,048 |
Recurring | Level 2 | Equity securities | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate accounts assets | 1 | 1 |
Recurring | Level 2 | Common/collective trusts | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate accounts assets | 410 | 547 |
Recurring | Level 3 | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate accounts assets | 0 | 0 |
Recurring | Level 3 | Cash and cash equivalents | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate accounts assets | 0 | 0 |
Recurring | Level 3 | Debt securities | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate accounts assets | 0 | 0 |
Recurring | Level 3 | Equity securities | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate accounts assets | 0 | 0 |
Recurring | Level 3 | Common/collective trusts | ||
Fair Value, Separate Account Investment [Line Items] | ||
Separate accounts assets | $ 0 | $ 0 |
Health Care Costs Payable - Components of Change in Health Care Costs Payable (Details) - USD ($) $ in Millions |
9 Months Ended | |
---|---|---|
Sep. 30, 2022 |
Sep. 30, 2021 |
|
Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward] | ||
Health care costs payable, beginning of the period | $ 8,808 | |
Less: Claims paid | ||
Health care costs payable, end of the period | 10,351 | |
Health Care Benefits | ||
Less: Claims paid | ||
Benefit costs recorded in other insurance liabilities | 56 | $ 45 |
Corporate / Other | ||
Less: Claims paid | ||
Benefit costs recorded in other insurance liabilities | 274 | 168 |
Health Insurance Product Line | ||
Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward] | ||
Health care costs payable, beginning of the period | 8,808 | 7,936 |
Less: Reinsurance recoverables | 8 | 10 |
Health care costs payable, beginning of the period, net | 8,800 | 7,926 |
Add: Components of incurred health care costs | ||
Current year | 53,311 | 48,243 |
Prior years | (670) | (771) |
Total incurred health care costs | 52,641 | 47,472 |
Less: Claims paid | ||
Current year | 43,632 | 39,887 |
Prior years | 7,468 | 6,639 |
Total claims paid | 51,100 | 46,526 |
Add: Premium deficiency reserve | 5 | 1 |
Health care costs payable, end of the period, net | 10,346 | 8,873 |
Add: Reinsurance recoverables | 5 | 4 |
Health care costs payable, end of the period | 10,351 | 8,877 |
Premium deficiency reserve | $ 5 | $ 1 |
Health Care Costs Payable - Narrative (Details) - USD ($) $ in Millions |
9 Months Ended | |
---|---|---|
Sep. 30, 2022 |
Sep. 30, 2021 |
|
Liability for Claims and Claims Adjustment Expense [Line Items] | ||
Incurred but not reported (IBNR) claims liability, net | $ 7,900 | |
Health Insurance Product Line | ||
Liability for Claims and Claims Adjustment Expense [Line Items] | ||
Decrease in prior years' healthcare costs payable | $ 670 | $ 771 |
Borrowings - Schedule of Borrowings (Details) - USD ($) $ in Millions |
Sep. 30, 2022 |
Aug. 31, 2022 |
May 31, 2022 |
Dec. 31, 2021 |
---|---|---|---|---|
Debt Instrument [Line Items] | ||||
Finance lease liabilities | $ 1,437 | $ 1,300 | ||
Total debt principal | 52,726 | 56,743 | ||
Debt premiums | 204 | 219 | ||
Debt discounts and deferred financing costs | (716) | (786) | ||
Long-term debt and lease obligation | 52,214 | 56,176 | ||
Current portion of long-term debt | (1,363) | (4,205) | ||
Long-term debt | $ 50,851 | $ 51,971 | ||
Finance Lease, Liability, Statement of Financial Position [Extensible Enumeration] | Long-term debt | Long-term debt | ||
Senior Notes | 3.5% senior notes due July 2022 | ||||
Debt Instrument [Line Items] | ||||
Debt interest rate | 3.50% | 3.50% | ||
Long-term debt | $ 0 | $ 1,500 | ||
Senior Notes | 2.75% senior notes due November 2022 | ||||
Debt Instrument [Line Items] | ||||
Debt interest rate | 2.75% | 2.75% | ||
Long-term debt | $ 0 | 1,000 | ||
Senior Notes | 2.75% senior notes due December 2022 | ||||
Debt Instrument [Line Items] | ||||
Debt interest rate | 2.75% | |||
Long-term debt | $ 0 | 1,250 | ||
Senior Notes | 4.75% senior notes due December 2022 | ||||
Debt Instrument [Line Items] | ||||
Debt interest rate | 4.75% | |||
Long-term debt | $ 0 | 399 | ||
Senior Notes | 2.8% senior notes due June 2023 | ||||
Debt Instrument [Line Items] | ||||
Debt interest rate | 2.80% | |||
Long-term debt | $ 1,300 | 1,300 | ||
Senior Notes | 4% senior notes due December 2023 | ||||
Debt Instrument [Line Items] | ||||
Debt interest rate | 4.00% | |||
Long-term debt | $ 414 | 414 | ||
Senior Notes | 3.375% senior notes due August 2024 | ||||
Debt Instrument [Line Items] | ||||
Debt interest rate | 3.375% | |||
Long-term debt | $ 650 | 650 | ||
Senior Notes | 2.625% senior notes due August 2024 | ||||
Debt Instrument [Line Items] | ||||
Debt interest rate | 2.625% | |||
Long-term debt | $ 1,000 | 1,000 | ||
Senior Notes | 3.5% senior notes due November 2024 | ||||
Debt Instrument [Line Items] | ||||
Debt interest rate | 3.50% | |||
Long-term debt | $ 750 | 750 | ||
Senior Notes | 5% senior notes due December 2024 | ||||
Debt Instrument [Line Items] | ||||
Debt interest rate | 5.00% | |||
Long-term debt | $ 299 | 299 | ||
Senior Notes | 5% senior notes due December 2024 | Disposal Group, Held-for-sale, Not Discontinued Operations | ||||
Debt Instrument [Line Items] | ||||
Long-term debt | $ 3 | |||
Senior Notes | 4.1% senior notes due March 2025 | ||||
Debt Instrument [Line Items] | ||||
Debt interest rate | 4.10% | |||
Long-term debt | $ 950 | 950 | ||
Senior Notes | 3.875% senior notes due July 2025 | ||||
Debt Instrument [Line Items] | ||||
Debt interest rate | 3.875% | |||
Long-term debt | $ 2,828 | 2,828 | ||
Senior Notes | 2.875% senior notes due June 2026 | ||||
Debt Instrument [Line Items] | ||||
Debt interest rate | 2.875% | |||
Long-term debt | $ 1,750 | 1,750 | ||
Senior Notes | 3% senior notes due August 2026 | ||||
Debt Instrument [Line Items] | ||||
Debt interest rate | 3.00% | |||
Long-term debt | $ 750 | 750 | ||
Senior Notes | 3.625% senior notes due April 2027 | ||||
Debt Instrument [Line Items] | ||||
Debt interest rate | 3.625% | |||
Long-term debt | $ 750 | 750 | ||
Senior Notes | 6.25% senior notes due June 2027 | ||||
Debt Instrument [Line Items] | ||||
Debt interest rate | 6.25% | |||
Long-term debt | $ 372 | 372 | ||
Senior Notes | 1.3% senior notes due August 2027 | ||||
Debt Instrument [Line Items] | ||||
Debt interest rate | 1.30% | |||
Long-term debt | $ 2,250 | 2,250 | ||
Senior Notes | 4.3% senior notes due March 2028 | ||||
Debt Instrument [Line Items] | ||||
Debt interest rate | 4.30% | |||
Long-term debt | $ 5,000 | 5,000 | ||
Senior Notes | 3.25% senior notes due August 2029 | ||||
Debt Instrument [Line Items] | ||||
Debt interest rate | 3.25% | |||
Long-term debt | $ 1,750 | 1,750 | ||
Senior Notes | 3.75% senior notes due April 2030 | ||||
Debt Instrument [Line Items] | ||||
Debt interest rate | 3.75% | |||
Long-term debt | $ 1,500 | 1,500 | ||
Senior Notes | 1.75% senior notes due August 2030 | ||||
Debt Instrument [Line Items] | ||||
Debt interest rate | 1.75% | |||
Long-term debt | $ 1,250 | 1,250 | ||
Senior Notes | 1.875% senior notes due February 2031 | ||||
Debt Instrument [Line Items] | ||||
Debt interest rate | 1.875% | |||
Long-term debt | $ 1,250 | 1,250 | ||
Senior Notes | 2.125% senior notes due September 2031 | ||||
Debt Instrument [Line Items] | ||||
Debt interest rate | 2.125% | |||
Long-term debt | $ 1,000 | 1,000 | ||
Senior Notes | 4.875% senior notes due July 2035 | ||||
Debt Instrument [Line Items] | ||||
Debt interest rate | 4.875% | |||
Long-term debt | $ 652 | 652 | ||
Senior Notes | 6.625% senior notes due June 2036 | ||||
Debt Instrument [Line Items] | ||||
Debt interest rate | 6.625% | |||
Long-term debt | $ 771 | 771 | ||
Senior Notes | 6.75% senior notes due December 2037 | ||||
Debt Instrument [Line Items] | ||||
Debt interest rate | 6.75% | |||
Long-term debt | $ 533 | 533 | ||
Senior Notes | 4.78% senior notes due March 2038 | ||||
Debt Instrument [Line Items] | ||||
Debt interest rate | 4.78% | |||
Long-term debt | $ 5,000 | 5,000 | ||
Senior Notes | 6.125% senior notes due September 2039 | ||||
Debt Instrument [Line Items] | ||||
Debt interest rate | 6.125% | |||
Long-term debt | $ 447 | 447 | ||
Senior Notes | 4.125% senior notes due April 2040 | ||||
Debt Instrument [Line Items] | ||||
Debt interest rate | 4.125% | |||
Long-term debt | $ 1,000 | 1,000 | ||
Senior Notes | 2.7% senior notes due August 2040 | ||||
Debt Instrument [Line Items] | ||||
Debt interest rate | 2.70% | |||
Long-term debt | $ 1,250 | 1,250 | ||
Senior Notes | 5.75% senior notes due May 2041 | ||||
Debt Instrument [Line Items] | ||||
Debt interest rate | 5.75% | |||
Long-term debt | $ 133 | 133 | ||
Senior Notes | 4.5% senior notes due May 2042 | ||||
Debt Instrument [Line Items] | ||||
Debt interest rate | 4.50% | |||
Long-term debt | $ 500 | 500 | ||
Senior Notes | 4.125% senior notes due November 2042 | ||||
Debt Instrument [Line Items] | ||||
Debt interest rate | 4.125% | |||
Long-term debt | $ 500 | 500 | ||
Senior Notes | 5.3% senior notes due December 2043 | ||||
Debt Instrument [Line Items] | ||||
Debt interest rate | 5.30% | |||
Long-term debt | $ 750 | 750 | ||
Senior Notes | 4.75% senior notes due March 2044 | ||||
Debt Instrument [Line Items] | ||||
Debt interest rate | 4.75% | |||
Long-term debt | $ 375 | 375 | ||
Senior Notes | 5.125% senior notes due July 2045 | ||||
Debt Instrument [Line Items] | ||||
Debt interest rate | 5.125% | |||
Long-term debt | $ 3,500 | 3,500 | ||
Senior Notes | 3.875% senior notes due August 2047 | ||||
Debt Instrument [Line Items] | ||||
Debt interest rate | 3.875% | |||
Long-term debt | $ 1,000 | 1,000 | ||
Senior Notes | 5.05% senior notes due March 2048 | ||||
Debt Instrument [Line Items] | ||||
Debt interest rate | 5.05% | |||
Long-term debt | $ 8,000 | 8,000 | ||
Senior Notes | 4.25% senior notes due April 2050 | ||||
Debt Instrument [Line Items] | ||||
Debt interest rate | 4.25% | |||
Long-term debt | $ 750 | 750 | ||
Other Debt Obligations | ||||
Debt Instrument [Line Items] | ||||
Long-term debt | $ 315 | $ 320 |
Borrowings - Narrative (Details) - USD ($) $ in Millions |
1 Months Ended | 9 Months Ended | |||
---|---|---|---|---|---|
Sep. 30, 2022 |
Aug. 31, 2022 |
May 31, 2022 |
Sep. 30, 2022 |
Sep. 30, 2021 |
|
Debt Instrument [Line Items] | |||||
Redeemed principal amount | $ 4,195 | $ 7,823 | |||
Senior Notes | 3.5% senior notes due July 2022 | |||||
Debt Instrument [Line Items] | |||||
Debt interest rate | 3.50% | 3.50% | 3.50% | ||
Redeemed principal amount | $ 1,500 | ||||
Senior Notes | 2.75% senior notes due November 2022 | |||||
Debt Instrument [Line Items] | |||||
Debt interest rate | 2.75% | 2.75% | 2.75% | ||
Redeemed principal amount | $ 1,000 | ||||
Senior Notes | 2.75% senior notes due December 2022 | |||||
Debt Instrument [Line Items] | |||||
Debt interest rate | 2.75% | 2.75% | |||
Redeemed principal amount | $ 1,250 | ||||
Senior Notes | 4.75% senior notes due December 2022 | |||||
Debt Instrument [Line Items] | |||||
Debt interest rate | 4.75% | 4.75% | |||
Redeemed principal amount | $ 399 |
Shareholders' Equity - Share Repurchases (Details) - USD ($) |
9 Months Ended | ||
---|---|---|---|
Sep. 30, 2022 |
Sep. 30, 2021 |
Dec. 09, 2021 |
|
Equity, Class of Treasury Stock [Line Items] | |||
Stock repurchased during period (in shares) | 0 | ||
2021 Repurchase Program | |||
Equity, Class of Treasury Stock [Line Items] | |||
Stock repurchase program, authorized amount | $ 10,000,000,000.0 | ||
Stock repurchase program, remaining authorized repurchase amount | $ 8,000,000,000.0 | ||
Stock repurchased during period (in shares) | 19,100,000 | ||
Stock repurchased during period, value | $ 2,000,000,000 |
Shareholders' Equity - Accelerated Share Repurchases (Details) - 2021 ASR - Barclays Bank - USD ($) $ / shares in Units, shares in Millions, $ in Billions |
Jan. 04, 2022 |
Feb. 28, 2022 |
---|---|---|
Equity, Class of Treasury Stock [Line Items] | ||
ASR agreement, amount | $ 1.5 | $ 1.5 |
Payments for ASR, amount | $ 1.5 | |
ASR percent of notional amount received in shares | 80.00% | |
Shares repurchased under ASR agreement (in shares) | 11.6 | 2.7 |
Share price (in dollars per share) | $ 103.34 | |
Transfer of shares to treasury stock value | $ 1.2 | |
ASR, shares to be received at the end of program as a percent of notional amount | 20.00% | |
Forward contract | ||
Equity, Class of Treasury Stock [Line Items] | ||
Forward contract, notional amount | $ 0.3 |
Shareholders' Equity - Dividends (Details) - $ / shares |
3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Sep. 30, 2022 |
Sep. 30, 2021 |
Sep. 30, 2022 |
Sep. 30, 2021 |
|
Equity [Abstract] | ||||
Dividends declared per share (in dollars per share) | $ 0.55 | $ 0.50 | $ 1.65 | $ 1.50 |
Other Comprehensive Income (Loss) (Details) - USD ($) $ in Millions |
3 Months Ended | 9 Months Ended | ||||||
---|---|---|---|---|---|---|---|---|
Sep. 30, 2022 |
Jun. 30, 2022 |
Mar. 31, 2022 |
Sep. 30, 2021 |
Jun. 30, 2021 |
Mar. 31, 2021 |
Sep. 30, 2022 |
Sep. 30, 2021 |
|
Changes in Accumulated Other Comprehensive Income (Loss) by Component | ||||||||
Balance at beginning of period | $ 75,506 | $ 74,140 | $ 75,381 | $ 73,565 | $ 71,164 | $ 69,701 | $ 75,381 | $ 69,701 |
Other comprehensive loss | (621) | (798) | (1,155) | (93) | 148 | (392) | (2,574) | (337) |
Balance at end of period | 71,011 | 75,506 | 74,140 | 74,618 | 73,565 | 71,164 | 71,011 | 74,618 |
Net unrealized investment gains (losses) | ||||||||
Changes in Accumulated Other Comprehensive Income (Loss) by Component | ||||||||
Balance at beginning of period | (1,190) | 778 | 977 | 1,214 | 778 | 1,214 | ||
Other comprehensive income (loss) before reclassifications, net of tax | (711) | (61) | (2,809) | (297) | ||||
Amounts reclassified from accumulated other comprehensive income (loss), net of tax | 88 | (12) | 218 | (13) | ||||
Other comprehensive loss | (623) | (73) | (2,591) | (310) | ||||
Balance at end of period | (1,813) | (1,190) | 904 | 977 | (1,813) | 904 | ||
OCI before reclassifications, pre-tax | (796) | (73) | (3,306) | (346) | ||||
Amounts reclassified, pre-tax | 99 | (14) | 253 | (15) | ||||
Foreign currency translation adjustments | ||||||||
Changes in Accumulated Other Comprehensive Income (Loss) by Component | ||||||||
Balance at beginning of period | 2 | 0 | 6 | 7 | 0 | 7 | ||
Other comprehensive income (loss) before reclassifications, net of tax | (7) | (5) | (5) | (6) | ||||
Other comprehensive loss | (7) | (5) | (5) | (6) | ||||
Balance at end of period | (5) | 2 | 1 | 6 | (5) | 1 | ||
Net cash flow hedges | ||||||||
Changes in Accumulated Other Comprehensive Income (Loss) by Component | ||||||||
Balance at beginning of period | 234 | 222 | 241 | 248 | 222 | 248 | ||
Other comprehensive income (loss) before reclassifications, net of tax | 10 | 0 | 28 | 0 | ||||
Amounts reclassified from accumulated other comprehensive income (loss), net of tax | (2) | (15) | (8) | (22) | ||||
Other comprehensive loss | 8 | (15) | 20 | (22) | ||||
Balance at end of period | 242 | 234 | 226 | 241 | 242 | 226 | ||
OCI before reclassifications, pre-tax | 13 | 0 | 37 | 0 | ||||
Amounts reclassified, pre-tax | (2) | (20) | (10) | (29) | ||||
Amount expected to be reclassified | 11 | 11 | ||||||
Pension and other postretirement benefits | ||||||||
Changes in Accumulated Other Comprehensive Income (Loss) by Component | ||||||||
Balance at beginning of period | (34) | (35) | (54) | (55) | (35) | (55) | ||
Amounts reclassified from accumulated other comprehensive income (loss), net of tax | 1 | 0 | 2 | 1 | ||||
Other comprehensive loss | 1 | 0 | 2 | 1 | ||||
Balance at end of period | (33) | (34) | (54) | (54) | (33) | (54) | ||
Amounts reclassified, pre-tax | 1 | 0 | 2 | 1 | ||||
AOCI Including Portion Attributable to Noncontrolling Interest | ||||||||
Changes in Accumulated Other Comprehensive Income (Loss) by Component | ||||||||
Balance at beginning of period | (988) | $ 965 | 1,170 | $ 1,414 | 965 | 1,414 | ||
Balance at end of period | $ (1,609) | $ (988) | $ 1,077 | $ 1,170 | $ (1,609) | $ 1,077 |
Earnings (Loss) Per Share (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions |
3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Sep. 30, 2022 |
Sep. 30, 2021 |
Sep. 30, 2022 |
Sep. 30, 2021 |
|
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||||
Antidilutive securities excluded from computation of EPS (in shares) | 8 | |||
Numerator for earnings (loss) per share calculation: | ||||
Net income (loss) attributable to CVS Health | $ (3,416) | $ 1,598 | $ 1,847 | $ 6,604 |
Denominator for earnings (loss) per share calculation: | ||||
Weighted average shares, basic (in shares) | 1,315 | 1,321 | 1,313 | 1,318 |
Weighted average diluted shares outstanding (in shares) | 1,315 | 1,329 | 1,324 | 1,326 |
Earnings (loss) per share: | ||||
Earnings (loss) per share, basic (in dollars per share) | $ (2.60) | $ 1.21 | $ 1.41 | $ 5.01 |
Earnings (loss) per share, diluted (in dollars per share) | $ (2.60) | $ 1.20 | $ 1.40 | $ 4.98 |
Restricted stock units and performance stock units | ||||
Denominator for earnings (loss) per share calculation: | ||||
Effect of dilutive securities (in shares) | 0 | 4 | 6 | 5 |
Stock options and stock appreciation rights | ||||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||||
Antidilutive securities excluded from computation of EPS (in shares) | 4 | 8 | 4 | 8 |
Denominator for earnings (loss) per share calculation: | ||||
Effect of dilutive securities (in shares) | 0 | 4 | 5 | 3 |
Commitments and Contingencies (Details) $ in Millions |
1 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Oct. 18, 2022
USD ($)
|
Aug. 31, 2022
USD ($)
|
Mar. 31, 2022
USD ($)
|
Sep. 30, 2022
USD ($)
lease
|
Sep. 30, 2021
USD ($)
|
Sep. 30, 2022
USD ($)
lease
|
Sep. 30, 2021
USD ($)
|
Dec. 31, 2024
USD ($)
|
Dec. 31, 2023
USD ($)
|
Dec. 31, 2012
member
|
Sep. 30, 2020
claim
|
|
Commitments and Contingencies Disclosure [Abstract] | |||||||||||
Guarantor obligations, number of leases | lease | 68 | 68 | |||||||||
Sample size | member | 200 | ||||||||||
Loss Contingencies [Line Items] | |||||||||||
Opioid litigation charges | $ 5,220 | $ 0 | $ 5,704 | $ 0 | |||||||
Federal Court in Ohio Judgment | Pending Litigation | |||||||||||
Loss Contingencies [Line Items] | |||||||||||
Legal settlement awarded to other party | $ 651 | ||||||||||
Legal settlement, period of payment | 15 years | ||||||||||
State of Florida Settlement | |||||||||||
Loss Contingencies [Line Items] | |||||||||||
Legal settlement, period of payment | 18 years | ||||||||||
Opioid litigation charges | $ 484 | ||||||||||
Liability recorded in association with legal settlement | $ 484 | ||||||||||
Radcliffe and Flaim v. Aetna Inc., et al | Pending Litigation | |||||||||||
Loss Contingencies [Line Items] | |||||||||||
Number of claims | claim | 2 | ||||||||||
Settlement Framework | Subsequent Event | |||||||||||
Loss Contingencies [Line Items] | |||||||||||
Legal settlement awarded to other party | $ 5,000 | ||||||||||
Legal settlement, period of payment | 10 years | ||||||||||
Settlement Framework | Subsequent Event | States and Political Subdivisions | |||||||||||
Loss Contingencies [Line Items] | |||||||||||
Legal settlement awarded to other party | $ 4,900 | ||||||||||
Settlement Framework | Subsequent Event | Tribal Entities | |||||||||||
Loss Contingencies [Line Items] | |||||||||||
Legal settlement awarded to other party | $ 130 | ||||||||||
Settlement Framework and Other Opioid-Related Claims | |||||||||||
Loss Contingencies [Line Items] | |||||||||||
Opioid litigation charges | $ 5,200 | ||||||||||
Settlement Framework and Other Opioid-Related Claims | Maximum | Forecast | |||||||||||
Loss Contingencies [Line Items] | |||||||||||
Cash impact of litigation settlement | $ 500 | $ 500 |
Segment Reporting - Narrative (Details) |
9 Months Ended |
---|---|
Sep. 30, 2022
Segment
| |
Segment Reporting [Abstract] | |
Number of operating segments | 3 |
Segment Reporting - Reconciliation of Financial Measures of Segments to Consolidated Totals (Details) - USD ($) $ in Millions |
3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Sep. 30, 2022 |
Sep. 30, 2021 |
Sep. 30, 2022 |
Sep. 30, 2021 |
|
Segment Reporting Information [Line Items] | ||||
Revenues from external customers | $ 80,958 | $ 73,548 | $ 238,106 | $ 214,675 |
Net investment income (loss) | 201 | 246 | 515 | 832 |
Total revenues | 81,159 | 73,794 | 238,621 | 215,507 |
Adjusted operating income (loss) | 4,233 | 4,073 | 13,526 | 13,165 |
Health Care Benefits | ||||
Segment Reporting Information [Line Items] | ||||
Total revenues | 22,511 | 20,479 | 68,376 | 61,487 |
Pharmacy Services | ||||
Segment Reporting Information [Line Items] | ||||
Total revenues | 43,216 | 39,046 | 125,489 | 113,681 |
Retail/ LTC | ||||
Segment Reporting Information [Line Items] | ||||
Total revenues | 26,706 | 24,992 | 78,410 | 72,994 |
Operating Segments | Health Care Benefits | ||||
Segment Reporting Information [Line Items] | ||||
Revenues from external customers | 22,387 | 20,311 | 68,029 | 60,993 |
Net investment income (loss) | 101 | 147 | 278 | 432 |
Total revenues | 22,511 | 20,479 | 68,376 | 61,487 |
Adjusted operating income (loss) | 1,544 | 1,106 | 5,126 | 4,502 |
Operating Segments | Pharmacy Services | ||||
Segment Reporting Information [Line Items] | ||||
Revenues from external customers | 40,545 | 36,851 | 116,600 | 105,909 |
Net investment income (loss) | 0 | 0 | 0 | 0 |
Total revenues | 43,216 | 39,046 | 125,489 | 113,681 |
Adjusted operating income (loss) | 1,877 | 1,773 | 5,368 | 5,035 |
Copayments | 2,900 | 2,800 | 9,800 | 9,000 |
Operating Segments | Retail/ LTC | ||||
Segment Reporting Information [Line Items] | ||||
Revenues from external customers | 17,994 | 16,347 | 53,380 | 47,672 |
Net investment income (loss) | (10) | (33) | (44) | 13 |
Total revenues | 26,706 | 24,992 | 78,410 | 72,994 |
Adjusted operating income (loss) | 1,398 | 1,723 | 4,865 | 5,166 |
Intersegment Eliminations | ||||
Segment Reporting Information [Line Items] | ||||
Intersegment revenues | (11,416) | (10,894) | (34,032) | (33,143) |
Net investment income (loss) | 0 | 0 | 0 | 0 |
Total revenues | (11,416) | (10,894) | (34,032) | (33,143) |
Adjusted operating income (loss) | (169) | (186) | (556) | (523) |
Intersegment Eliminations | Health Care Benefits | ||||
Segment Reporting Information [Line Items] | ||||
Intersegment revenues | 23 | 21 | 69 | 62 |
Intersegment Eliminations | Pharmacy Services | ||||
Segment Reporting Information [Line Items] | ||||
Intersegment revenues | 2,671 | 2,195 | 8,889 | 7,772 |
Intersegment Eliminations | Retail/ LTC | ||||
Segment Reporting Information [Line Items] | ||||
Intersegment revenues | 8,722 | 8,678 | 25,074 | 25,309 |
Corporate/ Other | ||||
Segment Reporting Information [Line Items] | ||||
Revenues from external customers | 32 | 39 | 97 | 101 |
Net investment income (loss) | 110 | 132 | 281 | 387 |
Total revenues | 142 | 171 | 378 | 488 |
Adjusted operating income (loss) | $ (417) | $ (343) | $ (1,277) | $ (1,015) |
Segment Reporting - Reconciliation of Consolidated Operating Income to Adjusted Operating Income (Details) - USD ($) $ in Millions |
1 Months Ended | 3 Months Ended | 9 Months Ended | |||
---|---|---|---|---|---|---|
Jun. 30, 2022 |
Jun. 30, 2021 |
Sep. 30, 2022 |
Sep. 30, 2021 |
Sep. 30, 2022 |
Sep. 30, 2021 |
|
Segment Reporting, Other Significant Reconciling Item [Line Items] | ||||||
Operating income (loss) (GAAP measure) | $ (3,931) | $ 3,061 | $ 4,128 | $ 10,964 | ||
Amortization of intangible assets | 464 | 561 | 1,398 | 1,730 | ||
Opioid litigation charges | 5,220 | 0 | 5,704 | 0 | ||
Loss on assets held for sale | 2,480 | 0 | 2,521 | 0 | ||
Gain on sale of subsidiary | 0 | 0 | (225) | 0 | ||
Acquisition-related integration costs | 0 | 20 | 0 | 101 | ||
Goodwill impairment | 0 | 431 | 0 | 431 | ||
Acquisition purchase price adjustment outside of measurement period | $ (61) | 0 | 0 | 0 | (61) | |
Adjusted operating income | $ 4,233 | $ 4,073 | 13,526 | $ 13,165 | ||
Disposal Group, Disposed of by Sale, Not Discontinued Operations | Payflex | Health Care Benefits | ||||||
Segment Reporting, Other Significant Reconciling Item [Line Items] | ||||||
Gain on sale of subsidiary | $ (225) | |||||
Proceeds from divestiture of subsidiary | $ 775 |
1:3\P%)8F::'5R4^N9\<$68Q5%@RB6",/,GJ='YDH15
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M>M[7V' +;%SR:2)>G^;\DD[";380!?180K 5Q?,29W$[6E++ZS
MG+]02P,$% @ BC1B55&'[F!Q @ V@4 !@ !X;"]W;W)K *)J_'BA"), P2))X!%CS#+R=C)/UY"ZN,1.9'I#"^1>UB2_&<0N),_/,9R
M8=@PY]4OJ*0Q)2!=+@T+XNF$Y8^%S$:+;Y4_=&X*$@[E/YV" *N^1+B3OR'M
M]Z=0QX0>->+262"]SFG?)Z'>Q23?47,-0N*,\A?3Z<,1K.NOZ[?_Y/VC&<-Q
MW,$+/&"_5RA28!^U')IQP!Y HG2HW B73!.:V85X<#TUP?XWU29-D6@7\)<.
M'6XJVA08&'9/V3P=(ROR#5=VI8.S?]BQK9@KYK#,+A@E[!?S'71ALZ$ 0G];Q'X0"KX4"'.CJ&2E7H /WUQAE@[(9Y"9LC(:-0F8>?.E
M$'J!(#44#6;&F%G K%K,O+8!C+9K,@3*)EN0LP4HUA[+E.*Q#G@($0WB,_C,
MV[>3BX)&Q: 4U;5K-O-&N-VG.X(4%U)KUM]:7*&5)HM.D
M50.ORM2E50T!W.5UUZ@L;VA:@%Y\Y=9S\Y=?W[T]CZ_LHGAL6H*&?#;$JQ)N
M\ Z6EY!V0'*P[4X3S3D6GK9L8QK7JQT9)^R;+OSMXO:"AZK8D!D3V'@3*